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Abstract 
 
Lantibiotics are post-translationally modified peptide antibiotics produced by Gram-
positive bacteria that contain characteristic ‘lanthionine’ residues and sometimes 
other unusual modifications. Cypemycin was identified as an anti-leukemia 
compound produced by Streptomyces sp. OH-4156. It contains two unique 
modifications (N,N-dimethylalanine and allo-isoleucine) and shares two further 
modifications with the lantibiotic family, namely 2,3-didehydrobutyrine and a S-[(Z)-
2-aminovinyl]-D-cysteine. Streptomycetes are filamentous soil-dwelling Gram-
positive bacteria that have a complex developmental cycle and are well known as 
producers of many antibiotics, immunosuppressants and anti-tumour compounds. 
 
The cypemycin biosynthetic gene cluster was identified, expressed in a 
heterologous host and a reduced gene set constructed that identified the genes 
sufficient for production. Mutational analysis of the individual genes within this set 
revealed that even the previously described modifications are carried out by 
unusual enzymes or via a modification pathway unrelated to lantibiotic 
biosynthesis. In vitro enzyme assays unambiguously confirmed the involvement of 
the two biosynthetic enzymes that are responsible for the modification of the N- 
and C-terminus of cypemycin. 
 
Bioinformatic analysis revealed the widespread occurrence of cypemycin-like gene 
clusters within the bacterial kingdom and in the Archaea. Cypemycin is the 
founding member of an unusual class of post-translationally modified peptides, the 
linaridins. Genetic analysis of a linaridin cluster in Streptomyces griseus resulted in 
the identification of grisemycin. 
 
Analysis of cryptic lantipeptide gene clusters (clusters for which the product has not 
yet been identified) in the genome of Streptomyces venezuelae identified a novel 
type of lanthionine-synthetase. Various genetic approaches were employed to 
identify the products from these clusters. Our collaborators reconstituted the 
activity of the unusual synthetase in vitro, revealing novel mechanistic and 
evolutionary insights. 
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General abbreviations 
 
ABC ATP-binding cassette 
Act actinorhodin 
AIP auto-inducing peptide 
Apra apramycin 
ATP adenosine triphosphate 
AviCys S-[(Z)-2-aminovinyl]-D-cysteine 
BSA bovine serum albumin 
Carb carbenicillin 
Cl-Trp 5-chlorotryptophan 
Cm chloramphenicol 
DAB deoxyactagardine B 
Dha 2,3-didehydroalanine 
Dhb (Z)-2,3-didehydrobutyrine 
DMSO dimethylsulfoxide 
DNA gluc Difco Nutrient agar with supplemented glucose 
EDTA ethylenediaminetetraacetic acid 
EF-Tu elongation factor Tu 
FAB-MS fast atom bombardment mass spectrometry 
GlcNAc N-acetylglucosamine 
HFCD homo-oligomeric flavin-containing cysteine-decarboxylases 
Hyg hygromycin B 
IC50 half maximum inhibitory concentration 
IPTG isopropyl β-D-1-thiogalactopyranoside  
Kan kanamycin 
Lab (2S,4S,8R)-labionin 
L-allo-Ile L-allo-Isoleucine 
Lan lanthionine 
MALDI-TOF 
MS 
matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry 
Mcc microcin 
Me2-Ala N,N-dimethylalanine 
MeAviCys S-[(Z)-2-aminovinyl]-3-methyl-D-cysteine 
MIC minimal inhibitory concentration 
MRSA methicillin resistant Staphylococcus aureus 
Nal nalidixic acid 
NMR nuclear magnetic resonance 
NRP non-ribosomal peptide 
NRPS non-ribosomal peptide synthase 
ORF open reading frame 
PAPA p-aminophenylalanine 
PCR polymerase chain reaction 
PE phosphatadylethanolamine 
PFGE pulsed-field gel electrophoresis 
PG peptidoglycan 
PPC 4'-phosphopanthothenoylcysteine 
QS quorum sensing 
Q-TOF quadrupole time-of-flight 
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RBS ribosome binding site 
Red undecylprodigiosin 
SAM S-adenosyl methionine 
SDS sodium dodecyl sulphate 
SNA soft nutrient agar 
sp. species 
Spec spectinomycin 
SRP signal recognition particle 
Strep streptomycin 
TEMED N,N,N',N'-tetramethylethylenediamine 
Tet tetracycline 
Thio thiostrepton 
Vio viomycin 
VRE vancomycin resistant enterococci 
WT wild-type 
 
 vi 
Table of contents 
 
Chapter I - Introduction 1 
 
I.1.  Post-translationally modified peptide natural products of bacterial 
origin 1 
I.2.   Bacteriocins that only require leader cleavage 4 
I.3.   Circular bacteriocins 5 
I.4.   Lantipeptides 7 
 I.4.1.   Introduction 7 
 I.4.2.   Lantibiotic gene clusters 8 
  I.4.2.a. Structural gene, lanA 9 
  I.4.2.b. lanB and lanC 10 
  I.4.2.c. lanM 11 
  I.4.2.d. lanP 11 
  I.4.2.e. lanD 12 
  I.4.2.f.  Other modifications 13 
  I.4.2.g. Regulatory genes 13 
  I.4.2.h. Transport genes 15 
  I.4.2.i.  Immunity genes 15 
 I.4.3.  The influence of recent developments in actinomycete research 
on classification of lantipeptides 16 
  I.4.3.a. Class I - LanBC (microbisporicin and planomonosporin) 21 
  I.4.3.b. Class II - LanM (cinnamycin and the duramycins, actagardine 
and michiganin A) 23 
 I.4.3.c. Class III - Lantionine synthetase containing a Ser/Thr kinase 
domain 25 
 I.4.4.   Mechanisms of action 28 
 I.4.5.   Engineering lantipeptides 30 
 I.4.6.   Genome mining to identify lantipeptide compounds 32 
  I.4.6.a. Biochemical approaches to genome mining 33 
  I.4.6.b. Molecular genetic approaches to genome mining 34 
I.5.   Microcins 35 
 I.5.1.   Microcin B17 contains thiazole and oxazole heterocycles 35 
 vii 
 I.5.2.   Lassopeptides 36 
 I.5.3.  Siderophore-peptides, a marriage between the ribosomal and 
non-ribosomal worlds 37 
 I.5.4.   Microcin C7 38 
I.6.   Modified peptides produced by cyanobacteria 38 
 I.6.1.   Cyanobactins 38 
 I.6.2.   Microviridins 39 
I.7.   Other five-membered heterocycle-containing peptides 40 
 I.7.1.   Linear toxins 40 
 I.7.2.   Thiopeptides 41 
I.8.   Linaridins 42 
I.9.   Modified quorum sensing peptides 43 
 I.9.1.   Cyclic (thio)lactones 43 
 I.9.2.   Bacillus pheromones 44 
 I.9.3.   Pep1357C 44 
I.10.   Aims of this project  45 
 
 
Chapter II – Materials and methods 46 
 
II.1.   Bacterial plasmids and strains 46 
II.2.   Culture media and antibiotics 53 
 II.2.1.   Antibiotics 53 
 II.2.2.   Culture media 53 
II.3.   Growth conditions and genetic manipulations 55 
 II.3.1.   Growth and storage of E. coli  55 
 II.3.2.   Growth and storage of Streptomyces 55 
 II.3.3.   Plasmid isolation from E. coli 56 
 II.3.4.   Cosmid isolation from E. coli 56 
 II.3.5.   Genomic DNA extractions from Streptomyces 57 
 II.3.6.   Digestion of DNA with restriction enzymes 57 
 II.3.7.   Agarose gel electrophoresis 58 
 II.3.8.   Extraction of DNA fragments from agarose gels 58 
 II.3.9.   Preparation and transformation of electro-competent E. coli 58 
 viii 
 II.3.10.  Preparation and transformation of chemically competent E. coli 59 
 II.3.11.  Ligation of DNA 59 
 II.3.12.  Conjugation of DNA into Streptomyces 59 
 II.3.13.  Construction of a Streptomyces sp. OH-4156 cosmid library 60 
 II.3.14.  Generation of protein fusion constructs 60 
 II.3.15.  Cypemycin bio-assays 61 
II.4.  Polymerase chain reaction (PCR) methods and DNA 
sequencing 61 
 II.4.1.   General PCR 61 
 II.4.2.   E. coli and Streptomyces colony PCR 62 
 II.4.3.   Purification of PCR products 62 
 II.4.4.   DNA sequencing 62 
II.5.   DNA hybridisation methods 70 
 II.5.1.   Non-radioactive Southern hybridisation 70 
 II.5.2.   Radioactive Southern hybridisation 72 
II.6.   PCR targeting 72 
 II.6.1.   PCR amplification of disruption cassette 72 
 II.6.2.   PCR targeting of a cosmid 74 
 II.6.3.   Transfer of mutant cosmids into Streptomyces 74 
II.7.   Protein methods 75 
 II.7.1.   Purification of His-tagged proteins 75 
 II.7.2.   Protein quantification 75 
 II.7.3.   SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 75 
II.8.   Mass spectrometry 76 
 II.8.1.   MALDI-ToF and Q-ToF MS 76 
 II.8.2.   Thiol alkylation 77 
 
 
Chapter III – Identification of the cypemycin gene cluster 78 
 
III.1.   Introduction 78 
III.2.   Characterisation of cypemycin and its producer strain 78 
 III.2.1.   Antibiotic sensitivities of S. sp. OH-4156 79 
 III.2.2.   Cypemycin detection by bio-assay and MALDI-ToF MS 80 
 ix 
 III.2.3.   Structure verification by Q-ToF 83 
III.3.   Generation and screening of a genomic cosmid library 84 
 III.3.1.   PCR based screening 84 
 III.3.2.   Southern hybridisation-based screening 86 
 III.3.3.   Ligation-mediated-PCR 88 
III.4.   Genome scanning  of S. sp. OH-4156  89 
III.5.  Identification of the cosmids bearing the cypemycin biosynthetic 
cluster 93 
 III.5.1.   Generation of specific cypA probe and library screen 93 
 III.5.2.  Heterologous expression of the positive cosmids in  
S. venezuelae 94 
III.6.   The cypemycin biosynthetic cluster 97 
III.7.   Discussion 99 
III.8.   Bullet point summary 101 
 
 
Chapter IV – Mutational analysis of cypemycin 
biosynthesis  102 
 
IV.1.   Introduction 102 
IV.2.   Generation of minimal gene set 102 
IV.3.   Mutational analysis of the cypemycin cluster 106 
IV.4.  Cypemycin is a member of a larger family of post-translationally 
modified peptides, the linaridins 113 
IV.5.   Generation of cypemycin variants 116 
IV.6.   Discussion 119 
IV.7.  Bullet point summary 123 
 
 
Chapter V – Biochemical analysis of cypemycin 
biosynthesis 124 
 
V.1.   Introduction 124 
 x 
V.2.   Substrate peptides for the enzymatic reactions 125 
V.3.   Formation of the AviCys residue 128 
V.4.   Methylation of the N-terminal alanine residue 134 
V.5.   Formation of the Dhb residues 136 
V.6.  Discussion 137 
V.7.   Bullet point summary 139 
 
 
Chapter VI – Characterisation of grisemycin, a linaridin 
produced by S. griseus 140 
 
VI.1.  Introduction 140 
VI.2.   Identification of grisemycin 141 
 VI.2.1.  Bio-informatical analysis of the grisemycin gene cluster 141 
 VI.2.2.  Grisemycin identification and structural verification 142 
VI.3.  Cloning and heterologous expression of the cluster and 
generation of a ∆grmA mutant 146 
 VI.3.1.  Cloning of the gene cluster and heterologous expression in 
M1146 146 
 VI.3.2.  Generation of a grmA deletion mutant 148 
VI.4.   Discussion 148 
VI.5.   Bullet point summary 151 
 
 
Chapter VII – Cryptic lantipeptide gene clusters from 
streptomycetes 152 
 
VII.1.  Introduction 152 
VII.2.  Bioinformatic analysis of cryptic lantipeptide gene clusters in 
sequenced streptomycetes 154 
VII.3.  Cryptic gene clusters in S. venezuelae 162 
 VII.3.1.  Deletion of the modification gene for each cluster 162 
 VII.3.2.  Micro-array expression data for the different clusters 163 
 xi 
 VII.3.3.  Heterologous expression of the clusters 166 
 VII.3.4.  Chemical induction of antibiotic production 167 
 VII.3.5.  Constitutive expression of the modification enzymes in each 
cluster 170 
VII.4.  Discussion 174 
VII.5.  Bullet point summary 177 
 
 
Chapter VIII – General discussion 178 
 
References 182 
 xii 
Index to figures 
 
Figure I.1.  Schematic representation of post-translationally modified 
bacterial peptides 3 
Figure I.2.  Schematic representation of the different types of 
lanthionine synthetases 19 
Figure I.3.  Schematic representation of lantipeptides produced by 
actinomycetes 20 
 
Figure III.1.  MALDI-ToF spectrum of cypemycin 82 
Figure III.2.  Q-ToF spectrum of cypemycin 83 
Figure III.3.  Design of degenerate primers and probes for cypA 85 
Figure III.4.  Hybridisation of a nylon membrane containing S. sp. OH-
4156 cosmid library clones with α-32P-dCTP labelled Cyp 
probe 87 
Figure III.5.  The principle of Ligation-Mediated-PCR (LM-PCR) 88 
Figure III.6.  Sequence of the cypemycin prepropeptide deducted by 
genome scanning 89 
Figure III.7.  Comparison of S. sp. OH-4156 genome scanning data and 
the S. venezuelae genome 91 
Figure III.8.  Analysis of the S. venezuelae chromosomal region 
harbouring the chloramphenicol biosynthetic gene cluster 92 
Figure III.9.  Hybridisation of a nylon membrane spotted with 3072 S. 
sp. OH-4156 genomic cosmid library clones with a 480 bp 
32P labelled cypA probe 93 
Figure III.10. Heterologous expression of the cypemycin biosynthetic 
gene cluster in S. venezuelae (MALDI-ToF) 95 
Figure III.11. Heterologous expression of the cypemycin biosynthetic 
gene cluster in S. venezuelae (bio-assay) 96 
Figure III.12. Schematic representation of the cypemycin biosynthetic 
gene cluster  98 
 
Figure IV.1. Strategy for the construction of a minimal cyp gene set 104 
Figure IV.2. M. luteus bio-assays for the minimal gene set construct and 
 xiii 
 the different scar mutants in the heterologous host M1146 105 
Figure IV.3.  MALDI-ToF spectra for scar mutants in M1146 107-108 
Figure IV.4.  MALDI-ToF spectra of the apramycin-marked mutants in 
S. sp. OH-4156 109-110 
Figure IV.5.  Structural verification of the truncated cypemycin 
derivatives 111 
Figure IV.6.  Analysis of the complementation of the ∆cypL mutant 
M1424 confirms production of both cypemycin and the 
non-decarboxylated form 112 
Figure IV.7.  The biosynthetic gene clusters of the linaridin family of 
peptides 114 
Figure IV.8.  Schematic representation of the three cypemycin variants 117 
Figure IV.9.  Mass spectrometric analysis of M1462 (cypA S-T)  118 
Figure IV.10. CypH and/or CypL are involved in the dehydratation of the 
residues from Dhb and catalyse a similar dethiolation 
reaction that converts Cys to Dha 120 
 
Figure V.1.  SDS-PAGE analysis of the 6His-MBP-proCypA fusion 
 protein purification 127 
Figure V.2.  Alignment of CypD with other HFCD-family 
decarboxylases 129 
Figure V.3.  Characterisation of the CypD cofactor 131 
Figure V.4.  Substrate preparation for the CypD decarboxylation assay 132 
Figure V.5.  CypD catalyses the in vitro decarboxylation of preproCypA 133 
Figure V.6.  CypM catalyses the in vitro dimethylation of the N-terminal 
Ala in non-methylated cypemycin 135 
 
Figure VI.1.  Comparison of the biosynthetic gene clusters for 
cypemycin and grisemycin production  141 
Figure VI.2.  MALDI-ToF MS spectrum of grisemycin 144 
Figure VI.3.  Q-ToF spectrum of grisemycin 145 
Figure VI.4.  MALDI-ToF MS spectra for M1457 and M1458 147 
Figure VI.5.  Alignment of the partial nucleotide sequences of cypH and 
grmH 150 
 xiv 
 
Figure VII.1. Schematic representation of gene clusters predicted to 
contain functional biosynthetic enzymes 157-158 
Figure VII.2. Multiple sequence alignment for related LanA peptides 159 
Figure VII.3. Gene expression profiles for selected secondary 
metabolite gene clusters from S. venezuelae 165 
Figure VII.4. Chemical induction of the heterologously expressed S. 
venezuelae lantipeptide clusters 169 
Figure VII.5. Act overproduction phenotype of S. coelicolor M1456 on 
SFM 172 
Figure VII.6. Identification of a possible product from the cryptic 
SMD01252 gene cluster 173 
 xv 
Index to tables 
 
Table II.1.  Plasmids and cosmids used and constructed in this study 46-49 
Table II.2.  Strains used or constructed in this study 50-52 
Table II.3.  Concentration of antibiotics used in this study 53 
Table II.4.  Additional fermentation media for actinomycetes 54 
Table II.5.  Primers used in this study 64-69 
 
Table III.1.  Minimal inhibitory concentration (MIC) values for S. sp. 
OH-4156 when grown on solid medium 80 
 
Table IV.1.  Putative structural peptides 115 
 
Table VII.1.  Lantibiotic synthetases of the LanB, LanC, LanM and LanL 
types identified in streptomycete genomes 155 
 
 
 
I – Post-translationally modified bacterial peptides 
 
 
1 
Chapter I – Introduction 
 
I.1. Post-translationally modified peptide natural products of 
bacterial origin 
 
Peptide natural products with various chemical structures and biological functions are 
produced by bacteria of all major phylogenetic lineages. These compounds can either be 
genetically encoded and ribosomally translated or they can be assembled on large 
multimodular enzymes called non-ribosomal peptide synthetases (NRPSs). The latter 
synthesise peptides via a mechanism similar to ribosomal translation, by linking amino 
acid monomers via a peptide bond to a growing chain.  However, the sequence of the 
final product is not determined by messenger RNA (mRNA), but by the substrate 
specificity of the enzyme’s successive modules, allowing the incorporation of non-
proteinogenic amino acids. Peptide natural products of NRPS origin are not a topic of 
this introductory chapter, but have been described in several recent review articles 
(Fischbach and Walsh 2006; Koglin and Walsh 2009).  
 
Although the ribosomal translation machinery can only use the 20 genetically encoded 
amino acids, Nature has invented several mechanisms to expand on this repertoire via 
the introduction of post-translational modifications. This introductory chapter presents an 
overview of the myriad of different post-translationally modified peptides that are 
produced by both Gram-positive and Gram-negative bacteria. These peptides are 
typically produced as short preproproteins consisting of N-terminal leader sequences 
and C-terminal proproteins that are post-translationally modified. Proteolytic cleavage of 
the leader peptide is generally required for liberation of the functional mature peptide 
product. Several ‘exceptions’ to this general ‘rule’ have been described, including C-
terminal extensions or even multiple peptide products that are processed from a single 
structural peptide. The genetic determinants involved in the biosynthesis of peptide 
natural products are usually found clustered in the bacterial genome or on a plasmid. 
Most of the compounds under discussion were originally characterised because of their 
antibacterial activity, but structurally related compounds with other biological functions 
will also be mentioned. Introduction of post-translational modifications are speculated to 
contribute to peptide structural rigidity, function and stability. Since there is no 
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unambiguous definition of a ‘peptide’, a size range up to 100 amino acids will be 
employed as an arbitrary cut-off value for inclusion of a compound in this chapter.  
 
Post-translationally modified peptides of bacterial origin are often intuitively associated 
with bacteriocins such as lantibiotics and microcins. The term ‘bacteriocin’ was used for 
the first time by Jacob et al. (1953) to refer to peptide compounds of the colicin type. 
Tagg et al. (1976) later expanded upon this to include peptides produced by Gram-
positive bacteria and defined a bacteriocin as a ‘proteinaceous compound that kills 
closely related bacteria’. A bacteriocin classification was proposed by Klaenhammer 
(1993) and as more compounds were characterised structurally and genetically, this 
classification was expanded and became the subject of lively debate (Jack et al. 1995; 
van Belkum and Stiles 2000; Diep and Nes 2002; Cotter et al. 2005; Franz et al. 2007; 
Zouhir et al. 2010). Unfortunately, there are almost as many different classification 
schemes as there are reviews on the subject. This overview is not intended as an 
attempt at classification and includes, but is not restricted to, modified bacteriocins. 
Instead it focuses on the wonderful world of post-translationally modified peptide 
structures (Figure I.1.), their biological function and underlying biosynthesis.  
 
Non-lantibiotic bacteriocins are not subject to extensive post-translational modification 
(Cotter et al. 2005). Since most of these compounds are produced as a precursor 
peptide that at least requires post-translational cleavage of the leader sequence, they 
will be discussed briefly in Chapters I.2. and I.3. Several leaderless bacteriocins have 
been reported, including enterocin I (Floriano et al. 1998), aureocin A53 (Netz et al. 
2002), mutacin BHT-B (Hyink et al. 2005) and lacticin Q (Fujita et al. 2007). These 
peptides contain a formylated N-terminal Met that is the result of the bacterial translation 
mechanism rather than a post-translational modification and thus they will not be 
discussed in this literature review. Chapter I.4. focuses in some detail on lantipeptides 
since they are central to this PhD thesis (Chapter VII). Other important families that will 
be discussed include microcins (Chapter I.5.), peptides produced by cyanobacteria 
(Chapter I.6.) and other five-membered heterocycle-containing peptides (Chapter I.7.). 
Cypemycin, the main subject of this thesis (Chapter III – V), was originally classified as a 
lantibiotic, but was identified in this work as the first representative of the linaridin family 
(Chapter I.8.). Finally, several types of modified peptides involved in quorum sensing will 
be discussed (Chapter I.9.). 
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Figure I.1. Schematic representation of post-translationally modified bacterial peptides. For 
information on the specific modifications, producing organisms and references, refer to the text. 
The N-terminal 74 amino acids of MccE492m are not shown. Residues resulting from 
modification of Ser and Thr are depicted in blue, and modified Cys are in orange. Unusual post-
translationally modified amino acids are depicted in yellow. The N-terminal amide ring in MccJ25 
is shown in grey. Five-membered heterocycles are represented by pentagons. The N- and C-
terminal ends of the peptides are indicated by N and C, respectively. Abu: aminobutyric acid; Ala-
S-Ala: lanthionine; Abu-S-Ala: methyllanthionine; Dha: didehydroalanine; Dhb: didehydrobutyrine; 
Ox: oxazole; Oi: oxazoline; mO: methyloxazole; mOi: methyloxazoline; T: thiazole. 
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I.2. Bacteriocins that only require leader cleavage 
 
Among bacteriocins that only require proteolytic cleavage of the leader peptide, both 
single peptides and two-peptide systems have been described. Single-peptide 
bacteriocins that resemble pediocin PA-1 are among the best characterised examples 
because of their anti-listerial activity (Eijsink et al. 1998). These peptides are cationic 
and partly amphiphilic or hydrophobic, containing a conserved ‘pediocin box’ sequence 
motif and two Cys residues that are linked by a disulfide bridge. The latter is predicted 
not to be required for activity since reduction and subsequent derivatisation with 
iodoacetamide did not result in loss of activity of sakacins A and P (Holck et al. 1992). 
Instead, the disulphide bridge is proposed to contribute to the rigidity and heat stability of 
pediocin-like bacteriocins.  
 
Pediocin-like bacteriocins exert their mechanism of action by permeabilisation of the 
cytoplasmic membrane in sensitive bacteria, resulting in a disruption of the proton 
motive force and a depletion of the ATP pool (Chikindas et al. 1993; Montville and Chen 
1998). The membrane-associated mannose phosphotransferase system permease has 
been implicated as a determinant for the specificity of these bacteriocins for their target 
strains (Ramnath et al. 2000). Single-peptide bacteriocins are produced as precursor 
peptides that are secreted and processed either by specialised ABC transporters or via 
the sec-dependent pathway. The former contain an N-terminal leader peptide with the 
characteristic double-Gly motif that is recognised by the N-terminal proteolytic domain of 
the ABC transporter (Havarstein et al. 1995). Production is usually controlled by a so-
called ‘three-component system’, involving a bacteriocin-like pheromone, a histidine 
kinase that can sense the secreted pheromone and a response regulator that can 
activate transcription of target promoters upon phosphorylation by the histidine kinase 
(Brurberg et al. 1997). The bacteriocin-like pheromone also has a double-Gly leader 
peptide and is processed and secreted by the same transporter as the bacteriocin, but 
their antibacterial activity is negligible compared to their associated bacteriocins (Eijsink 
et al. 1996). A mechanism for self-immunity is provided by a small protein of 88 to 115 
amino acids encoded by a gene in the bacteriocin cluster, often in the same operon as 
the structural gene to ensure co-regulation (Eijsink et al. 1998). In the case of the 
pediocin-like bacteriocins, the immunity proteins are located inside the cell, but could be 
loosely associated with the inside of the cell membrane (Quadri et al. 1995). A recent 
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study by Diep et al. (2007) revealed that immunity proteins bind to the mannose 
phosphotransferase permease, but only if the bacteriocin is already bound to this target. 
Thus, the immunity proteins are proposed to protect permease blockage and membrane 
leakage by recognition and binding of the permease-bacteriocin complex.  
 
Two-peptide bacteriocins consist of two very different peptides that are required in 
roughly equal amounts to function as one antimicrobial entity. Lactococcin G was the 
first two-peptide bacteriocin to be described (Nissen-Meyer et al. 1992). Two-peptide 
bacteriocins also kill susceptible cells by permeabilisation of the cytoplasmic membrane. 
With a few exceptions, the individual peptides do not display antimicrobial activity 
(Anderssen et al. 1998). The two-peptide bacteriocin biosynthetic gene clusters typically 
only contain one immunity protein, but the mechanism by which this works remains to be 
determined. 
 
I.3. Circular bacteriocins 
 
Circular bacteriocins are a family of peptides that have a peptide linkage between their 
N- and C-terminal ends, resulting in a circular backbone. Compounds belonging to this 
family have been described in the literature both as ‘cyclic’ and as ‘circular’, but Craik et 
al. (2003) proposed to use the latter name to distinguish these head-to-tail cyclised 
peptides from others containing different cross-links that make their structure only 
partially cyclic. About nine different circular bacteriocins have been described to date 
with a size range between 58 and 78 amino acid residues (reviewed in Maqueda et al. 
2008). Peptidase homologues have been proposed as candidates for the leader 
cleavage and cyclisation reactions (Kawulka et al. 2003), but the underlying mechanisms 
and order of these events remain speculative. A remarkable feature of several circular 
bacteriocins is that their propeptide sequence is preceded by a very short leader 
sequence. Circularin A (Kemperman et al. 2003), carnocyclin A (Martin-Visscher et al. 
2008), uberolysin (Wirawan et al. 2007) and subtilosin A (Zheng et al. 1999) have leader 
sequences of three, four, six and eight amino acids, respectively.  
 
Enterocin AS-48, the circular bacteriocin produced by Enterococcus faecalis, was the 
first compound to be identified from this family (Gálvez et al. 1986). The circular nature 
of enterocin AS-48 was determined by chemical degradation (Samyn et al. 1994) and 
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confirmed by the identification of its structural gene (Martinez-Bueno et al. 1994). The 
latter is a particularly challenging task in peptides from this family since it is impossible to 
tell from the mature structure where the original N- and C-terminal ends were linked 
together. The peptide exerts its antimicrobial activity by voltage-independent interaction 
with the cytoplasmic membrane of susceptible bacteria, followed by membrane insertion 
that probably leads to pore formation resulting in ion leakage and a collapse of 
membrane potential (Gonzalez et al. 2000). Structural analysis of carnocyclin A by 
nuclear magnetic resonance (NMR) revealed a fold that is surprisingly similar to the 
structure of enterocin AS-48, despite a low degree of sequence identity (Martin-Visscher 
et al. 2009). This study suggests that many circular bacteriocins might have a common 
structural motif, regardless of their amino acid sequence. 
 
The circular bacteriocin subtilosin A (Figure I.1.), which is produced by Bacillus subtilis, 
is thus far the only circular bacteriocin described that contains an additional type of post-
translational modification. The compound contains three linkages that involve the thiol 
groups of its three Cys residues and the α-carbon of two Phe and a Thr, resulting in the 
loss of a hydrogen from each of these six residues (Kawulka et al. 2003). Similar post-
translational modifications have been observed in thuricin CD, a two-peptide bacteriocin 
produced by Bacillus thuringiensis with potent activity against Clostridium difficile (Rea et 
al. 2010). The mature peptides Trnα and Trnβ are not circular, but each peptide contains 
three linkages between the thiol of Cys5, Cys9 and Cys13 and the α-carbon of the 
amino acid at position 28, 25 and 21, respectively. Sequencing and bioinformatic 
analysis of the thuricin gene cluster identified two radical S-adenosylmethionine (SAM) 
superfamily proteins that share only low sequence identity (19 % and 17 %) with the 
radical SAM enzyme AlbA encoded by the subtilosin A gene cluster (Zheng et al. 2000; 
Rea et al. 2010). These enzymes are proposed to be involved in the introduction of the 
Cys to α-carbon linkages. 
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I.4. Lantipeptides  
 
I.4.1. Introduction 
 
Lantibiotics are ribosomally synthesized peptide antibiotics that are extensively post-
translationally modified. They are produced by a variety of Gram-positive bacteria and 
their mechanisms of action include disruption of cell wall biosynthesis, inhibition of spore 
outgrowth, membrane permeabilisation and enzyme inhibition. Schnell et al. (1988) 
introduced the name lantibiotics as an abbreviation for ‘lanthionine-containing antibiotic 
peptides’, because of the occurrence of the unusual amino acid lanthionine (Lan) in their 
structures. The Lan residue consists of a thioether crosslink between the β-carbons of 
two alanine moieties and results from the intramolecular nucleophilic addition of a Cys 
residue onto 2,3-didehydroalanine (Dha). This unusual amino acid is introduced into the 
lantibiotic peptide by dehydration of Ser. Thr residues are also prone to dehydration, 
yielding (Z)-2,3-didehydrobutyrine (Dhb), which can form a methyl-lanthionine (MeLan) 
residue upon cyclisation with Cys. Most lantibiotics have been identified because of their 
antibacterial activity. However, several compounds are known that contain (Me)Lan 
residues, but do not display (significant) antibiotic activity. These are called lanthionine-
containing peptides or ‘lantipeptides’ (Goto et al. 2010) and they will be discussed in 
more detail in Chapter I.4.3.  
 
A wide range of additional amino acid modifications has been reported for lantipeptides, 
including S-[(Z)-2-aminovinyl]-D-cysteine (AviCys), (2S,8S)-lysinoalanine, β-hydroxy-
aspartate, D-alanine, 2-oxopropionyl, 5-chlorotryptophan and dihydroxylated proline. 
Consequently, a significant amount of research is directed at unveiling the novel 
enzymatic mechanisms responsible for these unusual amino acids. Better understanding 
of the biosynthetic machinery and of substrate specificity will provide powerful tools for 
both in vivo and in vitro protein engineering, eventually potentially leading to intelligent 
drug design (Pag and Sahl 2002). 
 
Nisin (Figure I.1.) has been studied intensively because of its widespread use in the food 
industry (Delves-Broughton et al. 1996), and is often considered as the “model 
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lantibiotic”. However, approximately 55 different lantibiotics have been described in the 
literature and the biosynthesis of many has been thoroughly characterised. 
 
Structural characterisation of lantibiotic peptides has proven problematic - dehydrated 
residues at the N-terminus of the peptide or exposed during Edman degradation 
spontaneously deaminate resulting in a sequence block (Jung 1991). A milestone in the 
structural determination of lantibiotics was a method developed by Meyer et al. (1994) 
that allowed direct sequencing of dehydroamino acids and thioethers after treatment with 
thiol compounds under alkaline conditions. More recently, a novel derivatisation 
technique was developed by Martin et al. (2004) to characterise the two-peptide 
lantibiotic lacticin 3147. This technique involves simultaneous hydrogenation of the 
dehydroamino acids and the desulphurisation of the thioethers by using nickel boride. If 
sodium borodeuteride is used, two deuterium ions will be incorporated into derivatives of 
Dha and Dhb, whereas only one deuterium will be present in residues resulting from Lan 
or MeLan residues. The derivate is amenable to Edman degradation and the location of 
the deuterated residues can be determined by mass spectrometry. A significant 
advantage of this methodology is that only small amounts of lantibiotic (micrograms) are 
required for analysis. The technique allows rapid differentiation between Dha/Dhb and 
(Me)Lan residues, but does not reveal the exact bridging pattern of the lantibiotic. 
Hence, a combination of this method and NMR spectroscopy is required to determine 
the precise structure. 
 
I.4.2. Lantibiotic gene clusters 
 
Thus far, genes encoding the biosynthetic machinery responsible for lantibiotic 
production are clustered together in the genome of the producing organism. In most 
cases, these gene clusters are located on the chromosome, but they can also reside on 
large plasmids, e.g. epidermin (Schnell et al. 1988), or on transposable elements, e.g. 
nisin (Horn et al. 1991). Each type of lantibiotic biosynthetic gene has been given a 
generic ‘lan’ designation. Prepropeptides are encoded by structural genes termed ‘lanA’ 
that are found in the clusters with genes required for Dha, Dhb and (Me)Lan formation 
(lanB, lanC, lanM, ramC, lanL, labKC), proteolytic processing (lanP), transport (lanT, 
lanH), immunity (lanI, lanFEG),  regulation (lanR, lanK, lanQ) and additional modification 
(lanD, lanJ). In the following sections, the products of each of these gene types will be 
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described in more detail and in vitro reconstitution of specific enzyme activities will be 
discussed. 
 
I.4.2.a. Structural gene, lanA 
 
Epidermin was the first lantibiotic for which the structural gene was identified, thereby 
confirming its ribosomal origin and by extension that of other lantibiotics (Schnell et al. 
1988). Epidermin was also the first lantibiotic for which the biosynthetic gene cluster was 
cloned and heterologously expressed in a closely related strain (Schnell et al. 1992). 
 
The lantibiotic structural genes encode a prepropeptide (LanA), consisting of an N-
terminal leader sequence of 23 to 59 amino acids, and the structural region or 
propeptide, which is modified to yield the mature lantibiotic. During the last step of 
biosynthesis - secretion and subsequent cleavage of the leader sequence from the 
mature peptide - the lantibiotic is activated. The leader peptide generally has no 
similarity to Sec or Tat signal sequences but may play a role in immunity (by keeping the 
antibiotic inactive in the cell), in transport, and/or as a recognition sequence for the 
biosynthetic enzymes (Chatterjee et al. 2005; Oman and van der Donk 2010). It has 
been demonstrated for Pep5 that although the leader peptide contains Ser and Thr 
residues, only residues in the propeptide undergo modification (Weil et al. 1990). The 
leader peptides of all characterised lantibiotics are also devoid of Cys, in contrast to their 
Cys-rich propeptides.  
 
Analogous to ‘unmodified’ two-peptide bacteriocins, two-peptide lantibiotics have also 
been described where a combination of both peptides is required for significant activity. 
Each prepropeptide of a two-peptide lantibiotic is genetically encoded and requires its 
own dedicated LanM enzyme for modification. The only exception to date is cytolysin, 
where only one LanM modifies both structural peptides (Gilmore et al. 1994). The gene 
clusters of some lantibiotics (for example ruminococcin, macedocin and Bsa) contain two 
or more homologous structural genes with a high degree of amino acid identity (Marcille 
et al. 2002; Papadelli et al. 2007; Daly et al. 2010). The reason for this is not clear, but in 
the case of mutacin I and III, inactivation of one lanA completely abolished antimicrobial 
activity whereas inactivation of the homologous lanA did not (Qi et al. 1999; Qi et al. 
2000).  
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I.4.2.b. lanB and lanC 
 
The products of the lanB and lanC genes are responsible for the introduction of the Dha 
and Dhb residues into lantibiotic propeptides and the subsequent intramolecular 
nucleophilic attack of a Cys residue, resulting in the formation of a Lan or MeLan bridge. 
 
lanB genes encode large proteins (of approximately 1000 amino acids in size) which are 
overall of a hydrophilic nature. However, the LanB proteins also contain hydrophobic 
domains, suggesting an interaction with the cell membrane, as has been shown for NisB  
and SpaB (Engelke et al. 1992). Koponen et al. (2002) demonstrated the role of NisB 
and NisC in nisin biosynthesis. An unmodified His-tagged nisin precursor was isolated 
from a ∆nisB mutant, indicating that NisB was involved in dehydration of the Ser and Thr 
residues. The His-tagged prepropeptide isolated from the ∆nisC mutant was dehydrated, 
but no cyclisation reactions had occurred, making the NisC protein a good candidate for 
the cyclisation reaction. In another study, the activity of NisB was demonstrated by 
expressing a non-lantibiotic peptide as a fusion construct with the C-terminal part of the 
NisA leader peptide (Kuipers et al. 2004). The peptide was expressed in a non-nisin 
producing Lactococcus lactis strain harbouring the nisABT genes on a plasmid. The 
peptide was dehydrated by NisB and secreted by the NisT transporter, demonstrating 
the rather broad substrate specificity of the NisB dehydratase. No in vitro reconstitution 
of an active LanB-family enzyme has been reported to date. 
 
The lanC genes encode for cyclases ranging from 398 to 455 amino acids in size. In 
lanC deletion strains, only dehydrated peptides are formed (Meyer et al. 1995; Koponen 
et al. 2002). This illustrates the essential role of LanCs in the cyclisation reaction. NisC 
and SpaC are zinc binding proteins containing His and Cys residues, which are 
conserved in both LanC and LanM proteins (Okeley et al. 2003). Structural analysis of 
NisC showed that these residues are involved in binding the zinc ligand (Li et al. 2006). 
This study also reports the in vitro reconstitution of NisC activity, providing the first 
biochemical characterisation of a LanC cyclase. A site-directed mutagenesis study of the 
enzyme revealed essential catalytic residues and confirmed the involvement of the 
metal-binding residues (Li and van der Donk 2007). 
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I.4.2.c. lanM 
 
Lantipeptide gene clusters that do not contain lanB or lanC genes have a single gene 
instead that encodes an enzyme that catalyses both the dehydration and cyclisation 
reactions during maturation of the prepropeptide. Two major types of these 
multifunctional enzymes have been reported, namely LanMs and proteins belonging the 
RamC-LanL-LabKC family. Members of the latter family contain an internal domain 
homologous to Ser/Thr kinases and will be discussed in more detail in Chapter I.4.3. 
lanM genes encode for a protein of approximately 900-1000 amino acids in size, 
containing a C-terminal part with 20-27% sequence identity to LanC proteins (Okeley et 
al. 2003). This domain contains the conserved residues involved in catalysis and the 
metal-binding site mentioned above. No homology can be detected between the N-
terminal part of LanM and LanB proteins, indicating the lanM genes did not simply 
originate from a gene fusion between a lanB and a lanC gene (Siezen et al. 1996). 
Experiments involving the in vitro biosynthesis of lacticin 481, catalysed by LctM, 
provided proof that LanM proteins are involved in both dehydration and cyclisation (Xie 
et al. 2004). This study also encompasses the first in vitro production of a lantibiotic. 
Purified His-tagged LctM was incubated with a His-tagged LctA prepropeptide and after 
protease treatment to remove the leader sequence, the bio-active lantibiotic was formed. 
Both a Mg2+ ion and ATP are required for LctM activity.  
 
I.4.2.d. lanP 
 
After or upon secretion of the lantibiotic, a protease is required for cleavage of the leader 
peptide resulting in activation of the mature peptide. In some gene clusters, a lanP gene, 
encoding a dedicated subtilisin-type Ser protease is present. LanP proteins vary in size 
from 266 to 682 amino acids and several possess an N-terminal signal sequence which 
implies they can be directed out of the cell and act extracellular. NisP contains a C-
terminal extension that could act as a membrane anchor, suggesting that the protease 
may become attached to the outside of the cytoplasmic membrane (van der Meer et al. 
1993).   
 
When the lantibiotic gene cluster does not harbour a lanP gene, one or several 
extracellular proteases are capable of activating the lantibiotic by removing the leader 
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sequence, as has been shown for subtilin (Corvey et al. 2003). Alternatively, in LanM-
type lantibiotic gene clusters, the cleavage is performed by a chimeric ABC-transporter 
LanT(P) that contains an N-terminal protease domain. This implies that LanT(P) 
transporters are capable of removing the leader peptide while translocating the 
lantibiotic, as has been shown for MrsT (mersacidin), LctT (lacticin 481), CylT (cytolysin) 
and ScnT (SA-FF22). Lactocin S is an exception as it is processed and translocated by 
seprate LasP and LasT proteins (Skaugen et al. 1997). The in vitro leader peptidase 
activity of the N-terminal domain of the lacticin 481 transporter LctT has been reported 
(Furgerson Ihnken et al. 2008). Lantibiotic clusters from actinomycete origin 
(cinnamycin, actagardine A, deoxyactagardine B, michiganin A and microbisporicin) 
contain no designated protease gene, suggesting that the leader sequence is cleaved by 
an enzyme encoded elsewhere in the genome (Widdick et al. 2003; Holtsmark et al. 
2006; Boakes et al. 2009; Boakes et al. 2010; Foulston and Bibb 2010). 
 
I.4.2.e. lanD 
 
The additional enzyme LanD is involved in further modification of epidermin and 
mersacidin. The 181 amino acid, FMN-containing EpiD functions as a peptidyl-Cys 
decarboxylase, catalysing the oxidative decarboxylation of the C-terminal Cys residue to 
AviCys (Kupke et al. 1994). The reaction mechanism involves the oxidation of the Cys22 
thiol to a thioaldehyde, which is hypothesised to tautomerise to a more stable ene-
thiolate via decarboxylation of the C-terminus. This is followed by thioether ring 
formation by attacking an internal Dha residue at position 19 (Blaesse et al. 2000). MrsD 
is a 194 amino acid FAD-containing enzyme catalysing the analogous reaction to form 
S-aminovinyl-3-methyl-D-cysteine (AviMeCys) in the lantibiotic mersacidin (Majer et al. 
2002; Blaesse et al. 2003). The structures of epidermin and mersacidin reveal that 
requirements for the position of the dehydrated residue, involved in formation of the 
Avi(Me)Cys, are quite relaxed. In epidermin, the AviCys bridge spans two other amino 
acids, whereas in mersacidin four amino acids are spanned by AviMeCys. 
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I.4.2.f. Other modifications 
 
Both lactocin S and lacticin 3147 contain D-Ala residues that result from the modification 
of an L-Ser in the propeptide (Skaugen et al. 1994; Ryan et al. 1999). These modified 
residues are introduced in a two-step process initiated by dehydration of L-Ser to 
nonchiral Dha by a lanthionine synthetase, followed by a stereospecific hydrogenation to 
form D-Ala, a reaction catalysed by LanJ enzymes (Cotter et al. 2005). Site-directed 
mutagenesis of the individual three Ser codons to Ala resulted in mature lacticin 3147 
peptides that contain the L- rather than the D-isoform. These changes were found to 
have a negative effect on production and activity of the lantibiotic (Cotter et al. 2005). 
 
Despite the fact that almost all Cys residues are involved in (Me)Lan formation, several 
compounds with a disulfide bridge or ‘cystine’ have been described, namely sublancin 
168, plwα, bovicin HJ50, thermophilin 1277 and the  labyrinthopeptins (Paik et al. 1998; 
Holo et al. 2001; Xiao et al. 2004; Kabuki et al. 2009; Meindl et al. 2010). A thiol-disulfide 
oxidoreductase, BdbD was implied in the introduction of the cystine residues in 
sublancin 168 (Dorenbos et al. 2002). Deletion of a thiol-disulfide oxidoreductase 
downstream of the bovicin HJ50 gene cluster did not alter the mass of the compound, 
indicating the disulfide bridge remained intact (Liu et al. 2009). Heterologous expression 
in a L. lactis strain lacking thiol-disulfide reductases, resulted in production of bovicin 
HJ50 without the disulfide bridge, but the cystine appeared not to be required for 
antimicrobial activity. 
      
I.4.2.g. Regulatory genes 
 
The biosynthesis of several lantibiotics appears to be regulated at a transcriptional level 
in a cell density dependent manner. This phenomenon, named quorum sensing (QS), is 
under control of a two-component regulatory system, encoded by the genes lanR and 
lanK. The lantibiotics themselves act as peptide pheromones capable of triggering a 
signal transduction mechanism, resulting in expression of biosynthetic genes which 
contain specific lantibiotic-responsive elements (lan-boxes) in their promoters 
(Kleerebezem et al. 2004). 
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Lantibiotic production is generally initiated during mid- to late-logarithmic growth phase, 
peaking at the onset of stationary phase. The QS regulated production allows 
environmental concentrations of the lantibiotic to rapidly reach the level required for 
killing competitors of the producer strain. The lantibiotic’s resulting high extracellular 
concentration ensures optimal effectiveness since the target strain is unlikely to be able 
to initiate or develop a fast defence reaction (Kleerebezem 2004). 
 
The two-component system comprises two different proteins, a sensor kinase (LanK) 
which is embedded in the cytoplasmatic membrane, and an intracellular response 
regulator (LanR). For nisin (Ra et al. 1996), subtilin (Stein et al. 2002; Kleerebezem et al. 
2004), salivaricin A (Upton et al. 2001) and mersacidin (Schmitz et al. 2006), it was 
shown that the lantibiotic itself functions as a signalling molecule, which is predicted to 
be recognised by the extracellular domain of LanK. Upon recognition, the sensor kinase 
autophosphorylates a conserved histidine residue in its intracellular C-terminal domain. 
This phosphate moiety, in turn, is transferred to a conserved asparagine residue in the 
N-terminal part of the response regulator. The C-terminal domain of the LanR protein 
undergoes a conformational change and gains the ability to act as a transcriptional 
regulator by binding to the operator sequence(s) of the target gene(s).  
 
While there is a wide diversity in the QS regulation of lantibiotic gene clusters, all studied 
examples are variants of the general mechanism described above. Biosynthesis of 
cytolysin LL/LS is regulated by two different regulator proteins, CylR1 and CylR2 (Haas et 
al. 2002). Lacticin 3147 and mutacin II do not have a dedicated sensor kinase in their 
gene clusters, however, they do have an orphan LanR response regulator (Pag and Sahl 
2002). In the case of lacticin 3147, LtnR was implicated in regulation of the immunity 
determinants in the biosynthetic gene cluster.  
 
A putative stem-loop structure has been identified downstream of the structural genes 
for mersacidin, cinnamycin, actagardine A and deoxyactagardine B (Altena et al. 2000; 
Widdick et al. 2003; Boakes et al. 2009; Boakes et al. 2010). This structural DNA 
element could function as a transcriptional attenuator that allows limited read-through to 
the downstream biosynthetic genes, probably serving to maintain an appropriate 
stoichiometry between the precursor peptide and the modification machinery. 
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I.4.2.h. Transport genes 
 
In LanBC gene clusters, a lanT gene encodes a transport protein of 500 to 600 amino 
acids in size. The LanT transporter belongs to the group A of ATP-binding-cassette 
(ABC)-transport family and is responsible for the translocation of the modified lantibiotic 
precursor across the cytoplasmic membrane. The protein consists of two functional 
domains, an N-terminal hydrophobic domain containing six transmembrane helices and 
a C-terminal domain containing two conserved ATP-binding motifs. Translocation is 
driven by ATP hydrolysis as a source of energy and for most LanT proteins, the active 
transporter is formed by dimerisation at the cytoplasmic membrane. Inactivation of nisT 
has shown that the NisT transporter is essential for export of nisin (Skaugen et al. 1997). 
In contrast, disruption of pepT resulted in reduced production of Pep5 (Bierbaum et al. 
1994) and in the epicidin 280 gene cluster, no lanT homologue was found (Heidrich et al. 
1998). These findings indicate that other cellular transporters might be involved in the 
secretion of some lantibiotics. Most lantibiotics that are activated by cleavage after a 
‘double glycine’ motif  harbour a dual function LanT transporter in their gene cluster, as 
discussed in section I.4.2.d. Epicidin 280 is the only characterised lantibiotic gene cluster 
to date that does not contain a dedicated ABC transporter (Heidrich et al. 1998; 
Chatterjee et al. 2005). 
 
I.4.2.i. Immunity genes 
 
An efficient auto-immune system is of vital importance for lantibiotic-producing strains. 
Therefore, most lantibiotic gene clusters contain specific genes that are involved in self-
protection. Two mechanisms for auto-immunity have been described in lantibiotic 
producing strains, namely the production of a specific immunity peptide LanI and the 
expression of a specialised transporter LanFEG. Whereas some lantibiotic gene clusters 
contain only one of these mechanisms, others contain both systems. 
 
LanI immunity peptides are small proteins ranging from 57 to 245 amino acids in size. 
NisI and SpaI are both lipoproteins containing an N-terminal Sec signal sequence and a 
membrane anchor immediately following the cleavage site (Qiao et al. 1995). The 
maturation of SpaI through the lipoprotein biosynthesis pathway was investigated and 
site-directed mutagenesis of the candidate lipobox identified variants that blocked the 
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protein’s acylation (Halami et al. 2010).  PepI also seems to be associated with the 
extracellular side of the cytoplasmic membrane and its immunity phenotype appears to 
be coupled to Pep5 production at a transcriptional level (Reis et al. 1994). The molecular 
immunity mechanism of the LanI peptides remains to be determined, but they have been 
proposed to bind the associated lantibiotic, thereby preventing its penetration and pore-
formation in the host cell membrane (Stein et al. 2003; Stein et al. 2005).  
 
The second mechanism for auto-immunity involves a transporter from the ABC family, 
which is encoded by the lanFEG genes. This transporter consists of membrane-
spanning subunits LanE and LanG, and the LanF protein which contains the ATP-
binding site. The LanFEG transporters are proposed to provide auto-immunity by 
extruding the lantibiotic into the surrounding medium and thus keeping its concentration 
in the cell at a low level. This way, the cell membrane of the producer is protected from 
the activity of its own lantibiotic, as shown for epidermin (Otto et al. 1998). A different 
kind of transporter, encoded by lanH, is involved in both secretion and  immunity in 
gallidermin biosynthesis (Hille et al. 2001). A recent study on the immunity mechanism of 
lacticin 3147 showed that producers of the closely related lantibiotic staphylococcin C55 
displayed cross-immunity to lacticin 3147 (Draper et al. 2009). Functionally equivalent 
LtnI and LtnFE homologues were also produced by Bacillus licheniformis and 
Enterococcus faecum. Although resistance to lantibiotics in food applications has not 
presented any problems despite several decades of use, these observations raise 
concerns that need to be taken into account when lantibiotics are employed for clinical 
application (Draper et al. 2009).  
 
I.4.3. The influence of recent developments in actinomycete research on 
classification of lantipeptides 
 
As is the case for bacteriocin classification, dividing lantibiotics into distinct subclasses is 
the subject of some controversy regarding the classification criteria. Several recent 
studies, mostly in actinomycetes, have identified lanthionine-containing peptides that 
fulfil a physiological role for the producer organism other than antimicrobial activity 
(Kodani et al. 2004; Kodani et al. 2005; Goto et al. 2010). Thus, these compounds are 
related to but not considered to be true ‘lanthionine containing antibiotics’, hence the 
name ‘lantipeptides’ was proposed (Goto et al. 2010). We would like to encourage the 
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use of the term lantipeptide to describe ‘lanthionine containing peptides’ for which it is 
unknown whether they possess antimicrobial activity. This includes situations where 
antibacterial activity has been suspected, but not proven, for example when discussing 
cryptic lantipeptide gene clusters that are identified by genome mining. Once the product 
is isolated and shown to display antibacterial activity, it can then be designated a 
‘lantibiotic’.  
 
A previously suggested classification scheme employed by Pag and Sahl (2002) was 
expanded by Willey and van der Donk (2007) to include the lantipeptides. This scheme 
uses the lanthionine synthetases as the main criterion for classification (Figure I.2.). 
Moreover, it is compatible with a further subclassification proposed by Cotter et al. 
(2005) that groups lantibiotic families according to their structural peptides. The three 
major groups that were proposed encompass the compounds that are modified by 
LanBC enzymes (Class I), LanM enzymes (Class II) and those that are modified by 
lanthionine synthetases that contain a Ser/Thr kinase domain (Class III). No generic 
‘Lan’-name has been designated to the Class III enzymes (RamC, LanL and LabKC) for 
historic reasons and because of the subtle differences between the different biosynthetic 
enzymes, as discussed below.  
 
Class I and II contain the lantibiotics and most compounds in Class III are lantipeptides. 
Class I lantibiotics have a molecular weight ranging from 2164 Da to 3764 Da and either 
carry no net charge or up to seven positive charges. Class II lantibiotics are generally 
smaller than their type A counterparts. They have a compact, globular structure and a 
molecular weight ranging from 1959 Da to 2041 Da and carry no net charge or a net 
negative charge. Both types are strongly amphiphilic, but unlike the flexible Class I 
lantibiotics, the Class II peptides are more conformationally constrained because of 
overlapping bridging patterns. Two-peptide lantibiotics are also included in Class II since 
they are modified by LanM enzymes. No two-peptide lantibiotic produced by an 
actinomycete has been reported to date. Interestingly, both globular and more elongated 
peptides are produced by the Class III type of modification enzyme (Figure I.3.). 
Sequence inspection of several lantibiotic leader peptides has revealed two different 
consensus motifs (Nes and Tagg 1996). Class I lantibiotics contain a ‘FNLD’ motif 
between positions -20 and -15 and usually a Pro residue at position -2. These lantibiotics 
are post-translationally modified by LanB and LanC enzymes. Class II lantibiotics on the 
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other hand, contain a typical ‘GG’ or ‘GA’ cleavage site, several Asp and Glu residues 
and are modified by a LanM enzyme. No conserved sequence motif has yet been 
identified for Class III lantipeptides. 
 
The classification of lantipeptides will further be exemplified in this section with an 
overview of the compounds produced by organisms belonging to the order of the 
Actinomycetales (Figure I.3.). Actinomycetes are Gram-positive bacteria with a high G+C 
content in their DNA. One of the most famous antibacterial, anti-fungal and anti-tumor 
compound producing genera within this order are the streptomycetes, which constitute a 
wide variety of soil-dwelling filamentous bacteria with a complex life cycle. The life cycle 
starts with a spore that germinates to yield an initial filamentous outgrowth that divides 
and branches to give a substrate mycelium. After this, an aerial mycelium is erected that 
will later in the developmental cycle septate to form chains of spores, hence completing 
the life cycle. Other actinomycetes are also well known for their production of secondary 
metabolites and several recent screens were set up aimed at the identification of novel 
compounds from these so-called ‘rare or uncommon actinomycetes’. Actinomycete 
lantipeptides contain a very wide range of post-translational modifications in addition to 
the commonly occurring dehydrated amino acids, (Me)Lan bridges and AviCys, making 
them an interesting object of study for enzymologists. Examples of these are mentioned 
below.  
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Figure I.2. Schematic representation of the different types of lanthionine synthetases. 
Homologous domains are depicted in the same colour. Class I lantibiotics are modified by a LanB 
dehydratase (light blue) and a LanC cyclase (green). The dehydration and cyclisation of Class II 
lantibiotics is performed by the bifunctional LanM enzyme, of which the C-terminal domain is 
homologous to LanC enzymes, but the N-terminal domain (dark blue) does not resemble LanBs. 
Class III enzymes consist of an N-terminal domain with homology to phosphoSer/Thr lyases 
(yellow), a middle domain resembling Ser/Thr kinases (orange) and a C-terminal LanC-like 
cyclase domain that lacks the conserved Zn2+ binding and catalytic residues. The LanC-like 
domain in LanL enzymes does contain these conserved residues.  
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Figure I.3. Schematic representation of lantipeptides produced by actinomycetes. Compounds 
are classified based on the scheme proposed by Willey and van der Donk (2007), for more 
information refer to the text. The colour coding and abbreviations are as in Figure I.1. 
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 I.4.3.a. Class I – LanBC (microbisporicin and planomonosporin) 
 
Microbisporicin (also known as 107891 or NAI-107; Figure I.3.) is the collective name for 
four structurally related lantibiotics produced by Microbispora corallina (Lazzarini et al. 
2005; Castiglione et al. 2008). The compound was identified in a large screen for 
peptidoglycan (PG) biosynthesis inhibitors and is the most potent lantibiotic 
characterised to date. Apart from the low MICs for important Gram-positive pathogens 
such as Staphylococcus aureus, Enterococcus faecalis, Clostridium difficile and 
Propionibacterium acnes, the inhibition spectrum also includes Gram-negative 
pathogens such as Neisseria gonorrhoeae and Moraxella catarrhalis, which is an 
uncommon feature for lantibiotics. Microbisporicin contains two post-translational 
modifications that have not previously been reported in lantibiotics, namely a 5-
chlorotryptophan (Cl-Trp) and mono- or dihydroxylated proline (Castiglione et al. 2008). 
The sequence of the N-terminal eleven amino acids of microbisporicin resembles that of 
nisin, in which it was shown to be required for binding the pyrophosphate moiety of lipid 
II (Breukink et al. 1999; Hasper et al. 2006). Microbisporicin blocks peptidoglycan 
biosynthesis resulting in the accumulation of UDP-linked PG precursors in the cytoplasm 
of Bacillus megaterium (Castiglione et al. 2008). Recently, the microbisporcin 
biosynthetic gene cluster was sequenced and cloned, providing the first representative 
of a Class I gene cluster of actinomycete origin (Foulston and Bibb 2010). Mutational 
analysis identified the product of mibH as the flavin-dependent Trp halogenase that is 
responsible for the introduction of the Cl-Trp residue. The non-chlorinated form of 
microbisporcin could have enhanced activity, judging from the comparison of the zones 
of inhibition against M. luteus of the ∆mibH mutant to the WT. This study also revealed 
that the gene cluster is under regulatory control of a pathway-specific extracytoplasmic 
function σ factor-anti-σ factor complex (MibX-MibW). The mechanism for self-immunity is 
likely through MibEF-mediated extrusion from the cell membrane, since deletion of 
mibEF resulted in greatly reduced microbisporicin export, possibly reflecting reduced 
gene expression (Foulston and Bibb 2010). 
 
Planosporicin (also known as 97518; Figure I.3.) was previously classified as a globular 
Class II mersacidin-like lantibiotic, based on its initial structural determination 
(Castiglione et al. 2007). However, more recent chemical data led to a structure revision 
involving a rearrangement two (Me)Lan bridges and a shift of the two C-terminal amino 
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acids to positions nine and ten in the new structure. This data is backed up by the 
determination of the structural gene sequence by genome scanning (Maffioli et al. 2009). 
Like microbisporicin, planosporicin exerts its mechanism of action by blocking PG 
biosynthesis (Castiglione et al. 2007). 
 
I.4.3.b. Class II – LanM (cinnamycin and the duramycins, actagardine and michiganin A) 
 
No two-peptide lantipeptide of actinomycete origin has been characterised to date. The 
best characterised two-peptide lantibiotic is lacticin 3147 (Ryan et al. 1996; Ryan et al. 
1999; Martin et al. 2004; Cotter et al. 2006; Field et al. 2007), but several others have 
been identified, including staphylococcin C55 (Navaratna et al. 1998; Navaratna et al. 
1999), plantaricin W (Holo et al. 2001), haloduracin (McClerren et al. 2006; Lawton et al. 
2007; Cooper et al. 2008), lichenicidin (Begley et al. 2009) and pneumococcin 
(Majchrzykiewicz et al. 2010). Two-peptide lantibiotics have been the subject of recent 
review (Breukink 2006; Lawton et al. 2007). 
  
Cinnamycin (formerly also known as Ro 09-0198 and lanthiopeptin; Figure I.3.) is 
produced by several Streptomyces strains, including Streptomyces cinnamoneus and 
contains unusual amino acid modifications not commonly found in other lantibiotics, 
namely β-hydroxy aspartate and a lysino-alanine bridge. Another interesting feature of 
cinnamycin is its mode of action, which is proposed to be exerted via binding of 
phosphatidylethanolamine (PE) (Hosoda et al. 1996; Machaidze et al. 2002). Binding 
requires the PE headgroup and at least one fatty acyl chain; the latter needs to have a 
chain length of eight carbons or larger for optimal binding (Machaidze and Seelig 2003). 
Apart from their antimicrobial activity, cinnamycin and the structurally related duramycins 
have several other properties that are of potential pharmaceutical interest. The 
compounds can act as an inhibitor for phospholipase A2 (Fredenhagen et al. 1990), 
angiotensin-converting enzyme (Kido et al. 1983) and prostaglandin and leukotriene 
biosynthesis. Inhibition of Herpes simplex virus (HSV-1) has also been reported (Naruse 
et al. 1989). Duramycin (Moli1901) is currently in phase II clinical trials for cystic fibrosis 
treatment (Grasemann et al. 2007). cinA was the first class II structural gene to be 
characterised and this revealed that the propeptide is preceded by a leader sequence of 
58 amino acid residues, which was longer than the class I leaders known at that time 
(Kaletta et al. 1991). This study also established that the lysino-alanine bridge is formed 
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from Lys and Ser (Dha) precursors in the propeptide. The cinnamycin gene cluster was 
the first lantipeptide gene cluster from a high G+C bacterium to be characterised 
(Widdick et al. 2003). This gene cluster was unusual since it contained several genes 
generally not found in lantibiotic clusters, including one that encodes a Streptomyces 
antibiotic regulatory protein (SARP). The ABC-transporter encoded by cinT and cinH is 
thought to be involved in resistance and/or secretion. A dedicated LanP protease 
appears to be missing, implying the requirement for a different activation mechanism. 
Closer inspection of the cinnamycin leader peptide cleavage site reveals the AXA motif, 
which might function as a recognition site for Type I signal peptidases involved in Sec-
mediated secretion. The cinM gene contains the rare streptomycetes TTA codon, which 
relies on the bldA encoded Leu-tRNA for translation in S. coelicolor (Leskiw et al. 1991). 
Widdick et al. (2003) constructed expression cassettes for the cinnamycin cluster and 
succeeded in utilising the cinnamycin machinery to produce duramycins A and B (each 
differing from cinnamycin by only one amino acid residue). Production of the more 
distantly related duramycin C (obtained from the primary structure of cinnamycin by 
altering six amino acids) was subsequently demonstrated (J. Cortes, personal 
communication). These results illustrate the relaxed substrate specificity of the 
modification machinery and are encouraging for lantibiotic engineering. 
 
Actagardine A (formerly known as gardimycin; Figure I.3.) was identified from the 
fermentation broth of Actinoplanes garbadinensis ATCC 31049 (Parenti et al. 1976). The 
compound was shown to inhibit peptidoglycan biosynthesis (Somma et al. 1977) and its 
mechanism of action later attributed to lipid II binding, thereby blocking 
transglycosylation in susceptible bacteria (Héchard and Sahl 2002). The structure of 
actagardine A was determined by NMR and showed the presence of one Lan and three 
MeLan ring structures that impose a compact, globular structure on the compound 
(Zimmermann and Jung 1997). The C-terminal MeLan ring in actagardine A is oxidised 
to a sulfoxide. Ala(0)-actagardine A, a variant of actagardine A with an additional N-
terminal Ala was identified and shown to have a slightly enhanced antibacterial activity 
(Vértesy et al. 1999). The gene cluster was recently cloned and a variant generation 
system was developed that allowed for alanine scanning of the compound (Boakes et al. 
2009). Deletion of the monooxygenase garO from A. garbadinensis resulted in a strain 
that only produced unoxidised actagardine A, indicating that introduction of the sulfoxide 
is catalysed by GarO (Boakes et al. 2009). The gene cluster of a natural variant, 
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deoxyactagardine B (DAB), was reported from Actinoplanes liguriae NCIMB41362 
(Boakes et al. 2010). Deoxyactagardine B lacks the sulfoxide present in actagardine A 
and differs in two amino acids. A monooxygenase with significant homology to garO was 
identified in the gene cluster and expression of the structural gene ligA in A. 
garbadinensis ∆garA resulted in production of the oxidised form of DAB (Boakes et al. 
2010). This suggests that the LigO monooxygenase is inactive or not expressed rather 
than lack of oxidation because of the two amino acid substitutions at positions 15 and 
16. The mechanism of self-immunity in the actagardine A and DAB producers is 
unknown, but a penicillin-binding protein and a putative transporter have been proposed 
for this function for actagardine A and DAB, respectively (Boakes et al. 2009; Boakes et 
al. 2010). It is noteworthy that these putative immunity systems are different in the two 
strains, indicating that neither may be involved in self-protection and that a separate 
immunity mechanism may exist. It is unclear why actagardine A is oxidised on ring D, 
since a recent study related the oxidation of Lan in nisin with greatly reduced 
antibacterial activity (Wilson-Stanford et al. 2009). The authors proposed that oxidised 
nisin lost its activity due to its inability to bind lipid II. The study did not address the effect 
of one Lan oxidation as nisin always had seven, eight or nine oxidations and contains 
only five bridges. Whether the loss in activity was primarily due to Lan oxidation or the 
result of additional Met or His oxidations is unknown. In contrast, the antibacterial activity 
of actagardine A is slightly higher than that of the non-oxidised compound produced by 
the ∆garO strain of A. garbadinensis, implying a role for the sulfoxide in activity or 
stability. 
 
Michiganin A is produced by the tomato pathogen Clavibacter michiganensis and its 
structure is related to actagardine A (Holtsmark et al. 2006). Michiganin A is longer by 
two residues (an N-terminal Ser and a C-terminal Arg) and has two amino acid 
substitutions (Leu5Val and Ile15Val) compared to actagardine. Interestingly, the first 
three amino acids of the propeptide are all Ser, but only the second one becomes 
dehydrated and is involved in formation of the A ring (Holtsmark et al. 2006). 
Actagardine A also contains a Ser that escaped dehydration C-terminal of the one 
involved in Lan ring formation. The bridging pattern for michiganin A was assigned 
based on the structure of actagardine A. Remarkably, the Edman degradation data 
indicated that the Dhb residue at position eight in the michiganin A propeptide is not 
involved in (Me)Lan bridge formation, leaving a free sulfhydryl group on one Cys 
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(Holtsmark et al. 2006). The β peptide of the two-peptide lantibiotic plantaricin W is the 
only other example of a lantibiotic with a free Cys residue described to date (Holo et al. 
2001). 
 
I.4.3.c. Class III – Lanthionine synthetases containing a Ser/Thr kinase domain  
 
This class was first proposed by Willey and van der Donk (2007). Despite the 
bioinformatic identification of putative Class III gene clusters in other bacterial phyla 
(Goto et al. 2010), all lantipeptides characterised to date are from actinomycete origin. 
These gene clusters are of minimal composition, in most cases just consisting of a 
structural gene, a lanthionine synthetase gene, (two) transporter genes and, in the case 
of the morphogens, a transcriptional regulatory gene. The simplicity of these gene 
clusters is reflected by the fact that none of the resulting compounds contain additional 
post-translational enzymatic modifications, just the expected dehydrated Ser/Thr or 
(Me)Lan bridges. The introduction of the unusual modified amino acid labionin in the 
labyrinthopeptins does not require additional enzyme activity. Further division into three 
subclasses is presented here because some enzymes contain the typical catalytic and 
Zn-binding residues in their cyclase domain and others introduce labionin in their 
associated structural peptides. In general, the lantipeptides belonging to Class III appear 
to have a function distinct from antibacterial activity. 
 
SapB (Figure I.3.) was previously known as a small peptide involved in morphological 
differentiation of S. coelicolor into an aerial mycelium (Willey et al. 1991). Its working 
mechanism is that of a surfactant, which allows the hyphae to escape from the aqueous 
environment of the colony surface (Tillotson et al. 1998). Among the genes known to be 
involved in morphological developmental are the bld genes (with mutants unable to form 
an aerial mycelium) and the ram genes (mutant forms of which confer rapid aerial 
mycelium formation in S. lividans) (Ma and Kendall 1994; Kelemen and Buttner 1998; 
O'Connor et al. 2002). Kodani et al. (2004) discovered that SapB is produced as a post-
translationally modified product of the prepropeptide encoded by ramS, which lies in the 
ramCSAB-operon. Although the C-terminus of RamC has some sequence similarity to 
the C-terminal domain of CinM and MrsM, the protein has a unique structure which is not 
found in any other lantibiotic modification enzymes. The N-terminus of RamC exhibits 
similarity to catalytic domains of Ser/Thr kinases, a feature that is not found in  LanM-like 
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or LanB-like enzymes. This domain is thought to be involved in phosphorylation of the 
hydroxyl moiety (which is a poor leaving group) in the Ser residues, thus facilitating 
dehydration. Interestingly, whereas four of the five Ser residues in RamS are 
dehydrated, none of the three Thr residues are (Kodani et al. 2004). This is a remarkable 
feature since Ser residues in lantibiotics are more likely to escape dehydration than Thr 
(Rink et al. 2005). The C-terminal domain is predicted to catalyse subsequent Lan bridge 
formation, despite the lack of the zinc binding and catalytic residues present in LanC-like 
domains (Li et al. 2006). RamA and RamB are components of an ABC-transporter which 
are proposed to be involved in export of SapB (Kodani et al. 2004). The product of the 
convergently transcribed ramR is a response regulator that binds the ramC promoter, 
inducing transcription of the ramCSAB operon (Keijser et al. 2002; O'Connor et al. 
2002). The identification of SapB as a lantipeptide was the first report of such a 
compound involved in a structural function rather than exhibiting antibiotic activity. 
 
A more recent study in Streptomyces tendae revealed another morphogenetic 
lantipeptide, SapT (Figure I.3.), which is able to restore formation of aerial hyphae in 
developmentally impaired S. coelicolor mutants (Kodani et al. 2005). Interestingly, the 
three Thr in SapT are involved in MeLan formation, whereas in SapB all three Thr 
residues escaped dehydration. Modelling of the SapT structure based on SapB predicts 
a similar amphiphilic nature, indicating this peptide also serves as a biosurfactant. The 
primary structure of both peptides is quite different, but their function appears to be 
conserved. The characterisation of a second distinct morphogen illustrates the broad 
diversity present in the world of lanthionine-containing peptides. These morphogens 
appear to be quite common among streptomycetes, as all genome sequences currently 
available contain at least one gene cluster likely to encode a Sap-like peptide. AmfS, the 
SapB counterpart in S. griseus, has been the subject of several studies but still awaits 
structural characterisation (Ueda et al. 2002; Ueda et al. 2005). Morphogenic peptides 
that do not contain labionin residues are proposed to constitute Subclass III.1.  
 
Venezuelin (Figure I.3.) was produced biochemically in an in vitro reaction with purified 
VenL synthetase and VenA prepropeptide, hereby uncovering a novel biosynthetic route 
to generate lantipeptides (Goto et al. 2010). VenL, the first characterised LanL-type 
lantipeptide synthetase, was identified bioinformatically in an S. venezuelae cryptic gene 
cluster. LanL enzymes contain three distinct catalytic domains, an N-terminal 
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phosphoSer/Thr lyase, a Ser/Thr kinase and a C-terminal LanC-like cyclase domain that 
contains a characteristic zinc-binding site and active-site residues. The activity of the 
three domains was dissected by individual expression and this revealed that Ser/Thr 
residues are first phosporylated by the kinase domain, followed by an elimination 
catalysed by the lyase domain, which results in Dha and Dhb residues. Subsequent 
addition of the Cys thiols onto these dehydrated residues is performed by the cyclase 
domain, yielding (Me)Lan bridges. The ‘artificially’ constructed VenL-∆C is the first 
example of an in vitro reconstituted peptide dehydratase, since before then only 
bifunctional lantipeptide synthetases had been reconstituted in vitro (Goto et al. 2010). 
The venezuelin ring topology was determined by site-directed mutagenisis of individual 
Cys residues and venezuelin’s structure most closely resembles cinnamycin. Since the 
cyclase domain of LanL enzymes is different from the other Class III enzymes, they are 
classified in a separate Subclass III.2. 
 
The labyrinthopeptins (Figure I.3.) were identified recently as a product of Actinomadura 
namibiensis (Meindl et al. 2010). Labyrinthopeptin A2 has activity against Herpes 
simplex and displayed potent activity in an in vivo mouse model system for neuropathic 
pain. The structure of labyrinthopeptin A2 was determined by X-ray crystallography and 
revealed a novel type of bridge structure, (2S,4S,8R)-labionin (Lab). This carbacyclic 
triamino acid residue results from the post-translational modification of two Ser and a 
Cys by the Class III kinase-cyclase LabKC. Labyrinthopeptin A2 has a globular structure 
and contains two Cys residues that are not involved in Lab-formation, but instead form a 
disulfide bond (Meindl et al. 2010). The activity of LabKC has been reconstituted in vitro 
and a model was proposed for Lab formation (Müller et al. 2010). LabKC was shown to 
require guanosine triphosphate (GTP) for Ser phosphorylation and dehydration. In other 
in vitro lantipeptide biosynthesis reconstitutions ATP has been used as phosphate 
donor, even with the closely related VenL (Xie et al. 2004; McClerren et al. 2006; Goto et 
al. 2010). This difference in nucleotide requirement and the occurance of Lab residues in 
the peptide products likely reflects currently unidentified differences in the LabKC 
biosynthetic enzyme compared to RamC and AmfT, justifying classification of the 
labyrinthopeptins in a distinct Subclass III.3. The laybrinthopeptin biosynthetic gene 
cluster closely resembles the SapB and venezuelin gene clusters, but no ramR 
homologue is present downstream of the two putative transport genes. Two structural 
genes are present, the first of which encodes LabA1/A3 and the other LabA2 (Meindl et 
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al. 2010). The presence of Lab (and the disulfide bridge) makes these compounds 
unique within Class III, for which no additional post-translational modifications have been 
described to date apart from the common Dha/Dhb and (Me)Lan residues. 
 
I.4.4. Mechanisms of action 
 
Lantibiotics generally exhibit activity against Gram-positive bacteria, whereas Gram- 
negative bacteria are only affected when their outer membrane is disturbed (Kordel et al. 
1988), for example by chelating agents such as EDTA. A great variety has been 
described in the range of susceptible organisms for different lantibiotics. Nisin displays a 
broad activity and even has an inhibitory effect on germination of Bacillus and 
Clostridium spores. In contrast, other lantibiotics only show a narrow inhibition spectrum 
(e.g. salivaricin A). Most Class I lantibiotics exert their activity by pore formation in the 
cytoplasmic membrane. For example, nisin binds lipid II with high affinity, and formation 
of pores consisting of eight nisin molecules and four lipid II molecules has been 
demonstrated by pyrene fluorescence (Breukink et al. 1999; Hasper et al. 2004). On the 
other hand, Class II lantibiotics act as inhibitors of different enzyme functions, most of 
which are involved in cell wall biosynthesis. 
 
The pore forming activity of Class I lantibiotics causes rapid leakage of ions, cytoplasmic 
solutes, amino acids and nucleotides from the cytoplasm. Moreover, this efflux causes a 
depolarisation of the cell membrane, resulting in an instant termination of all biosynthetic 
processes (Sahl et al. 1987). Studies with artificial membranes indicated that Class I 
lantibiotics adopt a helical amphiphilic conformation with their charged residues on one 
side and their hydrophobic residues on the other side of the helix. The hydrophobic face 
interacts with the phospholipid head groups of the cell membrane and causes a local 
disruption in the bilayer structure. Lipid II functions as a docking molecule for specific 
binding, making the process energetically more favourable. At the same time, the 
hydrophobic residues insert in the hydrophobic core of the membrane, forming small 
pores and thus achieving leakage of small cellular compounds (Breukink et al. 2003). 
Nisin was shown to be a dual-function antibiotic with two killing mechanisms: preventing 
lipid II incorporation in the peptidoglycan and simultaneously using lipid II for targeted 
pore formation (Hasper et al. 2006).  
 
I – Post-translationally modified bacterial peptides 
 
 
29 
Two different mechanisms of action have been described for Class II lantibiotics, 
involving enzyme inhibition. A first mechanism is characteristic of mersacidin and 
actagardine. These lantibiotics cause a block in the transglycosylation step of cell wall 
biosynthesis, resulting in a growth defect and the onset of cell lysis. Other fundamental 
cellular biosynthetic processes (DNA, RNA and protein biosynthesis) remain unharmed 
(Brötz et al. 1997).  
 
A group of Class II lantibiotics, containing cinnamycin, the duramycins and ancovenin, 
exerts antimicrobial activity against relatively few bacterial strains. Susceptible strains 
showed increased membrane permeability and reduced ATP-dependent calcium uptake 
and protein transport (Sheth et al. 1992). Cinnamycin has been shown to cause lysis of 
red blood cells and duramycin is involved in inhibition of phospholipase A2, which is 
involved in the synthesis of prostaglandins and leukotrienes. Both of these lantibiotics 
have been demonstrated to interact with phosphatidylethanolamine (Choung et al. 
1988).  
 
The two-peptide lantibiotics form a distinct subgroup of Class II lantibiotics. Members of 
this group consist of two different lantibiotic peptides that display synergistic antibacterial 
modes of action. Among the two-peptide lantibiotics characterised to date, lacticin 3147 
is the best studied. Moreover, the structure of both peptides was the first to be 
elucidated by using the sodium borodeuteride derivatisation process described by Martin 
et al. (2004). The lacticin 3147 gene cluster contains two distinct lanM genes, encoding 
for LtnM1 and LtnM2. These two genes were independently disrupted demonstrating 
that each prepropeptide (LtnA1 or LtnA2) required a dedicated LtnM gene for 
modification (McAuliffe et al. 2000). The mode of action for lacticin 3147 is similar to that 
for Class I lantibiotics, however in the two-peptide lantibiotic, each of the two 
components possesses a single functionality. The Ltnα peptide is involved in targeting of 
Lipid II and upon interaction, a binding site for the Ltnβ peptide is generated. 
Subsequently, the Ltnβ peptide binds and initiates pore formation in the cytoplasmic 
membrane. Thus the two peptides operate synergistically to produce a more efficient 
killing mechanism than the greatly reduced activity of Ltnα and complete lack of activity 
of Ltnβ when used alone (Wiedemann et al. 2006). The Ltnα peptide of lacticin 3147 
shares a conserved region with certain Lipid II-interacting Class II lantibiotics. Breukink 
I – Post-translationally modified bacterial peptides 
 
 
30 
(2006) hypothesised that this region might be responsible for the Lipid II interaction. 
Other two-peptide lantibiotics are expected to work in a similar way to lacticin 3147. 
 
I.4.5. Engineering lantipeptides 
 
Lantibiotics are ideal candidates for engineering of variants because of their peptidic 
nature and their ribosomal origin. This is exemplified by many successful studies aimed 
at improving antibacterial activity or pharmaceutical properties and understanding the 
structure-activity relationships of these compounds. Changes in residues that are 
involved in (Me)Lan formation have mostly led to either a reduction in or complete loss of 
activity of the respective lantibiotic (Ottenwalder et al. 1995; Bierbaum et al. 1996; Cotter 
et al. 2006; Cooper et al. 2008), while some other residues are more tolerant to 
variation. Several reviews have been published recently that adress this emerging topic 
in lantibiotic research (Bierbaum and Sahl 2009; Cortés et al. 2009).  
 
Generation of lantibiotic variants was pioneered in the early nineties by several groups. 
A site-directed mutagenesis technique was used to generate a series of variant nisA 
genes that were subsequently expressed using a lactococcal expression system in a 
∆nisA host strain (Dodd et al. 1992). Kuipers et al. (1992) developed a system that 
allowed for expression of PCR-mutagenised nisZ variants in a nisin A producing host 
strain. A Glu4Ile variant of subtilin was shown to stabilise degradation of the 
neighbouring Dha5 57-fold, resulting in a lantibiotic with prolonged activity (Liu and 
Hansen 1992). Chimeras of nisin and subtilin have been successfully generated, using 
the biosynthetic machinery of either of these two lantibiotics (Kuipers et al. 1993; 
Chakicherla and Hansen 1995). An expression system was also constructed for Pep5 
and two variants were generated, one of which was produced at wild type levels, but the 
other only in low quantities, indicating that not all amino acids in the propeptide are 
equally amenable to modification (Bierbaum et al. 1994). An expression system was 
developed to generate epidermin and gallidermin variants and applied to study the effect 
of a change in key amino acid residues on production, activity and stability (Ottenwalder 
et al. 1995). A Leu6Val variant exhibited enhanced antimicrobial activity and two others 
(Ala12Leu and Dhb14Pro) proved to be more resistant to proteolytic degradation. 
Interestingly, the authors noted a strong decrease in production when the Ser residues, 
involved in Lan formation, were replaced by Thr.  
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Several systems have been described that are employed to produce structurally related 
lantibiotics. The cinnamycin biosynthetic gene cluster has been heterologously 
expressed in S. lividans and this system has been used to generate the related 
duramycin and duramycin B compounds (Widdick et al. 2003). The lacticin 481 
synthetase was shown to be capable of producing related lantibiotics, including 
ruminococcin A, nukacin ISK-1 and mutacin II (Patton et al. 2008). 
 
The complete Ala scanning of the two-peptide lantibiotic lacticin 3147 was the first 
thorough systematic mutational analysis of a lantipeptide (Cotter et al. 2006). This study 
identified residue locations essential for efficient production, but also 36 out of 59 amino 
acids were found to be more amenable to change, as their replacement by Ala did not 
result in a complete loss of activity. An additional two-plasmid system was generated 
that allowed construction of a 1500-member random mutagenesis mutant lacticin 3147 
library (Field et al. 2007). A similar approach was successfully applied to generate nisin 
variants with elevated antimicrobial activity against specific pathogens (Field et al. 2008). 
 
A system for mersacidin engineering was constructed and led to the identification of two 
key residues in the peptide (Szekat et al. 2003). A more recent study described a 
thorough saturation mutagenesis approach that resulted in a 228 mrsA mutant library in 
which all amino acid residues that are not involved in (Me)Lan formation were replaced 
by the other proteogenic amino acids (Appleyard et al. 2009). About 35 % of the 
engineered variants were produced in good yield, resulting in 82 new compounds, most 
of which were either inactive or displayed a reduced antibacterial activity. However, 
several compounds had increased activity against specific Gram-positive pathogens, 
illustrating the potential for this approach to enhance lantibiotic activity. 
 
A heterologous expression system was developed for the nukacin ISK-1 biosynthetic 
gene cluster under the control of the nisin-inducible promoter PnisA (Nagao et al. 2007). 
This study also described a new method for the introduction of post-translational 
modifications into 6His-tagged NukA via co-expression with NukM in E. coli. 
 
A variant generation system has also been engineered for actagardine A and was used 
to do alanine scanning of the residues not involved in (Me)Lan formation (Boakes et al. 
2009). Five variants were produced by A. garbadinensis (out of ten constructs) and two 
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of these retained some antibacterial activity. The B ring of the compound proved to be 
least suited for Ala replacement since none of these variants were produced. This result 
is in agreement with data from the Ala scanning experiment in the analogous region of 
lacticin 3147 (Cotter et al. 2006). 
 
Although it cannot be considered ‘lantibiotic engineering’ per se, the use of lantibiotic-
derived post-translational modifications to stabilise peptide pharmaceuticals illustrates 
another application of fundamental research on lantibiotic biosynthesis. These 
applications are enabled by the relatively broad substrate specificity of lantibiotic 
modification enzymes. Rink et al. (2005) performed a bioinformatic study on 37 
lantibiotics, from which they distilled guidelines for lanA engineering. One important 
conclusion of this study was that hydrophobic neighbouring amino acids promote 
dehydration of Ser and Thr. This analysis also showed that Ser was more likely to 
escape dehydration than Thr. However, the analysis has to be approached with caution, 
since it does not distinguish between the different lantibiotic classes and the guidelines 
might vary with the substrate specificity of the respective modification enzymes 
(Appleyard et al. 2009). An engineered L. lactis strain containing nisBCT was used to 
dehydrate, cyclise and export several non-lantibiotic peptides of medical significance 
(Kluskens et al. 2005). The lacticin 481 synthase LctM was used to install dehydrated 
residues and ring structures into peptides in vitro (Chatterjee et al. 2006). An expression 
system was developed that utilised the L. lactis nisin biosynthetic machinery for 
production of a Luteinizing-Hormone-Release-Hormone (LHRH) analog containing a Lan 
bridge between residues four and seven (Rink et al. 2010). This modification conferred 
superior protease resistance on the LHRH analog and was compatible with subsequent 
in vitro derivatisation. 
 
I.4.6. Genome mining to identify lantipeptide compounds 
 
The recent surge in publicly available bacterial genome sequences has led to the 
identification of several cryptic gene clusters that potentially encode for interesting 
compounds. Several research groups have embraced the idea of lantipeptide genome 
mining, resulting in the identification of various compounds that would not necessarily 
have been found in an activity-based screening approach. A cryptic lantipeptide cluster 
can be of particular interest because the product may be related to potent known 
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compounds, because of a predicted novel lantipeptide scaffold, or even because the 
cluster is predicted to encode a novel biochemical mechanism of post-translational 
modification. Various high throughput tools will be required that will help to cope with the 
increasing amounts of bacterial genome data, but current techniques are already very 
promising. Lantibiotic detection by MALDI-ToF MS on whole cell samples can make 
compound screens more efficient since less handling is required (Hindré et al. 2003). 
Bioinformatic mining of genomic data for gene clusters involved in production of 
lantipeptides and non-modified bacteriocins can be performed with the BAGEL2 
software (de Jong et al. 2010). This section describes both biochemical and molecular 
genetic approaches aimed at the identification of a product from cryptic lantipeptide gene 
clusters. 
 
I.4.6.a. Biochemical approaches to genome mining 
 
One of the first successful genome mining attempts was the identification of the two-
peptide lantibiotic haloduracin from a cryptic cluster found in Bacillus halodurans 
(McClerren et al. 2006). Both LanM enzymes were purified from a heterologous E. coli 
host and shown to modify the purified HalA1 and HalA2 precursor peptides in vitro. A 
structure was proposed for the resulting modified peptides and they were shown to 
display antimicrobial activity when both of them were used together, a common feature 
of two-peptide lantibiotics. A further structure-activity relationship study identified the 
Halα B ring as expendable and that the Halα cystine is not required for activity, but 
protects the peptide against proteolytic degradation (Cooper et al. 2008). Two Ser 
residues were shown to escape dehydration, requiring the previous structure to be 
revised. In vivo production of haloduracin was also shown by purification from a B. 
halodurans fermentation and by mutational analysis (Lawton et al. 2007).  
 
A similar biochemical approach was taken for a cryptic gene cluster in S. venezuelae, 
which led to the identification of venezuelin (Goto et al. 2010). This case provides an 
example of a gene cluster that was of interest because of the unusual modification 
enzyme VenL. Venezuelin does not appear to have antibacterial activity and in vivo 
production has not yet been demonstrated. The genetic analysis of venezuelin 
production is a subject of this thesis and is discussed in more detail in Chapter VII. 
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A bioinformatic search designed to find examples of bacteria that can produce multiple 
lantipeptides with the same LanM enzyme identified several clusters in marine 
planktonic cyanobacteria (Li et al. 2010). The genome of Prochlorococcus MIT9313 
contains only one lanM homologue, but seven putative lanA genes in this cluster along 
with 22 additional lanA genes elsewhere in the genome. The prepropeptides display a 
remarkably high sequence identity in the leader region, but their propeptides (ranging 
from 13 to 32 amino acids in length) have very diverse sequences. An in vitro 
dehydration and cyclisation assay with purified ProcM and seventeen ProcA precursors 
showed that this enzyme was capable of efficient modification of this wide variety of 
substrates. Several of these, collectively called ‘prochlorosins’, were shown to be 
produced by Prochlorococcus MIT9313 in vivo (Li et al. 2010). This is a very nice 
example of how an organism uses a relatively simple biochemical system to generate a 
broad diversity of secondary metabolites. 
 
I.4.6.b. Molecular genetic approaches to genome mining 
 
The genome sequences of clinical isolates of S. aureus revealed the presence of a 
cryptic lantipeptide gene cluster (Daly et al. 2010). Reverse genetics and a mutational 
analysis of this cluster were performed to produce the Bsa (for bacteriocin of S. aureus) 
lantibiotic, which turned out to be identical to the previously identified, but not structurally 
characterised, bacteriocin staphylococcin Au-26 (Scott et al. 1992). Bsa is structurally 
related to gallidermin, but its immunity genes do not contribute significantly to gallidermin 
immunity. 
 
An in silico screening strategy of the public databases identified 89 LanM homologs, 
including 61 in strains that were known as lantibiotic producers. A cryptic gene cluster in 
Bacillus licheniformis was shown to produce a two-peptide lantibiotic, lichenicidin, which 
exhibits antimicrobial activity against important pathogens such as MRSA, VRE and 
Listeria monocytogenes (Begley et al. 2009). Insertion inactivation mutants were 
generated for the two lanM genes, linking them to the production of lichenicidin 
(Dischinger et al. 2009). A lichenicidin cluster with identical structural genes was 
identified in a different B. licheniformis strain and the structure of both the Lchα and Lchβ 
peptides were determined by NMR (Shenkarev et al. 2010). 
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An elegant system was devised that employed the nisin biosynthetic machinery to 
produce the previously uncharacterised two-peptide lantibiotic pneumococcin 
(Majchrzykiewicz et al. 2010). This demonstrated that the Class I nisin biosynthetic 
machinery was capable of post-translational modification of Class II propeptides when 
fused to the nisin leader sequence. Although this was a very nice proof of principle, it 
was also rather adventurous, since the use of the original or more closely related 
biosynthetic machinery intuitively seems to have a greater chance of success for correct 
production of cryptic lantipeptides. Indeed, several versions of both peptides were 
detected, each with different number of dehydrated residues (Majchrzykiewicz et al. 
2010). This could be indicative of inefficient modification, which in turn could have 
implications for correct (Me)Lan formation. The two modified pneumococcin peptides 
displayed antibacterial activity against Micrococcus flavus, but they were not found to act 
synergistically, as commonly observed for two-peptide lantibiotics. Another issue is the 
introduction of modifications that do not naturally occur in nisin, such as AviCys for 
example. 
 
I.5. Microcins 
 
Microcins are a class of low-molecular weight (< 10 kDa) ribosomal peptides produced 
by enterobacteria to kill off closely related competitors. Some microcins are unmodified 
and will not be discussed here. Others contain extensive post-translational modifications, 
resulting in a wide variety of structures (Figure I.1.). 
 
I.5.1. Microcin B17 contains thiazole and oxazole heterocycles 
 
Microcin B17 (MccB17; Figure I.1.) is a DNA gyrase inhibitor produced by E. coli strains 
that contain the pMccB17 plasmid (Baquero et al. 1978; Yorgey et al. 1994). The first 
four coding sequences in the seven gene MccB17 biosynthetic operon, mcbABCD, were 
identified as essential for biosynthesis (Genilloud et al. 1989), whereas mcbEFG are 
required for export and immunity (Garrido et al. 1988). The peptide is post-translationally 
modified by heterocyclisation of Gly, Ser and Cys residues, resulting in the formation of 
four thiazole and four oxazole moieties. Its biosynthesis was reconstituted in vitro by 
purification of the McbBCD synthetase and incubation with McbA precursor peptides, 
providing the first example of a biochemically produced modified peptide (Li et al. 1996). 
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The purified synthetase requires ATP or GTP for activity and purification of the individual 
subunits identified the cofactor requirements and putative functions of each enzyme 
(Milne et al. 1998; Milne et al. 1999). The cyclodehydratase McbB is a Zn-containing 
protein that catalyses the initial attack of a Ser or Cys side chain onto the upstream 
amide carbonyl in the peptide chain. Loss of a water molecule results in formation of 
thiazoline and oxazoline rings, which are desaturated by the FMN-containing protein 
McbC. McbD is an ATPase/GTPase that is proposed to act as a conformational switch. 
The combination of all three subunits was required for in vitro heterocyclisation. 
 
I.5.2. Lasso peptides 
 
Microcin J25 (MccJ25; Figure I.1.) is a 21 amino acid peptide that is produced by E. coli 
strains containing pTUC100 (Salomon and Farias 1992). Its structural gene, mcjA, 
encodes a 58 amino acid precursor with an N-terminal leader sequence (Solbiati et al. 
1999) and a C-terminal propeptide that becomes modified into a structure resembling a 
knot or ‘lasso’ (Bayro et al. 2003; Wilson et al. 2003). A loop is formed by linkage of the 
carboxylate side chain of Glu8 with the N-terminal Gly1 amino group. The C-terminal tail 
of the peptide is threaded through this ring structure and kept tightly into place by the 
side chains of Phe19 and Tyr20. The activity of McjB and McjC, which are both required 
for MccJ25 maturation, has recently been reconstituted in vitro (Duquesne et al. 2007). 
McjC is an ATP/Mg2+ -dependent enzyme that shares homology with class B asparagine 
synthetases and β-lactam synthetases, suggesting that it likely introduces the amide 
bond resulting in formation of the loop. McjB is homologous to transglutaminases and is 
proposed to possess the proteolytic activity for leader cleavage. MccJ25 exerts its 
antibacterial activity through inhibition of RNA polymerase and stimulation of reactive 
oxygen species production (Bellomio et al. 2007). Truncation of the 36 amino acid 
MccJ25 leader sequence revealed that a residual sequence of eight was sufficient to 
process the peptide, albeit at very low efficiency (Cheung et al. 2010). Deletion of the 
first 16 residues only led to a five-fold reduced production.  
 
Several members of the lasso peptide family have also been identified in actinobacteria 
belonging to the genera Streptomyces, Rhodococcus and Microbispora. MccJ25 and 
lariatins A and B are the only lasso peptides with antibacterial activity (Iwatsuki et al. 
2006), but different biological functions have been described for other members. For 
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example, anatin acts as an atrial natriuretic factor antagonist (Weber et al. 1991), RES-
701s is an endothelin receptor antagonist (Morishita et al. 1994) and propeptin inhibits 
prolyl endopeptidase activity (Kimura et al. 1997). 
 
I.5.3. Siderophore-peptides, a marriage between the ribosomal and non-
ribosomal worlds 
 
Microcin E492 (MccE492; Figure I.1.) was first characterised as an unmodified 84 
amino-acid (7886 Da) peptide produced by Klebsiella pneumoniae (de Lorenzo 1984). 
However, identification of the biosynthetic gene cluster unveiled several additional 
biosynthetic genes that encode for products with homology to glycosyltransferases, 
acyltransferases, enterobactin esterases (Lagos et al. 2001).  Inactivation of these 
biosynthetic genes resulted in the apparent loss of MccE492 antibacterial activity, but 
the compound’s primary structure appeared to remain unaltered (Corsini et al. 2002). 
Thomas et al. (2004) described the isolation and characterisation of the fully modified 
form of MccE492 (MccE492m; 8717 Da) that had a four- to eight-fold increased 
antibacterial activity compared to MccE492, explaining previous observations. The post-
translational modification was localised at the C-terminus and its structure determined by 
MS and NMR. It consists of a C-glycosylated linear derivative of the siderophore 
enterobactin that is attached to the carboxyl of the C-terminal Ser84 by an ester linkage. 
Because of this post-translational modification, the name siderophore-peptides was 
proposed for this novel family of antibacterial peptides (Thomas et al. 2004). MccE492m 
targets the iron uptake systems of enterobacteria and its mechanism of action involves 
pore formation, inner membrane depolarisation and eventually cell death (Destoumieux-
Garzon et al. 2003; Strahsburger et al. 2005; Destoumieux-Garzon et al. 2006). The two-
protein complex MceIJ was recently shown to be responsible for the post-translational 
modification of MccE492m by ATP and Mg2+ -dependent formation of the glycosyl ester 
linkage that connects the ribosomal and non-ribosomal peptide moieties (Nolan et al. 
2007; Nolan and Walsh 2008). Several other microcins are predicted to (or have been 
proven to) consist of a ribosomal and a non-ribosomal part, including H47, I47 and M 
(Duquesne et al. 2007; Vassiliadis et al. 2010). 
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I.5.4. Microcin C7 
 
Microcin C7 (MccC7; Figure I.1.) is produced by E. coli strains that harbour plasmid 
pMccC7 that carries the genes involved in its production and immunity (Novoa et al. 
1986; Gonzalez-Pastor et al. 1995). MccC7 is a heptapeptide that is post-translationally 
modified at the C-terminus by a non-hydrolysable phosphoramidate linkage to 
aminopropyl-modified AMP (Guijarro et al. 1995). mmcA is the smallest known bacterial 
gene with a coding sequence of 21 bp and was shown to encode the heptapeptide 
precursor MccA (Gonzalez-Pastor et al. 1994). Modification of the precursor involves 
three distinct steps, starting with the conversion of Asn7 to isoAsn7. The amide group of 
this residue is subsequently connected to Pα of ATP through a N-P bond and finally the 
phosphoramidate is aminopropylated. The enzyme MccB is homologous to adenylating 
enzymes and it was shown to be responsible for the formation of the N-P linkage at the 
expense of two ATP molecules (Roush et al. 2008). The target of MccC7 is aspartyl 
tRNA synthetase (Metlitskaya et al. 2006). 
 
I.6. Modified peptides produced by cyanobacteria 
 
I.6.1. Cyanobactins  
 
Patellamides (Figure I.1.) are a class of cyclic peptides that were identified from the 
extract of marine ascidians belonging to the Didemnidae family. They consist of two 
cyclised pseudosymmetrical dimers that each have a ‘thiazole–nonpolar amino acid–
oxazoline–nonpolar amino acid’ sequence.  The ascidians harbour obligate symbiotic 
cyanobacteria and genome sequencing of one of these, Prochloron didemni, revealed 
that the patellamides are produced by the symbiont rather than the host (Schmidt et al. 
2005). They result from post-translational modification of a genetically encoded 
precursor. Interestingly, a single 71 amino acid precursor peptide, PatE, contains the 
prosequence of both patellamide A and C (Schmidt et al. 2005). The N-terminal 37 
amino acids are proposed to serve as a leader sequence, which is followed by the eight 
residue patellamide C prosequence, an eight residue spacer, the eight residue 
patellamide A prosequence and finally a five amino acid C-terminal extension. 
Functionality of the patellamide gene cluster was demonstrated by heterologous 
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expression in E. coli (Schmidt et al. 2005). A large scale analysis revealed that 
Prochloron species use hypervariable cassettes in a conserved gene cluster to generate 
a wide diversity of patellamide structures (Donia et al. 2006). Each strain contains just 
one pathway, but the combination of multiple strains within the ascidians results in a 
diverse chemical library. Several additional patellamide-like gene clusters of 
cyanobacterial origin were identified and their products were collectively named 
‘cyanobactins’ (Donia et al. 2008). This study described the heterologous production of 
the prenylated antitumor compound trunkamide in E. coli. Investigation of the broad-
substrate heterocyclases PatD and TruD reveals that sequence variability in the putative 
substrate-binding domain accounts for the regioselectivity of the introduced post-
translational modifications (McIntosh et al. 2010). 
 
Aerucyclamides and microcyclamides are cyclic hexapeptides produced by the toxic 
freshwater cyanobacterium Microcystis aeruginosa (Portmann et al. 2008; Portmann et 
al. 2008). Their structure contains five-membered heterocycle modifications and 
aerucyclamide A, B and C each contain one D-allo-Ile residue. Identification of the 
biosynthetic gene clusters revealed genes with homology to the ones involved in 
patellamide biosynthesis (Ziemert et al. 2008). 
 
I.6.2. Microviridins 
 
Microviridin K (Figure I.1.) is an N-acetylated tricyclic peptidase inhibitor produced by 
Planktothrix agardhii (Philmus et al. 2008). Its structure contains three cross-links 
involving the ω-carboxy groups of Glu or Asp residues. Glu13 forms an amide bond with 
the ε-amino group of Lys9, and Asp10 and Glu12 are connected by an ester bond to the 
hydroxyl groups of Thr4 and Ser9, respectively. Similar linkages have been identified in 
peptides of non-ribosomal origin, but identification of the microviridin biosynthetic gene 
cluster revealed the compound’s ribosomal origin (Philmus et al. 2008; Ziemert et al. 
2008). The activity of the enzymes involved in ester and amide bond formation, as well 
as the acetyltransferase, have been reconstituted in vitro (Philmus et al. 2008). A 
subsequent biochemical study of the ligase involved in lactonisation showed that the 
larger ring is formed first and that the enzyme has some substrate tolerance, which 
could be useful for variant generation (Philmus et al. 2009). A PCR-based screen for 
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microviridin gene clusters led to the identification of 15 additional variants, illustrating the 
natural variety of these compounds (Ziemert et al. 2010). 
 
I.7. Other five-membered heterocycle-containing peptides 
 
Introduction of heterocycles into ribosomally synthesised peptides appears to be a 
frequently used strategy in Nature to convert flexible peptide backbones into a more rigid 
structure (Walsh and Nolan 2008). This type of modification has already been 
exemplified by MccB17 and the cyanobactins (Chapter I.5.1. and I.6.1.), but at least two 
other families exist that contain this type of modification, as discussed in this section. 
 
I.7.1. Linear toxins  
 
The biosynthetic gene cluster for production of streptolysin S, a haemolytic toxin 
produced by Streptococcus pyogenes, was identified by transposon mutagenesis and 
gene disruption analysis (Betschel et al. 1998; Datta et al. 2005). This showed that 
streptolysin S is ribosomally synthesised, but its exact structure in not known. The gene 
products encoded by the streptolysin S gene cluster display remarkable similarities to 
the enzymes involved in MccB17 maturation and this was predicted to reflect its 
structural characteristics. In vitro reconstitution of the streptolysin S biosynthetic 
enzymes confirmed this hypothesis (Lee et al. 2008). A bioinformatic analysis identified 
several related gene clusters in prokaryotic genomes, including those of important 
pathogens. These clusters are also predicted to be involved in the production of thiazole- 
and/or oxazole-containing toxins (Lee et al. 2008). Further experiments identified the 
sites of post-translational modification in the mature peptide and substrate recognition 
requirements of the biosynthetic machinery (Mitchell et al. 2009). A related toxin, 
clostridiolysin S, was identified from Clostridium botulinum and contains a single 
modified methyl-oxazole moiety (Gonzalez et al. 2010). 
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I.7.2. Thiopeptides 
 
Thiopeptides, or thiazolylpeptides, are a family encompassing over 50 antibiotics that 
exert their mechanism of action by interfering with bacterial protein synthesis (reviewed 
by Bagley et al. 2005). They are produced by actinomycetes, bacilli and staphylococci 
and 29 families have currently been described containing over 75 distinct compounds. 
Prior to 2009, thiopeptide research focused on total chemical synthesis of the 
compounds and feeding studies with isotopically labelled precursors. This was probably 
due to the difficulty in cloning the biosynthetic gene clusters because of the highly 
modified nature of these compounds and since resistance genes are not typically 
encoded in a genetic locus close to the biosynthetic machinery. 
 
Although goadsporin (Figure I.1.) is not a thiopeptide, the identification of its gene cluster 
from Streptomyces sp. TP-A0584 represented the first example of this kind (Onaka et al. 
2005), although this was not realised at the time. The primary function of goadsporin 
seems to involve stimulation of secondary metabolism and/or sporulation in 
actinomycetes, although some antibacterial activity was observed  at concentrations > 1 
µM (Onaka et al. 2001). The god (goadsporin) gene cluster was cloned and 
heterologously expressed in S lividans TK23 and appears to reflect a merger between 
the genetic determinants involved in MccB17 and lantibiotic biosynthesis (Onaka et al. 
2005). GodE is similar to McbC, while GodF and GodE both contain regions homologous 
to LanB-type dehydratases. GodH shares sequence identity to acetyltransferases and is 
thought to catalyse the acetylation of the N-terminal alanine. The godI product has 
homology to the signal recognition particle (SRP) from E. coli and was shown to be the 
goadsporin self-resistance protein by conferring goadsporin resistance on S. lividans 
TK23 (Onaka et al. 2005).  
 
The biosynthesis of thiopeptide antibiotics was eludicated in 2009 by four different 
groups simultaneously (Kelly et al. 2009; Liao et al. 2009; Morris et al. 2009; Wieland-
Brown et al. 2009). These studies show that the antibiotics are genetically encoded post-
translationally modified peptides rather than products of NRPS enzymes as previously 
believed. Important factors that likely played a role in this major finding include advanced 
genome sequencing techniques and the knowledge that other complex heterocyclic 
peptides, such as the cyanobactins, are processed from a ribosomal precursor (Arndt et 
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al. 2009). These recent advances will speed up investigations of producer self-immunity 
and attempts to carry out  rational drug design with molecules containing thiopeptide 
backbones. 
 
Thiopeptides are probably the most intensively post-translationnaly modified type of 
peptide discovered thus far, as exemplified by thiocillin (Figure I.1.), in which 13 out of 
14 residues in the mature peptide are modified. Thiopeptide gene clusters typically 
contain a structural gene with a propeptide that is rich in Ser, Thr and Cys and at least 
four biosynthetic genes: a cyclodehydratase homologous to PatD, a McbC-like 
dehydratase and two LanB-type dehydratases. Several additional enzymes can be found 
that are expected to be involved in further tailoring of the thiopeptide structure, for 
example SAM dependent methyltransferases or cytochrome P450 oxygenases. A further 
investigation of the biosynthetic gene clusters will be needed to assign functions to these 
additional enzymes and will shed more light on tailoring processes such as the 
introduction of a second macrocycle and the quinaldic acid moiety in thiostrepton (Li and 
Kelly 2010). 
 
I.8. Linaridins 
 
Cypemycin (Figure I.1.) is an unusual peptide antibiotic produced by Streptomyces sp. 
OH-4156 (Komiyama et al. 1993). While the mature peptide does not contain any Lan or 
MeLan bridges, four Dhb residues occur in its structure. Thus, strictly speaking, 
cypemycin is not a lantibiotic, but regardless it has always been considered a member of 
this peptide family. The compound was classified based on the producer strain and 
chemical composition, as being part of the Class II ‘cinnamycin group’ by Pag and Sahl 
(2002). Using different criteria, cypemycin was assigned to Class I because of its linear 
structure and the uncertainty whether its gene cluster contained lanBC or lanM 
modification genes (McAuliffe et al. 2001; Chatterjee et al. 2005). 
 
Apart from the four Dhb residues in its mature structure, cypemycin also contains the 
following special post-translational modifications: two L-allo-isoleucines (L-allo-Ile) 
residues, an AviCys and an N-terminal N,N-dimethylalanine (Me2-Ala) residue (Minami 
et al. 1994). AviCys residues occur in several lantibiotics (Chatterjee et al. 2005), but L-
allo-Ile and Me2-Ala have not been described in any other post-translationally modified 
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peptide. The mode of action for cypemycin remains to be determined, but the compound 
has antibiotic activity against Micrococcus luteus and is cytotoxic to mouse leukaemia 
cells in an in vitro assay (Komiyama et al. 1993). 
 
Cypemycin is the main subject of this PhD thesis (Chapter III – V) and the identification 
and characterisation of its biosynthetic gene cluster have revealed that its post-
translational modifications are introduced by enzymes and mechanisms unrelated to 
those described for lantibiotic biosynthesis (Claesen and Bibb 2010). A bioinformatic 
analysis identified ten similar gene clusters in the genomes of sequenced bacteria, 
including S. griseus. The products of these gene clusters constitute the linaridin family 
which was named after their predicted linear structure containing dehydrated (or ‘arid’) 
residues. The compound from the cryptic linaridin gene cluster of S. griseus is described 
in Chapter VI.  
 
I.9. Modified quorum sensing peptides 
 
I.9.1. Cyclic (thio)lactones 
 
Virulence and biofilm formation in S. aureus was found to be under the control of a QS 
system that uses a peptide pheromone (Ji et al. 1995). Structural analysis of the 
homologous Staphylococcus epidermis pheromone (Figure I.1.) revealed the presence 
of a thiolactone ring between the thiol group of Cys4 and the C-terminal carboxyl group 
of Phe8 (Otto et al. 1998). A typical agr QS system consists of a two-component His 
kinase and response regulator, an auto-inducing peptide (AIP) that is derived from a 
precursor peptide by post-translational modification and an enzyme involved in the 
processing of the AIP. At least 4 distinct families of S. aureus AIP exist and the peptide 
from one family can inhibit the QS system of another while stimulating gene regulation in 
cells belonging to its own family (Ji et al. 1997). agr pheromones are produced as a 
precursor peptide, encoded by agrD, and subsequently post-translationally processed by 
the transmembrane protein AgrB (Zhang et al. 2002). The N-terminal helix of the AgrD 
precursor is stabilised by integration into the cytoplasmic membrane and this is required 
for successful processing to form the mature AIP (Zhang et al. 2004). Two catalytic 
residues were identified in AgrB that form a putative endopeptidase catalytic centre for 
proteolytic cleavage of the C-terminal fragment of AgrD (Qiu et al. 2005).  
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A peptide QS system was implicated in gelatinase biosynthesis in Enterococcus faecalis 
(Nakayama et al. 2001). The AIP is an 11 amino acid cyclic peptide that resembles the 
agr molecules, but instead of a thiolactone, it contains a lactone ring between the 
hydroxyl group of Ser3 and the C-terminal carboxyl group. The propeptide FsrD is 
converted to the mature pheromone by Cys protease-like enzyme FsrB in a similar way 
to the staphylococcal agr system (Nakayama et al. 2006). The production of cyclic 
lactone QS pheromones has also been shown for six different strains of Staphylococcus 
intermedius (Ji et al. 2005). 
 
An agr-like gene cluster was identified in Lactobacillus plantarum and shown to be 
involved in regulation of adherence to glass slides (Sturme et al. 2005). The putative 
precursor gene and the gene encoding the processing protein were overexpressed 
under nisin control, which led to the identification of the cyclic thiolactone pentapeptide 
LamD558 (Figure I.1.). This study provided the first example of a functional agr-like 
system in a non-pathogenic bacterium (Sturme et al. 2005). 
 
I.9.2. Bacillus pheromones 
 
Genetic competence in Bacillus subtilis is under the regulatory control of a ComQXPA 
QS system (Magnuson et al. 1994). ComX (Figure I.1.) is an extracellular peptide 
pheromone that is post-translationally isoprenylated and secreted by ComQ (Okada et 
al. 2005). Characterisation of ComX pheromones from several natural Bacillus isolates 
showed that all are modified on a conserved Trp and that the modifications on the 
peptide backbones vary in mass among the different pheromones (Ansaldi et al. 2002).  
 
I.9.3. Pep1357C 
 
Pep1357C is a nonapeptide identified in the supernatant of Streptococcus thermophilus 
(Ibrahim et al. 2007). MALDI-ToF MS showed that the peptide is cyclised between Lys2 
and Trp6, but further structural analysis would be required to determine the nature of the 
linkage. A gene deletion analysis indicated that Pep1357C production is the target of a 
streptococcus-specific QS system (Ibrahim et al. 2007). 
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I.10. Aims of this project 
 
The main goal of this project was to identify and characterise the cypemycin biosynthetic 
gene cluster from S. sp. OH-4156. This was addressed using the following approaches: 
 
• Construction of a genomic cosmid library of the cypemycin producer strain and 
identification of the cosmids that contained the biosynthetic cluster by radio-
active colony hybridisation. The probe used for hybridisation was constructed 
based on S. sp. OH-4156 genome scanning data. 
 
• Heterologous expression of the gene cluster, the generation of a reduced gene 
set construct and a mutational analysis of the individual genes within this set. 
The resulting strains were characterised by Micrococcus luteus bio-assays and 
MALDI-ToF MS. 
 
• Setting up in vitro assays for the enzymes that introduce cypemycin’s post-
translational modifications.  
 
In a side project, an attempt was made to obtain products from the cryptic lantipeptide 
gene clusters of Streptomyces venezuelae. The following approaches were taken: 
 
• Screening S. venezuelae under various production conditions for inhibitory 
activity against M. luteus and the production of lantipeptide-candidates by 
MALDI-ToF MS. 
 
• The generation of deletion mutants and constitutively expressing strains in S. 
venezuelae, and the introduction of the gene clusters in Streptomyces lividans as 
a heterologous host. 
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Chapter II – Materials and methods 
 
II.1. Bacterial plasmids and strains 
 
Table II.1. Plasmids and cosmids used and constructed in this study. 
 
Plasmid Description Reference 
General plasmids  
 
pGEM-T TA-cloning vector Promega 
 
pIJ10257 oriT, φBT1 int-attB, hyg, ermEp* Hong et al. 2005 
 
pDONR 
207 
donor vector for Gateway Invitrogen 
 
pHM-GWA Gateway destination vector for MBP fusions Busso et al. 
2005 
 
pIJ10700 pBS SK+ containing cassette P1-FRT-oriT-hyg-FRT-
P2 
Gust et al. 2004 
 
pIJ10702 bla, aac(3)IV, oriT, φC31 int-attP (also known as 
pMJCos1) 
Boakes et al. 
2009 
 
pIJ10704 pGEM-T Easy containing cassette FRT-aac(3)IV-oriT-
FRT-ermEp* 
This work 
 
pIJ773 pBS SK+ containing cassette P1-FRT-oriT-aac(3)IV-
FRT-P2 
Gust et al. 2004 
 
pIJ790 λ-RED (gam, bet, exo), cat, araC, rep101ts Gust et al. 2004 
 
pIJ86 complementation plasmid containing oriColE1 SCP2*, 
aac(3)IV, ermEp* 
Healy et al. 2009 
 
pSET152 lacZα, pUC19ori, RP4oriT, φC31 int-attP, aac(3)IV Flett et al. 1997 
 
pUZ8002 tra, neo, RP4 Paget et al. 1999 
 
SuperCosI neo, bla Stratagene 
 
   
Chapter III and IV  
Library cosmids for heterologous expression in S. venezuelae  
 
pIJ12400 genomic library cosmid 1N16 in SupercosI This work 
 
pIJ12401 genomic library cosmid 3O03 in SupercosI This work 
 
pIJ12402 genomic library cosmid 4J11 in SupercosI This work 
 
pIJ12403 genomic library cosmid 6C03 in SupercosI This work 
 
pIJ12404 genomic library cosmid 6I23 in SupercosI This work 
 
pIJ12405 genomic library cosmid 7P24 in SupercosI This work 
 
pIJ12406 genomic library cosmid 8B19 in SupercosI This work 
 
pIJ12407 genomic library cosmid 8G13 in SupercosI This work 
 
pIJ12408 genomic library cosmid 8J18 in SupercosI This work 
 
pIJ12409 pIJ12400 with pIJ10702 backbone This work 
 
pIJ12410 pIJ12401 with pIJ10702 backbone This work 
 
pIJ12411 pIJ12402 with pIJ10702 backbone This work 
 
pIJ12412 pIJ12403 with pIJ10702 backbone This work 
 
pIJ12413 pIJ12404 with pIJ10702 backbone This work 
 
pIJ12414 pIJ12405 with pIJ10702 backbone This work 
 
pIJ12415 pIJ12406 with pIJ10702 backbone This work 
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Plasmid Description Reference 
 
pIJ12416 pIJ12407 with pIJ10702 backbone This work 
 
pIJ12417 pIJ12408 with pIJ10702 backbone This work 
 
   
Minimal gene set constructs  
 
pIJ12418 pIJ12404 targeted with 773 cassette upstream of orf1 This work 
 
pIJ12419 pIJ12418 with in-frame deletion upstream of orf1 This work 
 
pIJ12420 pIJ12419 targeted with 773 cassette downstream of cypI This work 
 
pIJ12421 pSET152 with minimal gene set excised from pIJ12420 This work 
 
   
Gene deletion constructs  
 
pIJ12422 pIJ12404 ∆orf1::(oriT-aac(3)IV) This work 
 
pIJ12423 pIJ12404 ∆cypA::(oriT-aac(3)IV) This work 
 
pIJ12424 pIJ12404 ∆cypH::(oriT-aac(3)IV) This work 
 
pIJ12425 pIJ12404 ∆cypL::(oriT-aac(3)IV) This work 
 
pIJ12426 pIJ12404 ∆cypD::(oriT-aac(3)IV) This work 
 
pIJ12427 pIJ12404 ∆cypM::(oriT-aac(3)IV) This work 
 
pIJ12428 pIJ12404 ∆cypT::(oriT-aac(3)IV) This work 
 
pIJ12429 pIJ12404 ∆cypP::(oriT-aac(3)IV) This work 
 
pIJ12430 pIJ12404 ∆cypI::(oriT-aac(3)IV) This work 
 
pIJ12431 pIJ12422 in-frame deletion of orf1 This work 
 
pIJ12432 pIJ12423 in-frame deletion of cypA This work 
 
pIJ12433 pIJ12424 in-frame deletion of cypH This work 
 
pIJ12434 pIJ12425 in-frame deletion of cypL This work 
 
pIJ12435 pIJ12426 in-frame deletion of cypD This work 
 
pIJ12436 pIJ12427 in-frame deletion of cypM This work 
 
pIJ12437 pIJ12428 in-frame deletion of cypT This work 
 
pIJ12438 pIJ12429 in-frame deletion of cypP This work 
 
pIJ12439 pIJ12430 in-frame deletion of cypI This work 
 
pIJ12440 pIJ12431 with pIJ10702 backbone This work 
 
pIJ12441 pIJ12432 with pIJ10702 backbone This work 
 
pIJ12442 pIJ12433 with pIJ10702 backbone This work 
 
pIJ12443 pIJ12434 with pIJ10702 backbone This work 
 
pIJ12444 pIJ12435 with pIJ10702 backbone This work 
 
pIJ12445 pIJ12436 with pIJ10702 backbone This work 
 
pIJ12446 pIJ12437 with pIJ10702 backbone This work 
 
pIJ12447 pIJ12438 with pIJ10702 backbone This work 
 
pIJ12448 pIJ12439 with pIJ10702 backbone This work 
 
   
Complementation constructs  
 
pIJ12449 pIJ10257 containing cloned cypA This work 
 
pIJ12450 pIJ10257 containing cloned cypH This work 
 
pIJ12451 pIJ10257 containing cloned cypL This work 
 
pIJ12452 pIJ10257 containing cloned cypD This work 
 
pIJ12453 pIJ10257 containing cloned cypM This work 
 
   
Variant constructs  
 
pIJ12477 pIJ86 neo This work 
 
pIJ12478 pIJ12477 cypA WT This work 
 
pIJ12479 pIJ12477 cypA 4S This work 
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Plasmid Description Reference 
 
pIJ12480 pIJ12477 cypA S-T This work 
 
pIJ12481 pIJ12477 cypA C-T This work 
 
   
Chapter V   
Entry vector constructs  
 
pIJ12482 pDONR containing cloned cypA This work 
 
pIJ12483 pDONR containing cloned pro-cypA This work 
 
pIJ12484 pDONR containing cloned cypH This work 
 
pIJ12485 pDONR containing cloned cypL This work 
 
pIJ12486 pDONR containing cloned cypD This work 
 
pIJ12487 pDONR containing cloned cypM This work 
 
pIJ12488 pDONR containing cloned cypI This work 
 
   
Expression vector constructs  
 
pIJ12489 pHM-GWA containing cloned cypA This work 
 
pIJ12490 pHM-GWA containing cloned pro-cypA This work 
 
pIJ12491 pHM-GWA containing cloned cypH This work 
 
pIJ12492 pHM-GWA containing cloned cypL This work 
 
pIJ12493 pHM-GWA containing cloned cypD This work 
 
pIJ12494 pHM-GWA containing cloned cypM This work 
 
pIJ12495 pHM-GWA containing cloned cypI This work 
 
   
Chapter VI   
Grisemycin-related constructs  
 
pIJ12474 pSET152 with grisemycin minimal gene set  This work 
 
pIJ12475 SuperCosI with grisemycin minimal gene set excised from 
pIJ12474 
This work 
 
pIJ12476 pIJ12475 DgrmA::(oriT-aac(3)IV) This work 
 
   
Chapter VII  
Constructs for S. venezuelae gene deletion and overexpression  
 
pIJ12454 4-G03 ∆SMD01140::(oriT-aac(3)IV) This work 
 
pIJ12455 4-G06 ∆SMD01224::(oriT-aac(3)IV) This work 
 
pIJ12456 4H08 ∆SMD01252::(oriT-aac(3)IV) This work 
 
pIJ12457 4-G03 ∆SMD01140::(oriT-hyg) This work 
 
pIJ12458 4H08 ∆SMD01252::(oriT-hyg) This work 
 
pIJ12459 4P22 ∆cmlPH::(oriT-aac(3)IV) This work 
 
pIJ12460 4-G03 ermEp*-SMD01140 This work 
 
pIJ12461 4-G06 ermEp*-SMD01224 This work 
 
pIJ12462 4H08 ermEp*-SMD01252 This work 
 
pIJ12463 4H08 ∆SMD01252.2::(oriT-aac(3)IV) This work 
 
   
S. lividans heterologous expression constructs  
 
pIJ12464 1-B5 with pIJ10702 backbone This work 
 
pIJ12465 4-G03 with pIJ10702 backbone This work 
 
pIJ12466 4H08 with pIJ10702 backbone This work 
 
pIJ12467 pIJ12464 ∆SMD01139::tet This work 
 
pIJ12468 pIJ12465 ∆SMD01139::tet This work 
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Plasmid Description Reference 
 
pIJ12469 pIJ12466 ∆SMD01252.2::tet This work 
 
pIJ12470 pIJ12464 ∆SMD01140::tet This work 
 
pIJ12471 pIJ12465 ∆SMD01140::tet This work 
 
pIJ12472 pIJ12466 ∆SMD01252::tet This work 
 
   
ermE* test construct  
 
pIJ12473 6F11 ermEp*-afsR This work 
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Table II.2. Strains used or constructed in this study. 
 
Strain Description Reference 
General strains  
M. luteus   
 
ATTCC4698 Indicator strain in bio-assay Boakes et al. 
2009 
 
   
E. coli   
 
BL21 (DE3) strain used for fusion protein production Studier and 
Moffatt 1986 
 
BT340 DH5α/pCP20 Cherepanov 
and 
Wackernagel 
1995 
 
BW25113 K-12 derivative: ∆araBAD, ∆rhaBAD Datsenko and 
Wanner 2000 
 
DH5α strain used for general cloning and plasmid maintenance Stratagene 
 
ET12567 dam, dcm, hsdM, hsdS, hsdR, cat, tet MacNeil et al. 
1992 
 
XL1-Blue strain used for SupercosI library Stratagene 
 
   
Chapter III and IV  
S. venezuelae  
 
ATCC10712 Wild type strain; used to construct the S. venezuelae 
derivatives 
Stuttard 1982 
 
M1400 pIJ10702 in φC31 attB (empty vector) This work 
 
M1401 pIJ12409 in φC31 attB This work 
 
M1402 pIJ12410 in φC31 attB This work 
 
M1403 pIJ12411 in φC31 attB This work 
 
M1404 pIJ12412 in φC31 attB This work 
 
M1405 pIJ12413 in φC31 attB This work 
 
M1406 pIJ12414 in φC31 attB This work 
 
M1407 pIJ12415 in φC31 attB This work 
 
M1408 pIJ12416 in φC31 attB This work 
 
M1409 pIJ12417 in φC31 attB This work 
 
   
S. coelicolor   
 
M1146 M145 ∆act ∆red ∆cpk ∆cda; parental strain used to 
construct the S. coelicolor derivatives 
J.P. Gomez-
Escribano 
 
M1410 pIJ10702 in φC31 attB (empty vector) This work 
 
M1411 pIJ12413 in φC31 attB (full cosmid insert) This work 
 
M1412 pIJ12421 in φC31 attB (minimal gene set) This work 
 
   
 
M1413 pIJ12440 in φC31 attB (∆orf1) This work 
 
M1414 pIJ12441 in φC31 attB (∆cypA) This work 
 
M1415 pIJ12442 in φC31 attB (∆cypH) This work 
 
M1416 pIJ12443 in φC31 attB (∆cypL) This work 
 
M1417 pIJ12444 in φC31 attB (∆cypD) This work 
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Strain Description Reference 
 
M1418 pIJ12445 in φC31 attB (∆cypM) This work 
 
M1419 pIJ12446 in φC31 attB (∆cypT) This work 
 
M1420 pIJ12447 in φC31 attB (∆cypP) This work 
 
M1421 pIJ12448 in φC31 attB (∆cypI) This work 
 
   
 
M1422 pIJ12441 in φC31 attB (∆cypA) and pIJ12449 in φBT1 attB This work 
 
M1423 pIJ12442 in φC31 attB (∆cypH) and pIJ12450 in φBT1 attB This work 
 
M1424 pIJ12443 in φC31 attB (∆cypL) and pIJ12451 in φBT1 attB This work 
 
M1425 pIJ12444 in φC31 attB (∆cypD) and pIJ12452 in φBT1 attB This work 
 
M1426 pIJ12445 in φC31 attB (∆cypM) and pIJ12453 in φBT1 attB This work 
 
   
 
M1459 M1414 (∆cypA) with pIJ12477 (empty vector) This work 
 
M1460 M1414 (∆cypA) with pIJ12478 (cypA WT) This work 
 
M1461 M1414 (∆cypA) with pIJ12479 (cypA 4S) This work 
 
M1462 M1414 (∆cypA) with pIJ12480 (cypA S-T) This work 
 
M1463 M1414 (∆cypA) with pIJ12481 (cypA C-T) This work 
 
   
S. sp. OH-4156  
 
WT Wild type strain; used to construct the S. sp. OH-4156 
mutants 
Komiyama et al. 
1993 
 
M1427 ∆orf1::(oriT-aac(3)IV) This work 
 
M1428 ∆cypA::(oriT-aac(3)IV) This work 
 
M1429 ∆cypH::(oriT-aac(3)IV) This work 
 
M1430 ∆cypL::(oriT-aac(3)IV) This work 
 
M1431 ∆cypD::(oriT-aac(3)IV) This work 
 
M1432 ∆cypM::(oriT-aac(3)IV) This work 
 
M1433 ∆cypT::(oriT-aac(3)IV) This work 
 
M1434 ∆cypP::(oriT-aac(3)IV) This work 
 
M1435 ∆cypI::(oriT-aac(3)IV) This work 
 
   
Chapter VI   
S. coelicolor   
 
M1457 pIJ12474 in φC31 attB (grisemycin minimal gene set) This work 
 
   
S. griseus   
 
IFO 13350 Wild type strain; used to construct the S. griseus mutant Shirling and 
Gottlieb 1972 
 
M1458 ∆grmA::(oriT-aac(3)IV) This work 
 
   
Chapter VII  
S. venezuelae  
 
M1436 ∆SMD01140::(oriT-aac(3)IV) This work 
 
M1437 ∆SMD01224::(oriT-aac(3)IV) This work 
 
M1438 ∆SMD01252::(oriT-aac(3)IV) This work 
 
M1439 ∆SMD01140::(oriT-aac(3)IV) and ∆SMD01252::(oriT-hyg) This work 
 
M1440 ∆SMD01252::(oriT-aac(3)IV) and ∆SMD01140::(oriT-hyg) This work 
 
M1441 ∆cmlPH::(oriT-aac(3)IV) This work 
 
M1442 ermEp*-SMD01140 This work 
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Strain Description Reference 
 
M1443 ermEp*-SMD01224 This work 
 
M1444 ermEp*-SMD01252 This work 
 
M1445 ∆SMD01252.2::(oriT-aac(3)IV) This work 
 
   
S. lividans   
 
TK24 Wild type strain (SLP2- SLP3- str-6); used to construct the 
S. lividans derivatives 
Hopwood et al. 
1983 
 
M1446 pIJ10702 in φC31 attB (empty vector) This work 
 
M1447 pIJ12464 in φC31 attB (1-B5) This work 
 
M1448 pIJ12465 in φC31 attB (4-G03) This work 
 
M1449 pIJ12466 in φC31 attB (4H08) This work 
 
M1450 pIJ12467 in φC31 attB (1-B5 ∆SMD01139::tet) This work 
 
M1451 pIJ12468 in φC31 attB (4G03 ∆SMD01139::tet) This work 
 
M1452 pIJ12469 in φC31 attB (4H08 ∆SMD01252.2::tet) This work 
 
M1453 pIJ12470 in φC31 attB (1-B5 ∆SMD01140::tet) This work 
 
M1454 pIJ12471 in φC31 attB (4-G03 ∆SMD01140::tet) This work 
 
M1455 pIJ12472 in φC31 attB (4H08 ∆SMD01252::tet) This work 
 
   
S. coelicolor   
 
M600 Wild type strain (SCP1- SCP2-); used to test the pIJ10704 
construct 
Chakraburtty and 
Bibb 1997 
 
M1456 M600 ermEp*-afsR This work 
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II.2. Culture media and antibiotics 
 
II.2.1. Antibiotics 
 
Table II.3. Concentration of antibiotics used in this study. 
 
Antibiotic Concentration in media (mg/ml) 
Apramycin (Apra) 50 
Carbenicillin (Carb) 100 
Chloramphenicol (Cm) 25 
Hygromycin (Hyg) 40 
Kanamycin (Kan) 50 
Nalidixic acid (Nal) 20 
Spectinomycin (Spec)* 200 
Streptomycin (Strep)* 10 
Tetracyclin (Tet) 10 
  
*added in combination  
 
 
II.2.2. Culture media 
 
Common culture media used for Streptomyces and E. coli were prepared as 
previously described (Kieser et al. 2000). Cypemycin production medium (MarM) is 
described in Komiyama et al. (1993). Additional growth media for actinomycetes 
used in screening for cryptic lantipeptides are described in Table II.4. (Flavia 
Marinelli, personal communication). 
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II.3. Growth conditions and genetic manipulations 
 
II.3.1. Growth and storage of E. coli  
 
E. coli was grown at 37 °C overnight on L-agar or shaking in LB broth (30 °C for 
BW25113 carrying pIJ790). For selection of plasmid-containing cells, appropriate 
antibiotics were added at appropriate concentrations (Table II.3.). For long-term 
storage, overnight LB cultures of E. coli strains were mixed with an equal volume of 
40 % glycerol and stored at -80 °C.  
 
II.3.2. Growth and storage of Streptomyces  
 
Unless stated otherwise, all of the culturing methods for Streptomyces were taken 
or adapted from those described by Kieser et al. (2000).  
 
For liquid growth of Streptomyces, ~ 108 spores were heat shocked at 50 °C for 10 
min in 5 ml TES buffer (10 mM Tris-HCl pH 8.0, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 1 M NaCl). For S. venezuelae, the heat 
shock step was omitted. An equal volume of 2 x YT medium was added and the 
mixture incubated at 37 °C for 3-4 h. The emerging germ tubes were 
microscopically visible at this stage. The germinated spores were recovered by 
centrifugation at 3000 g on a benchtop centrifuge and resuspended in 500 µl of 
water. The cells were vortexed to disperse the clumps. R5 or TSB liquid medium 
was inoculated to OD450 of 0.03-0.05. Cultures were grown with shaking at 30 °C 
until late stationary phase. Mycelium was harvested by centrifugation at 3000 g in a 
benchtop centrifuge.  
 
For the generation of spore stocks, S. lividans, S. coelicolor and S. sp. OH-4156  
mycelium was streaked out onto SFM solid medium. Mycelium of S. venezuelae or 
S. griseus was streaked out onto MYM tap + TE. The plates were incubated at 30 
°C for up to 7 days. Spores were harvested according to the protocol described in 
Kieser et al. (2000). Spore stocks were stored in 20 % glycerol at -20 °C or -80 °C.  
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II.3.3. Plasmid isolation from E. coli  
 
Qiagen miniprep kits were used according to the manufacturer’s instructions. 
Briefly, 5 ml of an overnight LB culture harbouring the plasmid of interest was 
centrifuged at 3000 g for 10 min. The cell pellet was then resuspended and 
underwent alkaline lysis. The lysate was then neutralised and centrifuged in a 
microcentrifuge at 16000 g to remove cell debris and precipitated protein. The 
supernatant was then applied to a silica membrane mounted in a microcentrifuge 
tube where it was washed under high salt and ethanolic buffer conditions during 
which time the DNA remains bound to the column. DNA was eluted from the 
column in elution buffer. Plasmid DNA was routinely stored at -20 °C.  
 
II.3.4. Cosmid isolation from E. coli  
 
Cosmid isolation from E. coli was carried out by alkaline lysis as described by 
Sambrook et al. (2001). The cell pellet from 1.5 ml of culture was resuspended by 
vortexing in 100 µl solution I (50 mM Tris-HCl pH 8.0, 10 mM EDTA). 200 µl 
solution II (200 mM NaOH, 1 % sodium dodecyl sulphate (SDS)) were added and 
the tubes inverted ten times. 150 µl solution III (3 M potassium acetate pH 5.5) 
were then added and mixed in by inverting the tube five times. The tube was then 
centrifuged at 16000 g in a microcentrifuge for 5 min at room temperature. The 
supernatant was mixed with 400 µl phenol/chloroform, vortexed briefly to mix and 
then centrifuged at 16000 g in a microcentrifuge for 5 min. The upper phase was 
transferred to a 1.5 ml tube, 600 µl of ice cold isopropanol was added and DNA 
precipitation was achieved by placing the tube on ice for 10 min followed by 
centrifuging at 16000 g in a microcentrifuge for 5 min. The pellet was washed with 
200 µl 70 % ethanol and centrifuged at 16000 g in a microcentrifuge. Leaving the 
tube open for 20 min at room temperature allowed the pellet to dry prior to 
resuspending in 50 µl 10 mM Tris-HCl (pH 8.0).  
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II.3.5. Genomic DNA extractions from Streptomyces  
 
2 µl of each Streptomyces spore stock was used to inoculate 10 ml SOC medium 
and grown overnight with shaking at 30 °C. The mycelium was recovered by 
centrifugation at 3000 g for 5 min at 4 °C in a Sorvall GS3 rotor. The mycelium was 
resuspended in 500 µl of lysozyme solution. The mycelium was incubated at 37 °C 
for 60 min. 50 µl 10 % SDS was then added and incubation continued at 37 °C for 
a further 15 min. The sample was then vortexed until the viscosity of the solution 
had decreased. 300 µl phenol/chloroform were added and vortexed briefly until 
completely mixed. The sample was centrifuged in a microcentrifuge at 16000 g for 
8 min. Following centrifugation, the aqueous phase was removed to a fresh tube. 
To decrease viscosity, 200 µl water was added to the supernatant. The 
supernatant was extracted twice with phenol/chloroform. Precipitation of the DNA 
was achieved by the addition of 0.1 volumes 3 M sodium acetate and 1 volume of 
ice-cold isopropanol and leaving for 10 min on ice. The precipitated DNA was then 
recovered by centrifugation in a microcentrifuge at 16000 g for 5 min. The DNA 
pellet was washed with 70% ethanol before dissolving in 500 µl elution buffer at 
room temperature for 2 h. DNAse free RNAse was added to a final concentration of 
40 µg/ml and the sample incubated at 37 °C for 30 min. The DNA sample then 
underwent a phenol/chloroform extraction. The DNA was precipitated and washed 
as before and then dissolved in 100 µl elution buffer. DNA concentration was 
determined by spectrophotometry using the ND-1000 spectrophotometer 
(NanoDrop). 
  
II.3.6. Digestion of DNA with restriction enzymes  
 
Restriction enzyme digestion of cosmids, plasmids or genomic DNA was carried 
out according to the enzyme manufacturer’s instructions. In the case of double 
digests, an appropriate buffer was selected after consulting the manufacturer’s 
literature. The reaction volume was usually 20 µl for analytical digests and 50 µl for 
preparative digests. Unless otherwise instructed, digests were typically carried out 
for 1 h at 37 °C. 
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II.3.7. Agarose gel electrophoresis  
 
1 % agarose gels were prepared and run in 1% TAE buffer (40 mM Tris, 1.142 % 
acetic acid, 1 mM EDTA) at 100 V. Hyperladder I (Bioline) was used to provide size 
markers. Gels were stained in 0.5 µg/ml ethidium bromide in water for 10-15 min.  
 
II.3.8. Extraction of DNA fragments from agarose gels  
 
DNA fragments separated in agarose gels were excised from the gel using a clean 
scalpel and purified using the Qiaquick gel extraction kit, following the 
manufacturer’s instructions. Briefly, the agarose gel slice containing the DNA 
fragment of interest was dissolved in a neutral pH, high salt buffer provided with 
the kit and applied to a silica gel membrane mounted in a microcentrifuge tube. 
The column was washed and the DNA fragment was eluted in elution buffer.  
 
II.3.9. Preparation and transformation of electro-competent E. coli  
 
A single colony was used to inoculate 10 ml LB and grown overnight with shaking 
at 37 °C. 100 µl of this preculture were inoculated into 10 ml SOB and grown at 37 
°C for 3-4 h with shaking at 200 rpm to an OD600 of ~ 0.6. The cells were recovered 
by centrifugation at 3000 g for 5 min at 4 °C in a Sorvall GS3 rotor. After decanting 
the medium, the pellet was resuspended by gentle mixing in 10 ml ice-cold 10 % 
glycerol. The cells were centrifuged as before and washed in 10 % glycerol a 
further two times. After decanting the supernatant from the final wash, cells were 
resuspended in the remaining ~ 100 µl of 10 % glycerol.  
 
50 µl electro-competent cell suspension were mixed with ~ 100 ng DNA per 
transformation. Electroporation was carried out in a 0.2 cm ice-cold electroporation 
cuvette using a GenePulser II (Bio-Rad) set to 200 Ω, 25 µF and 2,5 kV. The 
expected time constant is 4.5 – 4.9 ms. After electroporation, 1 ml ice cold LB was 
immediately added to the shocked cells which were incubated with shaking for 1 h 
at 37 °C. Transformants were selected by spreading the mixture onto LB agar 
containing the appropriate antibiotic (or on DNA agar for selection with Hyg).  
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II.3.10. Preparation and transformation of chemically competent E. coli  
 
A single colony was used to inoculate 10 ml LB and grown overnight with shaking 
at 37 °C. 500 µl of this culture were used to inoculate 50 ml LB and grown at 37 °C 
for 3-4 h with shaking at 200 rpm to an OD600 of ~ 0.6. The cells were transferred to 
a 50 ml polypropylene Falcon tube and stored on ice for 10 min. The cells were 
recovered by centrifugation at 3000 g in a Sorvall GS3 rotor for 10 min at 4 °C. The 
medium was decanted and the cell pellet was resuspended in 10 ml ice-cold 0.1 M 
CaCl2. The cells were recovered by centrifugation at 3000 g for 10 min at 4 °C. The 
pellet was then resuspended in 2 ml of ice-cold 0.1 M CaCl2 and stored on ice.  
 
For transformation, 50 µl of the competent cell suspension were transferred to a 
1.5 ml microcentrifuge tube. DNA was added (no more then 100 ng in a 10 µl 
volume) and the suspension was mixed by gently swirling the tube. The tube was 
stored on ice for 30 min. The tube was then transferred to a water bath preheated 
to 42 °C and incubated without shaking for 45 s. 950 µl of LB (prewarmed to 37 °C) 
was added to the cells which were incubated with shaking at 37 °C for 1 h. 
Transformants were selected by plating the transformation mix on to L agar plates 
containing the appropriate antibiotic. 
  
II.3.11. Ligation of DNA  
 
Fragments to be ligated were purified from solution using a Qiagen PCR 
purification kit or from an agarose gel using a Qiagen gel extraction kit. 
Purifications were carried out according to the manufacturer’s instructions. DNA 
was eluted in elution buffer. A ligation reaction volume of 10 µl was prepared with 
an insert/vector molar ratio of 3:1. Ligations were carried out overnight at 16 °C 
using T4 DNA ligase (Promega).  
 
II.3.12. Conjugation of DNA into Streptomyces  
 
ET12567/pUZ8002 harbouring an oriT-containing vector was inoculated into 10 ml 
LB containing Cm, Kan and the appropriate antibiotic for selection of the oriT-
containing vector and grown overnight at 37 °C. 100 µl of overnight culture were 
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inoculated into 10 ml fresh LB plus antibiotics as above and grown for ~ 4 h at 37 
°C to an OD600 of 0.4 - 0.6. The cells were washed twice with 10 ml of LB to 
remove antibiotics that might inhibit the growth of Streptomyces, and were 
resuspended in 1 ml of LB. While washing the E. coli cells, 10 µl Streptomyces 
spore stock was added to 500 µl 2 x YT Broth for each conjugation, heat-shocked 
at 50 °C for 10 min and then allowed to cool slowly. 0.5 ml E. coli cell suspension 
was mixed with 0.5 ml heat-shocked spores and centrifuged briefly in a 
microcentrifuge. 800 µl of the supernatant was poured off and the pellet was 
resuspended in 200 µl residual liquid. A stepwise dilution series from 10-1 to 10-5 
was generated. Each dilution was plated out on MS agar + 10 mM MgCl2 (without 
antibiotics) and incubated at 30 °C for 16-20 h. Plates were overlaid with 1 ml of 
water containing 0.5 mg Nal and the appropriate plasmid selection for the isolation 
of exconjugants. Incubation was continued at 30 °C for several days. 
 
II.3.13. Construction of a S. sp. OH-4156 cosmid library  
 
High molecular weight genomic DNA was isolated from a stationary phase culture 
and cleaved partially with Sau3AI. The DNA was size-fractionated by pulsed field 
gel electrophoresis and fragments between 35 and 50 kb excised and gel-purified 
(Qiaex II gel extraction kit, Qiagen). The DNA was ligated with BamHI/XbaI-
cleaved SuperCosI cosmid vector and encapsulated in phage particles (using the 
Gigapack III Gold in vitro packaging system (Stratagene)) which were then used to 
transfect E. coli XL1-Blue. 3072 library clones were picked into 384 well microtiter 
plates and arrayed onto nylon membranes. The filters were baked and bacterial 
debris rinsed off prior to hybridisation. 
 
II.3.14. Generation of protein fusion constructs 
 
Gateway primer couples (Table II.5.) were used to amplify cypA, cypH, cypL, cypD, 
cypM and cypI. The resulting PCR products were introduced into the pDONR207 
entry vector and shuttled into the pHM-GWA destination vector (following the 
protocol of the Gateway cloning kit, Invitrogen). The resulting plasmids pIJ12489 - 
pIJ12495 (Table II.1.) were introduced into E. coli BL21 (DE3) by transformation. 
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II.3.15. Cypemycin bio-assays  
 
Seed cultures were grown in SOC medium for three days and used to inoculate 
MarM medium and grown for a further three days. Equal volumes of culture 
medium were taken from comparably grown cultures and extracted with CHCl3 
unless otherwise stated. The solvent was evaporated and the resulting pellet 
dissolved in methanol (at 1/10 of the original CHCl3 volume). 20 µl of these 
samples were spotted onto 6 mm Whatman paper discs. After all methanol had 
evaporated, the discs were placed on top of soft nutrient agar containing the 
indicator strain M. luteus. Typically, the agar was inoculated with 1/8th volume of a 
culture of M. luteus grown at 37 °C to an OD600 of 0.4-0.5. Bio-assay plates were 
incubated overnight at 30 °C and zones of inhibition were recorded after 18-24 h. 
 
II.4. Polymerase chain reaction (PCR) methods and DNA 
sequencing  
 
II.4.1. General PCR  
 
PCR from Streptomyces genomic DNA was typically carried out using 10 ng DNA 
as template (prepared according to Section II.3.5.). PCR from an E. coli plasmid  or 
cosmid DNA template was typically carried out using 1 µl of a standard preparation 
(Section II.3.3. and II.3.4.).  
 
Reaction mixture: 
Forward primer (100 pmoles/µl)  0.2 µl   20 pmoles  
Reverse primer (100 pmoles/µl)  0.2 µl   20 pmoles  
Template DNA    x µl  
Buffer (10x)     5 µl   1 x  
dNTPs (40 nmoles/l)    1 µl   50 µM each  
Dimethylsulfoxide (DMSO)   2.5µl   5 %  
DNA polymerase (2.5 U/µl)   1 µl   2.5 Units  
Water up to a total volume of  50 µl  
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Cycle conditions (Touchgene Gradient, Techne):  
Initial denaturation:  96 °C, 3 min  
Denaturation:   96 °C, 30 s  
Primer annealing:  55 °C, 30 s   30 cycles  
Extension:   72 °C, x s  
Final extension:  72 °C, 10 min  
 
For all PCR reactions, an extension rate of 1 kb per min was assumed for DNA 
polymerase.  
 
II.4.2. E. coli and Streptomyces colony PCR  
 
Colony PCR was used for the rapid screening of recombinant plasmids from E. coli 
colonies during cloning or for verifying plasmid transformations in Streptomyces. 
PCR was carried out as described in Section II.4.1., except that template DNA was 
substituted with E. coli cells or Streptomyces mycelium dissolved in the DMSO and 
the initial denaturation cycle was extended for an additional 2 min.  
 
II.4.3. Purification of PCR products  
 
The Qiaquick PCR purification kit (Qiagen) was used to remove enzymes and 
unincorporated primers and dNTPs from completed PCR reactions. 1/10 of the 
PCR reaction mixture was submitted to agarose gel electrophoresis and stained for 
visualisation (Section II.3.7.). The remaining PCR mixture was diluted 5 times in 
the manufacturer’s high salt buffer and applied to a silica gel membrane mounted 
in a microcentrifuge tube. The PCR products were washed and the DNA fragments 
eluted in elution buffer.  
 
II.4.4. DNA sequencing  
 
DNA sequencing was used to confirm the correct sequence of PCR-amplified DNA 
fragments. DNA sequencing was carried out using the BigDye 3.1 dye-terminator 
reaction mix (Applied Biosystems) with plasmid DNA template according to the 
manufacturer’s instructions.  
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Cycle conditions (Touchgene Gradient, Techne):  
Initial denaturation:  96 °C, 1 min  
Denaturation:   96 °C, 10 s  
Primer annealing:  50 °C, 5 s   30 cycles  
Extension:   60 °C, 4 min  
 
Sequence analysis was carried out by the John Innes Centre Genome Laboratory. 
Sequence chromatograms were analysed using the chromatogram trace viewer 
software FinchTV (version 1.4; http://www.softpedia.com). 
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Table II.5. Primers used in this study. 
 
Primer Sequence Site 
General primers  
 
P1 attccggggatccgtcgaccaataggcgtatcacgaggc  
 
P2 tgtaggctggagctgcttccgccggcttccattc  
 
bla F ccctgataaatgcttcaataatattgaaaaaggaag  
 
bla R2 aatcaatctaaagtatatatgagtaaacttggtctgacag  
 
UNIV5-AD1 gactcgcgaattccgacagttga  
 
EAGI-AD2 ggcctcaactgtcg  
 
M13 seq F gtaaaacgacggccagt  
 
M13 seq R caggaaacagctatgac  
 
pSET152 R tcgccattcaggctgc  
 
pSET152 F ctcattaggcaccccagg  
 
T3 aattaaccctcactaaaggg  
 
T7 gtaatacgactcactatagggc  
 
pDONR F tcgcgttaacgctagcatggatctc  
 
pDONR R gtaacatcagagattttgagacac  
 
10257 seq F acgtccatgcgagtgtcc  
 
10257 seq R ccaaacggcattgagcgtc  
 
86 seq R tcggtcatggtcggtctc  
 
   
Chapter III and IV  
Degenerate primers and probes for cypA  
 
Cyp deg F gcnacnccngcnacnc  
 
Cyp deg R rcanacnawdagngtn  
 
Cyp probe 1 gcsacsccsgcsacsccsacsgtsgcscagttcgtsatccagggs  
 
Cyp probe 2 gcsacsccsgcsacsccsacsgtsgcscagttcgtsatccagggstcsacsatctcscts
gtstgc 
 
 
   
cypA specific probe/test primers  
 
cypA T1 gacggtctcttgaaggtctg  
 
cypA T2 cctccgccacttccatc  
 
   
Minimal gene set PCR-targeting primers and test primers  
 
Up F agaattcgcggccgcataatacgactcactatagggatcattccggggatccgtcgacc  
 
Up R gccccgtaccgctggggcacgggcccgggggcgggtcggtctagatgtaggctggagc
tgcttc 
XbaI 
 
Down F ggaggggcggcggggccgcgccgtgccgggcgtcgtcgcaatattattccggggatcc
gtcgacc 
SspI 
 
Down R caagaattcgcggccgcaattaaccctcactaaaggatctgtaggctggagctgcttc  
 
Up T1 tggaatgaacaatggaagtcaac  
 
Up T2 cggtgaagtacgggc  
 
Down T1 gagttcccgctgctgag  
 
Down T2 ccgaaaagtgccacctgac  
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Primer Sequence Site 
Individual gene deletion PCR-targeting primers and test primers  
 
orf1 F caccgcgtccgggggtgccgtcatggaacggcccggctaactagtattccggggatccg
tcgacc 
SpeI 
 
orf1 R gacgggatgggcgggcacgcgcggagggggacgcacatggctagctgtaggctgga
gctgcttc 
NheI 
 
cypA F gaccaccgacgaagggttagtgaagtgcgatctgagatgactagtattccggggatccgt
cgacc 
SpeI 
 
cypA R gtgacgggcctctccggcggcaggctcagtcccgcgtcagctagctgtaggctggagct
gcttc 
NheI 
 
cypH F tctacctgctgccgcgcgagcaggcctcgtacgcgctccactagtattccggggatccgtc
gacc 
SpeI 
 
cypH R gatcgaccggtgcgccgagccgcgcaccacctcgaacttgctagctgtaggctggagct
gcttc 
NheI 
 
cypL F ggggcgctcgccgcgcacctggtcgcgaccgtgctgcagactagtattccggggatccg
tcgacc 
SpeI 
 
cypL R cactcggaggtgaggatcggcttcatccgctggtccgcggctagctgtaggctggagctg
cttc 
NheI 
 
cypD F ccatgtcacgggctccatcagcgcggcgctcgtgccgtgactagtattccggggatccgt
cgacc 
SpeI 
 
cypD R ggcaggttgaaccccacctcggccgtctgccggttgctcgctagctgtaggctggagctg
cttc 
NheI 
 
cypM F gccaacaggatgcggaaggaagggcgttccggtgagtgaactagtattccggggatcc
gtcgacc 
SpeI 
 
cypM R tggcgccctccgcggcgatcgccggcacttcgctcactggctagctgtaggctggagctg
cttc 
NheI 
 
cypT F cgctcgcgggagatgctggtcgttctggagcggcagtgaactagtattccggggatccgt
cgacc 
SpeI 
 
cypT R ggtcggcctcgaccgcggtgatgctgtccgtggtcatccgctagctgtaggctggagctgc
ttc 
NheI 
 
cypP F atggtggacgcctgcgacggcctcatggagctgggatgaactagtattccggggatccgt
cgacc 
SpeI 
 
cypP R cccaggcggaccgggggccactcccgcggggctccgttagctagctgtaggctggagc
tgcttc 
NheI 
 
cypI F caggggtcccgcgcgactccgggacggcagggcaggatgactagtattccggggatcc
gtcgacc 
SpeI 
 
cypI R cggaggggtcgcggggccgtccccgttccggaggcctcagctagctgtaggctggagct
gcttc 
NheI 
 
orf1 T1 ggcccgtacttcaccg  
 
orf1 T2 gtccggggtctgacag  
 
cypH T1 atccgtgaagaattcgaagacga  
 
cypH T2 gcagcacggtcgc  
 
cypL T1 aagttcgaggtggtgcg  
 
cypL T2 cccgcagccagtgg  
 
cypD T1 gatgaagccgatcctcacc  
 
cypD T2 acacccaggcgacgag  
 
cypM T1 cgagttcgcgccgc  
 
cypM T2 gttgcttccggtgaggc  
 
cypT T1 ggtctggaggtgacgg  
 
cypT T2 gtgtacgcccagtcctg  
 
cypP T1 cctggtcgccaccc  
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Primer Sequence Site 
 
cypP T2 catggtgtccatcctgcc  
 
cypI T1 acgacggtgtcctggag  
 
cypI T2 ctcagcagcgggaactc  
 
   
Primers for complementation constructs  
 
cypA 10257 
F 
aaaaacatatgactcttacgagcacgaattccgc NdeI 
 
cypA 10257 
R 
aaaaaaagctttcagcagaccaggcagatcg HindIII 
 
cypH 10257 
F 
aaaaacatatgctcgcgggagtgacc NdeI 
 
cypH 10257 
R 
aaaaaaagctttcagtaagcatccatgaaccttc HindIII 
 
cypL 10257 
F 
aaaaacatatgcttactgaccggatcaaggg NdeI 
 
cypL 10257 
R 
aaaaaaagctttcacgcggcggctcccg HindIII 
 
cypD 10257 
F 
aaaaacatatgaacgtggagaagttcgaggg NdeI 
 
cypD 10257 
R 
aaaaaaagctttcactcaccggaacgccc HindIII 
 
cypM 10257 
F 
aaaaacatatgagtgacccgagcgtgta NdeI 
 
cypM 10257 
R 
aaaaaaagctttcactgccgctccagaacga HindIII 
 
10257 seq F acgtccatgcgagtgtcc  
 
10257 seq R ccaaacggcattgagcgtc  
 
   
Primers for variant constructs  
 
neo F tatatgctagccgccctctggtaaggttgg NheI 
 
neo R tatatgctagcgaaccccagagtcccgctc NheI 
 
WT 86 F tatatggatcccgcatgaccaccgacgaagg BamHI 
 
WT 86 R tatataagctttcagcagaccaggcagatcgtgc HindIII 
 
C-T 86 R tatataagctttcagcagaccagggtgatcgtgctgc HindIII 
 
S-T 86 R tatataagctttcagcagaccaggcagatcgtggtgccctggatcacg HindIII 
 
4S 86 R tatataagctttcagcagaccaggcagatggagc HindIII 
 
   
Chapter V   
Primers for fusion protein constructs 
 
 
Gat cypA F  ggggacaagtttgtacaaaaaagcaggcttagaaaacctgtattttcagggcatgactctt
acgagcacgaattccgc 
 
 
Gat procypA 
F 
ggggacaagtttgtacaaaaaagcaggcttaatcgaaggtcgtgccaccccggccacg
ccgac 
 
 
Gat cypA R  ggggaccactttgtacaagaaagctgggtttcagcagaccaggcagatcg  
 
Gat cypH F  ggggacaagtttgtacaaaaaagcaggcttagaaaacctgtattttcagggcgtgctcgc
gggagtgacc 
 
 
Gat cypH R  ggggaccactttgtacaagaaagctgggtttcagtaagcatccatgaaccttc  
 
Gat cypL F  ggggacaagtttgtacaaaaaagcaggcttagaaaacctgtattttcagggcatgcttact
gaccggatcaaggg 
 
 
Gat cypL R  ggggaccactttgtacaagaaagctgggtttcacgcggcggctcccg  
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Primer Sequence Site 
 
Gat cypD F ggggacaagtttgtacaaaaaagcaggcttagaaaacctgtattttcagggcgtgaacgt
ggagaagttcgaggg 
 
 
Gat cypD R  ggggaccactttgtacaagaaagctgggtttcactcaccggaacgccc  
 
Gat cypM F ggggacaagtttgtacaaaaaagcaggcttagaaaacctgtattttcagggcgtgagtga
cccgagcgtgta 
 
 
Gat cypM R  ggggaccactttgtacaagaaagctgggtttcactgccgctccagaacga  
 
Gat cypI F  ggggacaagtttgtacaaaaaagcaggcttagaaaacctgtattttcagggcatggaca
ccatggcgaaccg 
 
 
Gat cypI R  ggggaccactttgtacaagaaagctgggtttcagagcttccggcgcagt  
 
Gat cypH int cgtcggaacggtggtgtg  
 
Gat cypI int 1 gcatcgtgaaggacctcg  
 
Gat cypI int 2 ggtgaagcggtcgatgac  
 
   
Chapter VI   
Grisemycin-related primers  
 
grmA F tttcgctcagcataggttccgaggaaggacagcgaaatgactagtattccggggatccgt
cgacc 
SpeI 
 
grmA R  agggcggacccctccgacacgcgagtcagcccaccatcaactagttgtaggctggagc
tgcttc 
SpeI 
 
grmA T1 aggagcgggccttgctc  
 
grmA T2 cgccgcgagtgtcacc  
 
Gris F1 T1 accctgggcgagatacc  
 
Gris F1 T2 caccggcgtctcatgg  
 
Gris F2 T1 tcagggtgtccagggtc  
 
Gris F2 T2 ggtcggccatgtgctg  
 
Gris F3 T1 acagacgttcgagtaccgtc  
 
Gris F3 T2 cgaagtcgcgcagcag  
 
   
Chapter VII   
Primers for S. venezuelae gene deletion and test primers  
 
1136 F gcctccgggcccgccccgccccgcgccccttccggtctaactagtattccggggatccgt
cgacc 
SpeI 
 
1136 R ccaccgtccgccccaccacgaacgagggagccccgagtgtctagatgtaggctggag
ctgcttc 
XbaI 
 
1137 F ccgaccgactcccgtcgccatacggaggtttgctcgatgactagtattccggggatccgtc
gacc 
SpeI 
 
1137 R gggcccggaggccgggcccggccgcctcccgggcggtcatctagatgtaggctggag
ctgcttc 
XbaI 
 
1138 F ctgccgtgcgcgaatcggttcaagtagcctgcgctcatgactagtattccggggatccgtc
gacc 
SpeI 
 
1138 R    cccagacatcgcgccggagggttccgggccggcccgtcatctagatgtaggctggagct
gcttc 
XbaI 
 
1139 F caccactcccgcggacacgaaggacgagtgaggaccatgactagtattccggggatcc
gtcgacc 
SpeI 
 
1139 R tcccggacacgtcacgcgcggcgtgtccgccgcccgtcatctagatgtaggctggagct
gcttc 
XbaI 
 
1140 F atccgcggggcggagggccgacggggcggggcggcttcaactagtattccggggatc
cgtcgacc 
SpeI 
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Primer Sequence Site 
 
1140 R tgggccgggtcgggtacggagcggtgcgagggggctatgtctagatgtaggctggagct
gcttc 
XbaI 
 
1141 F ccgaggccggcgggccggcgggcggcggcccggcctatgactagtattccggggatc
cgtcgacc 
SpeI 
 
1141 R cccccatgtttgtgcgggcgcggggacggccgggggttatctagatgtaggctggagctg
cttc 
XbaI 
 
1224.2 F cgcggccgtcggctgacggcgtcgggcgcgcgtcccatgactagtattccggggatccg
tcgacc 
SpeI 
 
1224.2 R ctcccggggatcggtgcgttacatcggctcggggaagattctagatgtaggctggagctg
cttc 
XbaI 
 
1252 F  tccggtcagcggacctcaccgtcgagaaggacacgcatgactagtattccggggatccg
tcgacc 
SpeI 
 
1252 R  ttcgatgtcgtggttctccatggttctctccttcgttcatctagatgtaggctggagctgcttc XbaI 
 
1252.2 F ggactgtcgccggctcactgaacgaaggagagaaccatgactagtattccggggatcc
gtcgacc 
SpeI 
 
1252.2 R ttcccgggcgggccgccggccggatgcatgggtgcgtgctctagatgtaggctggagct
gcttc 
XbaI 
 
1255 F gcgcgccgcttcaaccgtcctgactgacgtaccggttcaactagtattccggggatccgtc
gacc 
SpeI 
 
1255 R atgttgcaacgaaccactccagagacggggaccaaagtgtctagatgtaggctggagct
gcttc 
XbaI 
 
cmlPH F acgagtagcgcatgggggactacggctccgttcctgtcaactagtattccggggatccgtc
gacc 
SpeI 
 
cmlPH R gtcgagttcggctggggcacgacggtgacccgatgaccgtctagatgtaggctggagct
gcttc 
XbaI 
 
1136 T1 caccgctcctgaccgccc  
 
1136 T2 gaaccgcccgcgacggac  
 
1137 T1 gactgtgcgggtccggca  
 
1137 T2 acgttcctggcccagcggg  
 
1138 T1 gatcgacgtgccctacacc  
 
1138 T2 tgccggacccgcacagtc  
 
1139 T1 ggcacgggccacctgac  
 
1139 T2 ggctacttgaaccgattcg  
 
1140 T1 ccgagtcgctgatctgcatg  
 
1140 T2 cacaaacatggggggatgttc  
 
1141 T1 ctgcacgtcaagcacggcg  
 
1141 T2 gaacatccccccatgtttgtg  
 
1224.2 T1 ctgtggaagtacgccgtc  
 
1224.2 T2 gtacccacgcgtcgac  
 
1252 T1 gttcaagtgaatgcgggcgg  
 
1252 T2 ctcacacgtcgccgcgaac  
 
1252.2 T1 cacgcagacccccggcactg  
 
1252.2 T2 ggtcctccctgcggttcc  
 
1255 T1 gtgggcaggcggagac  
 
1255 T2 ctcgccgtgccattcg  
 
cmlPH T1 gaccagccgtaccagcc  
 
cmlPH T2 ccacaccctcctcaccg  
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Primers for S. coelicolor and S. venezuelae constitutive gene expression  
 
afsR ermE F gatcggcgtctcccacggctgacgtggtcggcatgaacaaatttaaattgtaggctggag
ctgc 
 
 
afsR ermE R cgggacgccgctgctccggaacccgcggtccaccgtccatatggggcctcctgttcta  
 
1140 ermE F aggcgccccccgtaccaggatcggacgtggcccggagcggatttaaattgtaggctgg
agctga 
 
 
1140 ermE R gcgcggccccaccccgcccgtgtccggcctccaccgccatatggggcctcctgttcta  
 
1224 ermE F cgtaccggcggctgaaaccgatcgcctgccgaccgcatgatttaaattgtaggctggagc
tgc 
 
 
1224 ermE R cacgggatctcctcgcgggatggggacgggcggccacatatggggcctcctgttcta  
 
1252 ermE F gtgtgttggttccgtgatgcggtcgggaaccttccggtcaatttaaattgtaggctggagctg
c 
 
 
1252 ermE R gcagtccttccagctcgacttccgtaacccggctcgtcatatggggcctcctgttcta  
 
afsR ermE 
T1 
ggggcaaagccgaagaag  
 
afsR ermE 
T2 
cgattcctcctcttccgc  
 
1140 ermE 
T2 
gtcccaccaccgctc  
 
1224 ermE 
T1 
tcttcgtatcgggctctgtg  
 
1224 ermE 
T2 
ggacacgtggatcttccag  
 
1252 ermE 
T2 
gcttcgaccgcccagc  
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II.5. DNA hybridisation methods 
 
II.5.1. Non-radioactive Southern hybridisation  
 
4 µg of Streptomyces genomic DNA were digested with the appropriate restriction 
enzyme at 37 °C overnight. Extraction with phenol/chloroform was carried out to 
remove the enzyme. The digested DNA was precipitated by the addition of 0.1 
volumes 3 M sodium acetate and 1 volume of ice-cold isopropanol and leaving for 
10 min on ice. The precipitated DNA was recovered by centrifugation in a 
microcentrifuge at 16000 g for 5 min. The DNA pellet was washed with 70 % 
ethanol before dissolving in 15 µl water and loaded on to one lane of a 1 % TAE 
gel. The gel was typically 20 cm in length and run at 30 V for 16-18 h. The 
inclusion of 5 ng of 1 kb DNA ladder (Invitrogen) was used to determine the size of 
the bands on the developed Southern blot. The gel was stained with 0.5 µg/ml 
ethidium bromide both prior to blotting and after capillary transfer to confirm 
efficient transfer to the membrane. The gel was rinsed in distilled water and soaked 
twice with shaking for 15 min in denaturation buffer (500 mM NaOH, 1.5 M NaCl) at 
room temperature. The gel was subsequently washed in distilled water and soaked 
twice with shaking for 15 min in neutralisation buffer (3 M NaCl, 500 mM Tris-HCl 
pH 7.5) at room temperature. DNA was transferred to a Hybond-N nylon 
membrane (Amersham) using capillary transfer. 20 x SSC (3 M NaCl, 300 mM 
trisodium citrate dihydrate) was poured into a plastic tray and a glass plate was 
placed across it. A sheet of 3MM paper (Whatman) was soaked in 20 x SSC and 
placed on the plate so that the ends of the paper were in contact with the buffer in 
the tray. The treated and neutralised agarose gel was placed on the paper pad. A 
piece of nylon membrane cut to the size of the gel was placed on top of the gel, 
followed by three pieces of 3MM paper of the same size, stacks of paper towels, a 
glass plate and finally a weight. The DNA was allowed to transfer overnight by 
capillary action. After transfer, the filter was removed and the transferred DNA was 
permanently fixed to the membrane by UV-cross-linking in a UV Stratalinker 2400 
(Stratagene). The membranes were stored between sheets of 3MM paper inside a 
plastic bag at 4 °C until further use.  
 
II – Materials and methods 
 
 
71 
For generation of the digoxigenin (DIG)-labelled DNA probes, DNA was labelled 
with DIG-11-dUTP using the random primed DNA labelling method. 1 µg of cosmid 
DNA template (or 1 kb ladder for the ladder probe) was used in a labelling reaction. 
1 g DNA template was diluted in H2O to a total volume of 16 µl. The DNA template 
was heat-denatured in a boiling water bath for 10 min, and quickly chilled on ice. 2 
µl of hexanucleotide mixture (10 x) and 2 µl dNTP labelling mixture (10 x) were 
added to the tube. 1 µl Klenow enzyme was added for a final concentration of 100 
U/ml and mixed. The reaction mixture was incubated at 37 °C for 20 h. The probe 
was purified using a Qiagen PCR purification kit according to the manufacturer’s 
instructions to remove unincorporated label and enzyme. The probe was eluted 
from the Qiagen column in 50 µl of elution buffer. 
  
For hybridisation of the DNA probes with membrane-bound DNA, the membrane 
was placed in a hybridisation tube containing 20 ml prehybridisation solution (5 x 
SSC, 0.1 % N-lauroylsarcosine, 0.2 % SDS, 1 % blocking reagent) per 100 cm2 of 
membrane surface area. Prehybridisation was carried out at 67 °C for at least 2 h. 
The DIG-labelled DNA probe was denatured by heating in a boiling water bath for 
10 min and chilled directly on ice. After discarding the prehybridisation solution, the 
hybridisation solution (= prehybridisation solution containing the DIG-labelled probe 
at 25 ng/ml) was added. The hybridisation was carried out overnight at 67 °C. The 
hybridisation solution was discarded and the membrane was washed twice, 15 min 
per wash, in 50 ml of preheated wash solution I (0.5 x SSC, 0.1 % SDS) at 67 °C. 
This was followed by three washes, 20 min per wash with 50 ml of preheated wash 
solution II (0.1 x SSC, 0.1 % SDS) at 67 °C. 
 
For detection of the membrane-bound DIG-labelled probe, the membrane was 
transferred to a freshly washed dish and equilibrated in maleic acid buffer (0.1 M 
maleic acid, 0.15 M NaCl, NaOH to pH 7.5) for 1 min at room temperature. The 
membrane was blocked by gently agitating it in 30 ml of blocking solution (1 % 
(w/v) blocking reagent in maleic acid buffer) for 60 min at room temperature. The 
blocking solution was discarded and replaced with 30 ml of blocking solution 
containing the anti-DIG antibody-conjugate diluted 1:10,000. The membrane was 
incubated for 30 min with gentle agitation. The antibody solution was discarded 
and the membrane was washed twice, 15 min per wash in maleic acid buffer and 
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then equilibrated for 2 min in 30 ml of detection buffer (100 mM Tris-HCl pH 9.5, 
100 mM NaCl). Diluting CSPD* (Roche) 1:100 in detection buffer generated the 
working chemiluminescent substrate. The membrane was placed between two 
sheets of plastic and 0.5-1 ml of working chemiluminescent substrate was added to 
the membrane (per 100 cm2 of surface area) ensuring it was dispersed evenly 
across the surface of the membrane. The membrane was incubated for 5 min at 
room temperature. The membrane was then sealed in a fresh plastic bag and 
incubated at 37 °C for 15 min to allow the alkaline phosphatase chemiluminescent 
reaction to reach a steady state. For detection of the chemiluminescent signal, the 
membrane was exposed to X-ray film for 30 min, adjusting the exposure time to 
optimise the signal. 
 
II.5.2. Radioactive Southern hybridisation 
 
A 480 bp PCR product corresponding to cypA and flanking regions was generated 
using primers cypA T1 and cypA T2 and genomic DNA of S. sp. OH-4156 as 
template. The fragment was labelled with α-32P-dCTP (following the protocol of the 
Prime-It Random Primer Labeling Kit, Stratagene). Library membranes (Section 
II.3.13.) were hybridized with this probe under the conditions are described in 
Section II.5.1., identifying cosmids containing cypA. 
 
II.6. PCR targeting  
 
PCR targeting (also known as the Redirect technology) was used to construct 
mutagenised cosmids in E. coli that could subsequently be used for generating 
mutants or heterologous expression strains after conjugation into Streptomyces. 
The method was performed according to Gust et al. (2004). 
 
II.6.1. PCR amplification of disruption cassette  
 
The pIJ773 (ApraR) and pIJ10700 (HygR) templates were used for the generation of 
deletion mutants. pIJ10704 was used as template for the replacement of native 
promoters with the constitutively transcribed ermEp* promoter. The 5.2-kb SspI 
fragment of pIJ10702 containing oriT, φC31 int and attP was used to target the 
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backbone of cosmids that needed to be integrated into the host genome for 
heterologous expression. Gene specific primers for the generation of each deletion 
mutant were designed in accordance with the criteria specified by (Gust et al. 
2004). These primer pairs were used in association with the appropriate disruption 
template to generate cassettes flanked by the gene-specific 39 nt homology 
extensions and are listed in Table II.5.  
 
All PCR amplifications were performed using the Expand high fidelity PCR system 
(Roche) according to the manufacturer’s instructions.  
 
Reaction mixture:  
Primers (100 pmoles/µl)  0.5 µl each  50 pmoles each  
Template DNA (100 ng/µl)  0.5 µl   50 ng  
Buffer (10x)    5 µl   1 x  
dNTPs (10 mM)   1 µl each  50 µM each  
DMSO    2.5 µl   5%  
DNA polymerase (2.5 U/µl)  1 µl   2.5 Units  
Water     36 µl  
 
Cycle conditions (Touchgene Gradient, Techne):  
Initial denaturation:  94 °C, 2 min  
Denaturation:   94 °C, 45 s  
Primer annealing:  50 °C, 45 s   10 cycles  
Extension:   72 °C, 90 s 
Denaturation:   94 °C, 45 s  
Primer annealing:  55 °C, 45 s   15 cycles  
Extension:   72 °C, 90 s  
Final extension:  72 °C, 5 min  
 
5 µl of the PCR product was used for analysis by agarose gel electrophoresis 
(Section II.3.7.). To remove enzymes and unincorporated primers and dNTPs, the 
remaining 45 µl of the PCR product were treated as in Section II.4.3. The PCR 
product was eluted from the column with 20 µl of elution buffer to yield a DNA 
concentration of approximately 100 ng/µl.  
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II.6.2. PCR targeting of a cosmid  
 
Streptomyces Supercos I-based cosmids were introduced into E. coli 
BW25113/pIJ790 by electroporation (Section II.3.9.). E. coli BW25113 is a λ-RED 
recombination-proficient host strain. pIJ790 carries the antibiotic resistance marker 
cat (CmR) and a temperature sensitive origin of replication (i.e. it replicates at 30 
°C, but not at 37 °C). Transformants from the electroporation were selected by 
spreading onto L agar containing Carb, Kan and Cm and incubated overnight at 30 
°C.  
 
10 ml SOB (without MgSO4) containing Carb, Kan and Cm was inoculated at a 
concentration of 1 % with an overnight culture of E. coli BW25113/pIJ790 
containing the cosmid of interest. 100 µl 1 M L-arabinose was added to a final 
concentration of 10 mM to induce the λ-RED recombination system. The culture 
was grown for 3-4 h at 30 °C with shaking at 200 rpm to an OD600 of ~ 0.6 and 
electrocompetent cells were prepared. 50 µl cell suspension were then mixed with 
1 µl (~ 100 ng) of PCR product and electroporated (Section II.3.9.). Selection for 
targeted cosmids was carried out on L agar containing Carb, Kan and Apra or Hyg 
(on DNA medium) overnight at 37 °C. Correct targeting of cosmids was confirmed 
by PCR and restriction analysis.  
 
II.6.3. Transfer of mutant cosmids into Streptomyces 
 
For Streptomyces species that carry a methyl-specific restriction system, it was 
necessary to passage the targeted cosmids through the non-methylating host E. 
coli ET12567, which contains the RP4 derivative pUZ8002. The cosmid was 
subsequently transferred to Streptomyces by conjugation (Section II.3.12.) and 
exconjugants were selected using the appropriate antibiotics. Single colonies were 
replica-plated onto DNA medium containing Nal and Apra or Hyg with and without 
Kan, which allowed for the identification of double crossover exconjugants (KanS 
and ApraR). These were picked from the DNA medium and streaked for single 
colonies on SFM containing Nal and Apra or Hyg. The Kan sensitivity was 
reconfirmed by replica plating onto DNA medium containing Nal with and without 
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Kan. Purified KanS strains were verified by PCR and for replacement mutants as 
well by Southern hybridisation analysis (Section II.5.1.). 
 
II.7. Protein Methods  
 
II.7.1. Purification of His-tagged proteins  
 
Recombinant 6His-MBP fusion proteins were purified from 3 liters of L medium 
after induction with 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) at 30 °C 
for 4 h. Cell pellets were resuspended in 40 ml lysis buffer (50 mM Tris HCl pH 7.9, 
10 % glycerol, 1 mM phenylmethanesulfonyl fluoride), lysed with a French press, 
and the cell lysate clarified by centrifugation (20 min at 40,000 g). The cleared 
lysate was applied to a 1 ml Ni2+-loaded Hi-Trap Chelating HD column (GE 
Healthcare), washed with 25 mM K2HPO4 pH 7.9, 200 mM NaCl, 20 mM imidazole 
and eluted with an imidazole gradient. The eluted proteins were dialysed into 
storage buffer (50 mM Tris HCl pH 7.9, 50 mM NaCl, 1 mM tris(2-
carboxyethyl)phosphine (TCEP)), aliquoted and stored at -80 ºC. 
 
II.7.2. Protein quantification  
 
Bovine serum albumin (BSA) standards of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.4 
ng/ml were prepared in cuvettes in 0.5 ml volumes. Unknown samples were diluted 
to fit within the range of standards. The DC protein assay (Bio-Rad) was used 
according to the manufacturer’s instructions, with an equivalent amount of protein 
buffer in each BSA standard, sample and blank. The standard curve generated 
from the standards was used to calculate the protein concentrations in the 
experimental samples.  
 
II.7.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Polyacrylamide gels were assembled in their casting stands and prepared using 
the Bio-Rad system. Resolving gels of between 10-15 % acrylamide were 
prepared, containing 0.325 M Tris-HCl pH 8.8, 0.1 % (w/v) SDS, 0.01 % (v/v) 
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N,N,N’,N’-tetramethylethylenediamine (TEMED), 0.1 % (v/v) ammonium 
persulphate. The mixture was poured into the plates to 2 cm below the top and 
covered with 0.1 % SDS. After polymerisation, the 0.1 % SDS was poured off and 
a stacking gel, comprising 3 % acrylamide, 0.125 M Tris-HCl pH 6.8, 0.1 % (w/v) 
SDS, 0.01 % (v/v) TEMED, 0.1 % (w/v) ammonium persulphate, was poured on top 
and a comb inserted. After polymerisation, gels were removed from their casting 
holders, fitted to electrodes and placed into the tank supplied which was filled with 
1 x SDS running buffer (25 mM Tris, 200 mM glycine, 0.1 % SDS). Samples were 
prepared for loading by dilution in SDS loading buffer (62.5 mM Tris-HCl, 10 % 
glycerol, 2 % SDS, 0.01 mg/ml bromophenol blue, 5 % β-mercaptoethanol) and 
boiled for 10 min after which they were placed immediately on ice. Gels were 
typically run at 150 V until the bromophenol blue had passed through the resolving 
gel. To visualise protein bands, the gel was removed from between the glass 
plates, rinsed in de-ionised water and immersed in InstantBlue protein gel stain 
(Expedeon). Gels were incubated with gentle shaking at room temperature to allow 
protein bands to appear. 
 
II.8. Mass spectrometry 
 
II.8.1. MALDI-ToF and Q-ToF MS 
 
CHCl3 was evaporated from 1 ml of production culture extract and the resulting 
pellet dissolved in 50 µl 5% formic acid. Samples (ca. 0.8 µl) were spotted onto a 
PAC plate (Prespotted AnchorChip MALDI target plate, Bruker Daltonics, Bremen, 
Germany) and washed briefly with 8 µl 5% formic acid. After drying, the samples 
were analyzed by Matrix-Assisted Laser Desorption Ionization-Time-of-Flight MS 
on a Bruker Ultraflex TOF/TOF. The instrument was calibrated using pre-spotted 
standards (ca. 200 laser shots). Samples were analyzed using a laser power of 
approx. 25% and spectra were summed from ca. 20 x 20 laser shots. For Q-ToF 
MS analysis, the peptide was directly infused into a QToF II (Waters, Manchester, 
UK), and analysed with MassLynx 4.1. The sample was diluted into 30% 
methanol/30% Acetonitrile/1% acetic acid and applied with a GlassTip (New 
Objective, Woburn, MA 01801, USA) by nano-electrospray. Full MS scan analysis 
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was performed with standard settings, and fragmentation was achieved by 
increasing the collision energy up to 40.  
 
II.8.2. Thiol alkylation 
 
Alkylation of the free thiol group in the cypemycin intermediate produced by M1517 
(∆cypD) was adapted from Sechi and Chait (1998). Briefly, culture medium from a 
three day old production culture was incubated at 60°C for 30 min under reducing 
conditions in the presence of 5 mM tris(2-carboxyethyl)phosphine (TCEP). The 
mixture was allowed to cool to 25 °C. Iodoacetamide was added to a final 
concentration of 10 mM and the mixture incubated in the dark at 25 °C for 30 min. 
CHCl3 extraction was performed as described before and the sample analyzed by 
MALDI-ToF and Q-ToF MS. 
  
III – Identification of the cypemycin gene cluster 
 
78 
Chapter III – Identification of the cypemycin gene cluster 
 
III.1. Introduction 
 
Cypemycin is a linear peptide antibiotic that is produced by Streptomyces sp. OH-
4156 (Komiyama et al. 1993)(Chapter I.8.). It displays potent cytocidal activity (half 
maximum inhibitory concentration (IC50) = 1.3 µg/ml) against P388 mouse leukemia 
cells in an in vitro assay and it inhibits growth of Micrococcus luteus (minimal 
inhibitory concentration (MIC) = 0.2 µg/ml) (Komiyama et al. 1993). The structure of 
cypemycin was determined by fast atom bombardment mass spectrometry (FAB-
MS), nuclear magnetic resonance (NMR) and amino acid analysis (Minami et al. 
1994). This revealed the occurrence of four different non-proteogenic amino acids, 
two of which are unique to cypemycin. The first unique residue is a dimethylalanine 
(Me2-Ala), located at the N-terminus. Cypemycin also contains two L-allo-
isoleucines (L-allo-Ile), the second modification that is unique to cypemycin 
(reviewed in McIntosh et al. 2009). The two remaining modifications are also found 
in lantibiotics. There are four dehydrobutyrine (Dhb), residues that result from the 
dehydration of Thr in the propeptides of lantibiotics (Chatterjee et al. 2005), and at 
the C-terminus, a S-[(Z)-2-aminovinyl]-D-cysteine (AviCys). This latter modification 
also occurs in the lantibiotics epidermin (Allgaier et al. 1986), gallidermin (Kellner 
et al. 1988), mutacin 1140 (Smith et al. 2000) and microbisporicin (Castiglione et 
al. 2008; Foulston & Bibb, 2010). Mersacidin contains the related S-[(Z)-2-
aminovinyl]-3-methyl-D-cysteine (MeAviCys), which is in essence a methylated 
version of AviCys (Schneider et al. 2000). At the start of this thesis, the information 
available on cypemycin was restricted to its structural properties, its producer 
organism S. sp. OJ-4156 and the fermentation conditions for production. A genetic 
analysis of cypemycin biosynthesis was therefore performed to obtain more insight 
into the production of this unusual peptide. 
 
This chapter deals with the identification of the cypemycin gene cluster. First, some 
general experiments will be discussed that characterise the strain and its 
compound. A cosmid library was generated from genomic DNA of S. sp. OH-4156 
as a first step towards the identification of the cluster. Next, experiments based on 
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the predicted degenerate nucleotide sequence of the precursor gene cypA will be 
described that were aimed at identifying cosmids from the genomic library 
containing the cluster. These attempts failed and a genome scanning approach 
was adopted that revealed a striking similarity between the genomes of S. sp. OH-
4156 and S. venezuelae. The data acquired from genome scanning provided us 
with sufficient DNA sequence to generate a specific probe for the cypemycin 
structural gene. This probe was used in a Southern hybridisation experiment to 
identify cosmids containing cypA and subsequent heterologous expression 
identified those that contained all necessary genes for cypemycin production. A 
candidate cosmid was sequenced and this revealed that the cypemycin 
biosynthetic gene cluster encodes novel enzymes and that cypemycin is not, in 
fact, a lantibiotic. 
 
III.2. Characterisation of cypemycin and its producer strain 
 
III.2.1. Antibiotic sensitivities of S. sp. OH-4156 
 
The taxonomy of and culture conditions for S. sp. OH-4156 were described in 
Komiyama et al. (1993). Since no information was available on antibiotic resistance 
in this strain, the minimal inhibitory concentration (MIC) was determined for 
apramycin (Apra), kanamycin (Kan), hygromycin B (Hyg), thiostrepton (Thio) and 
spectinomycin/streptomycin (Spec/Strep) on a range of different media. The results 
of the MIC determination are summarised in Table III.1. Apra and Kan appeared to 
be good candidates for selection at their standardly used (for streptomycetes) 
concentration of 50 µg/ml. Thio and Spec/Strep also appeared suitable for 
selection at concentrations of 50 and 400/10 µg/ml, respectively. S. sp. OH-4156 
was resistant to high levels of Hyg (up to 35 µg/ml) and use of this antibiotic, which 
is commonly added at a final concentration of 40 µg/ml, was avoided. The most 
commonly used resistance markers in PCR targeting mutagenesis are Apra and 
Kan, and cassettes with resistance markers for Hyg and Spec/Strep are also 
available. The antibiotic sensitivity profile of S. sp. OH-4156 suggested that genetic 
manipulation by PCR targeting might be possible, provided that the resistance 
markers for these antibiotics were functional in this strain.  
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Table III.1. Minimal inhibitory concentration (MIC) values for S. sp. OH-4156 when grown 
on solid medium. Values shown in the table are the minimal concentration (in µg/ml) for 
which no growth of S. sp. OH-4156 was observed. Spec/Strep are commonly added in 
combination for selection. N/D = Not determined. 
 
SFM MYM tap DNA
Kan 35 5 5
Apra 20 5 5
Thio 20 5 N/D
Spec/Strep 100 / 2.5 200 / 5 N/D
Hyg N/D N/D 35
 
 
 
III.2.2. Cypemycin detection by bio-assay and MALDI-ToF MS 
 
S. sp. OH-4156 was grown on common agar media for culturing Streptomyces 
species (Kieser et al. 2000) to determine suitable conditions for cypemycin 
production. Cypemycin was known to be produced in liquid culture (Komiyama et 
al. 1993) and an adapted version of the medium described in that study (called 
MarM in this thesis) was also used in solid agar form to grow S. sp. OH-4156. 
Production of antimicrobial activity was assayed after three and five days by 
overlaying the plates with soft nutrient agar (SNA) containing M. luteus as an 
indicator strain (Chapter II.3.15.). The antimicrobial activity of S. lividans TK24 was 
assessed under the same conditions to identify media that would be suitable for 
screening for heterologous cypemycin production. Neither S. sp. OH-4156 nor S. 
lividans developed morphologically on solid MarM medium, even after prolonged 
incubation for up to two weeks. Moreover, the cypemycin producer spread out 
across the medium surface far beyond the location of the initial inoculation, making 
overlay assays very challenging. However, a zone of inhibition was observed 
around S. sp. OH-4156 but not S. lividans on MarM (data not shown). Similar 
observations were made for R5 and SFM, indicating that these three media could 
be used for heterologous expression in S. lividans. 
 
Because of difficulties with the overlay assay using the cypemycin production 
medium MarM, bio-assays from liquid grown cultures were also considered. S. sp. 
OH-4156 was grown for three days in a SOC seed culture which was used to 
inoculate MarM production medium. After another three days of growth, 
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comparably grown cultures were extracted with CHCl3. This method proved best 
for cypemycin detection by bio-assay and Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight mass spectrometry (MALDI-ToF MS) and was 
used for all further experiments described in this thesis. Growth of S. lividans under 
similar conditions did not result in the production of antibacterial activity in a M. 
luteus bio-assay. 
 
Several streptomycetes are known to produce multiple compounds with antibiotic 
activity and M. luteus is an indicator organism that is sensitive to many antibiotics 
(Young et al. 2010). To assess whether the observed antibacterial activity against 
M. luteus could reflect, at least in part, cypemycin production, the extract from the 
liquid MarM grown culture of S. sp. OH-4156 was analysed by MALDI-ToF MS. A 
set of three peaks ([M+H]+ = 2096 Da, [M+Na]+ = 2118 Da and [M+K]+ = 2134 Da) 
was observed in the spectrum, which is in good agreement with the calculated 
mono-isotopic mass of 2095.13 Da for cypemycin (Figure III.1.). Note that even 
though Minami et al. (1994) reported the correct molecular formula for cypemycin 
as C99H154N24O24S, an [M+H]+ of 2095 Da is reported, which in its turn is 
inconsistent with the [M+H]+ = 2097 Da in the preceding paper by the same group 
(Komiyama et al. 1993). 
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Figure III.1. MALDI-ToF MS spectrum of cypemycin ([M+H]+ = 2096 Da, [M+Na]+ = 2118 Da 
and [M+K]+ = 2134 Da). 
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III.2.3. Structure verification by Q-ToF 
 
Quadrupole Time-of-Flight (Q-ToF) MS was also employed to analyze the structure 
of cypemycin (Figure III.2.). This allowed the determination of the amino acid 
sequence between Pro3 and the C-terminal AviCys residue (the latter did not 
fragment into readily identifiable sub-fragments). Cypemycin is especially suitable 
for this approach as it does not contain any Me(Lan) or other bridge structures, 
apart from the C-terminal AviCys. Q-TOF MS analysis was also used subsequently 
to study the location and nature of the modifications in cypemycin and its 
intermediates without the need for pure compound or large quantities. 
 
 
Figure III.2. Q-ToF spectrum of cypemycin. Fragmentation of the modified linear peptide allows 
determination of the amino acid sequence, and the nature and locations of modified residues. 
The amino acid sequence between Pro3 and the AviCys residue (which does not fragment into 
easily interpretable masses) can be readily discerned and is shown above the spectrum. 
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III.3. Generation and screening of a genomic cosmid library  
 
To clone the cypemycin biosynthetic gene cluster, a cosmid library was generated 
from genomic DNA of S. sp. OH-4156 in SuperCosI (Chapter II.3.13). Various 
methods were employed to either identify the cosmids from this library that 
harboured the cypemycin biosynthetic gene cluster or to obtain a specific 
sequence for the region containing the structural gene cypA.  
 
III.3.1. PCR based screening 
 
All amino acids in cypemycin are in the L-configuration (Minami et al. 1994), 
presumably reflecting the post-translational modification of a ribosomal precursor 
peptide. A propeptide sequence was predicted based on the mature peptide and 
assuming that the Dhb residues result from Thr dehydration and that AviCys is 
formed from a Ser at position 19 and a C-terminal Cys, as observed in lantibiotics 
(Chatterjee et al. 2005). The other two modifications in cypemycin have not been 
described previously, so the two L-allo-Ile residues were assumed to result from 
modification of Ile, and the N-terminal Me2-Ala from methylation of an Ala in the 
prosequence (Figure III.3.). This predicted pro-CypA sequence was reverse 
translated to give a degenerate nucleotide sequence that was used to design 16 nt 
primers Cyp deg F and Cyp deg R. These primers were used in a gradient PCR 
with S. sp. OH-4156 genomic DNA as a template to amplify a predicted 66 bp DNA 
fragment. Such a fragment would allow for the identification of a partial non-
degenerate pro-cypA sequence, which could then be used to generate a specific 
probe for screening the cosmid library. Unfortunately, no amplification product was 
obtained, possibly because of the high degree of degeneracy of the 16 nt primers 
(1024-fold and 2048-fold respectively).  
 
An attempt was made to reduce the degeneracy of the probe sequence by 
adopting the preferred GC-rich Streptomyces codon usage (Kieser et al. 2000). 
The resulting modified sequence was used to generate a 20 nt probe (Cyp probe 
1) with only four-fold degeneracy and full length probe of 66 bp (Cyp probe 2) with 
65536-fold degeneracy (Figure III.3.). Although the latter probe appears highly 
degenerate, it is only 64-fold more degenerate than the much shorter 16 nt primers 
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Cyp deg F and Cyp deg R. Cyp probe 1 and 2 were used subsequently for 
Southern hybridisation (Chapter III.3.2.) and ligation-mediated PCR (LM-PCR) 
(Chapter III.3.3.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.3. Design of degenerate primers and probes for cypA. The predicted propeptide 
sequence for cypA was reverse translated and the resulting degenerate sequence was 
used to design primers Cyp deg F and Cyp deg R as indicated by the blue arrows. This 
sequence was then adapted to the preferential Streptomyces codon usage to reduce 
degeneracy. Degenerate positions are indicated in red, codon positions for which other 
bases are possible are underlined. N = A, C, T or G; S = C or G; W = A or T; R = A or G; Y 
= C or T; H = A, C or T. 
 
CA
CA
CA
CA
Degenerate probes (preferential Streptomyces codon usage): 
GCS ACS CCS GCS ACS CCS ACS GTS GCS G TTC GTS ATC G GGS TCS ACS ATC TCS CTS GTS TGC
GCS G TTC GTS ATC G GG
Ala Thr Pro Ala Thr Pro Thr Val Ala Gln Phe Val Ile Gln Gly Ser Thr Ile Ser Leu Val Cys
GCN  ACN CCN  GCN  ACN CCN  ACN  GTN GCN CAR  TTY   GTN  ATH 
Cyp deg F
Cyp deg R
CAR  GGN WSN  ACN ATH WSN YTN   GTN   TGY   
Predicted propeptide sequence and reverse translation:
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III.3.2. Southern hybridisation-based screening 
 
Cyp probe 2 was labelled with digoxigenin (DIG) and used in a Southern 
hybridisation experiment to probe S. sp. OH-4156 genomic DNA digested with an 
enzyme for which recognition sites were predicted to occur frequently (BamHI), 
intermediately (BglII) or infrequently (EcoRI). Despite the use of low-stringency 
conditions in the hybridisation, no hybridising fragments were identified with the 
Cyp probe 2. A possible explanation could be that detection with DIG-labelled 
degenerate probes of this size is not sensitive enough. 
 
To increase the sensitivity of the Southern hybridisation, Cyp probe 2 was labelled 
with α-32P-dCTP (Chapter II.5.2.). The resulting probe was used in a hybridisation 
with a membrane that was spotted with 3072 clones from the genomic cosmid 
library of S. sp. OH-4156. After incubation under low-stringency conditions, a high 
background signal was detected, but two double dot patterns could be identified 
indicating putative hybridising cosmid clones (Figure III.4.). Subsequent washes of 
the membrane at stepwise temperature increments succeeded in removing the 
background noise, but no additional pairs of dots were observed. The two 
candidate cosmids were taken from the library and spotted onto a nylon 
membrane. Unfortunately, neither cosmid hybridised with the Cyp probe 2, 
suggesting spurious initial hybridisation. 
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Figure III.4. Hybridisation of a nylon membrane containing S. sp. OH-4156 cosmid library 
clones with α-32P-CTP labelled Cyp probe 2. Two double dot patterns  indicative of putative 
hybridising cosmids are circled. 
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III.3.3. Ligation-mediated-PCR 
 
An LM-PCR-based approach was taken to try and acquire sequence information of 
the cypA region that could be used to generate a specific probe. LM-PCR is a 
technique that was previously used to identify the location of transposon insertions 
in the genome of S. coelicolor. The principle is based on a PCR with one primer 
that is homologous to a known sequence and a second primer that anneals to a 
designed linker sequence (Figure III.5.). Genomic DNA is digested with a 
frequently cutting restriction enzyme (such as EagI) and subsequently ligated to 
double stranded oligonucleotides with complementary overhanging ends. The 
resulting ligation product is used as template in the LM-PCR reaction. Only 
fragments that contain the complementary sequence to the internal primer will 
generate an amplification product.  
 
 
 
 
 
 
 
 
Figure III.5. The principle of Ligation-Mediated-PCR (LM-PCR). Genomic DNA is digested 
with a frequent cutting restriction enzyme (e.g. EagI). Double stranded oligonucleotides with 
complementary overhanging sequences (depicted in pink) are ligated to the restriction 
fragments. The resulting ligation product is used as template in the LM-PCR reaction with 
one linker primer (pink arrow) and one primer complementary to a known sequence (blue 
arrow). 
 
 
The LM-PCR approach was applied to S. sp. OH-4156 genomic DNA (and the two 
putative positive cosmids identified in Chapter III.3.2.) as template, using an EagI 
linker and Cyp probe 1 as the internal primer. An advantage of LM-PCR over 
amplification with degenerate primers (Chapter III.3.1.) is that only one degenerate 
primer is used in the reaction mix. Also, the expected PCR products are larger, 
facilitating their detection by agarose gel-electrophoresis. The LM-PCR reaction 
EagI cypA
cypA
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yielded a number of different sized amplicons that were cloned in pGEM-T Easy for 
sequencing. Unfortunately, none of the resulting sequences appeared to be 
derived from the cypA region of the genome, indicating that all presumably resulted 
from non-specific annealing of Cyp probe 1. 
 
III.4. Genome scanning of S. sp. OH-4156 
 
Since the strategies described in the previous section all proved to be 
unsuccessful, Solexa-based genome scanning of S. sp. OH-4156 was carried out. 
15471 contigs were generated with a median length of 378 bp and an additive 
length of 8.5 Mb, typical of a Streptomyces genome (Bentley et al. 2002). A 
tBLASTn search of the contig database with cypemycin’s predicted propeptide 
sequence identified a 1888 bp contig containing the cypemycin precursor gene, 
cypA, confirming that cypemycin is indeed ribosomally synthesized (Figure III.6.).  
 
 
A
B
vrsemtltstnsaealaaqdfantvlsaaapgfhadcetpam
ATPATPTVAQFVIQGSTICLVC
1 21
-1
 
Figure III.6. Sequence of the cypemycin prepropeptide deduced by genome scanning. A) 
Schematic representation of fully modified cypemycin and B) the unmodified CypA 
preproprotein. 
 
 
The 22 amino acid CypA propeptide sequence revealed the identity of the residues 
subjected to post-translational modification. As expected, the four Dhb residues of 
cypemycin result from dehydration of Thr, Me2-Ala is formed by methylation of an 
alanine residue and the two L-allo-Iles are introduced by side-chain isomerization 
of L-Ile. Surprisingly, the AviCys modification is formed from two Cys residues. This 
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is unprecedented - previously described AviCys residues are generated from an 
internal Ser and a C-terminal Cys. The first step in AviCys formation is LanD-
mediated oxidative decarboxylation of the propeptide’s C-terminal Cys. This yields 
an enethiol intermediate that can form the AviCys after addition to a Dha, created 
by dehydration from the internal Ser (Blaesse et al. 2000).  
 
As in most other post-translationally modified peptides, the propeptide is preceded 
by a leader sequence that is removed during or after maturation (Oman and van 
der Donk 2010). The CypA propeptide is preceded by a 42 amino acid leader 
sequence that does not display similarity to lantibiotic leader peptides. Moreover, 
while lantibiotic leader sequences are always devoid of Cys (Chatterjee et al. 
2005), the CypA leader peptide contains a Cys at position -6 relative to the 
cleavage site.  
 
Additional tBLASTn searches of the Solexa data were performed to identify 
putative cypemycin biosynthetic genes. Using amino acid sequences of LanB and 
LanM dehydratases from the NCBI database, a few contigs with apparent 
homology to lanM were identified. Physical linkage between these and the cypA 
contig could not be established by PCR analysis. While tBLASTn searches with 
LanD decarboxylases did not identify a LanD homologue, a contig with the partial 
sequence of a 4’-phosphopanthothenoylcysteine (PPC) decarboxylase was found. 
PPC decarboxylases belong to the homo-oligomeric flavin-containing Cys-
decarboxylase (HFCD) family that also encompasses LanD proteins (Kupke et al. 
2000).  
 
BLAST searches revealed that contigs from the S. sp. OH-4156 genome scanning 
closely resembled the genome sequence of S. venezuelae. When the S. sp. OH-
4156 contigs were mapped onto their orthologous sequences in the S. venezuelae 
genome (>95 % identity for contigs of 100 bp or longer), only a few gaps remained 
for which no corresponding contigs were identified (Govind Chandra, Figure III.7.). 
Interestingly, most of the known or predicted secondary metabolite gene clusters 
from S. venezuelae fall into these gaps. Conversely, the four putative lantipeptide 
clusters in S. venezuelae (Chapter VII.3.) all have an orthologous counterpart in S. 
sp. OH-4156.  
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Figure III.7. Comparison between S. sp. OH-4156 genome scanning data and the S. 
venezuelae genome. Orthologous S. sp. OH-4156 contigs were mapped onto the genome 
sequence of S. venezuelae (>95 % identity for contigs of 100 bp or longer). Areas that are 
not covered by the S. sp. OH-4156 contigs are colour coded: Orthologous predicted or 
known secondary metabolism gene clusters present in both species (green), partially 
present in S. sp. OH-4156 (orange) and absent from S.sp. OH-4156 (red) are shown. 
Regions of the S. venezuelae genome not represented in S. sp OH-4156 and lacking  
predicted secondary metabolite gene clusters are shown in blue.  
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An interesting observation was made when the gaps corresponding to the S. 
venezuelae secondary metabolite gene clusters were investigated in more detail. 
The predicted extent of the S. venezuelae gene clusters generally correlated well 
with the boundaries for the orthologous S. sp. OH-4156 sequence data. This is 
illustrated for the chloramphenicol gene cluster (Figure III.8.). He et al. (2001) 
reported the involvement of SMD01679 to SMD01694 in chloramphenicol 
biosynthesis. The region onto which orthologous S. sp. OH-4156 contigs map in 
the S. venezuelae genome starts eight genes to the left and ends four genes to the 
right of the chloramphenicol gene cluster, suggesting that these additional flanking 
genes may also be involved in chloramphenicol biosynthesis. Similar examples of 
corresponding gaps are found for seven additional S. venezuelae gene clusters 
(data not shown). 
 
 
 
 
Figure III.8. Analysis of the S. venezuelae chromosomal region harbouring the 
chloramphenicol biosynthetic gene cluster. S. venezuelae genes are represented by yellow 
arrows, orthologous S. sp. OH-4156 contigs by blue arrows. The published 
chloramphenicol gene cluster spans from SMD01679 to SMD01694. Note: the S. 
venezuelae gene annotations do not have successive numbers in this region of the 
genome. 
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III.5. Identification of the cosmids bearing the cypemycin 
biosynthetic cluster 
 
III.5.1. Generation of specific cypA probe and library screen 
 
The Solexa data was used to generate a specific 480 bp probe by PCR using 
primers cypA T1 and T2 that encompassed cypA and flanking sequences. The 
probe was labelled with α-32P-dCTP and hybridized to a nylon membrane spotted 
with the S. sp. OH-4156 genomic cosmid library (Chapter II.3.13.). Fourteen 
hybridizing cosmids were identified (Figure III.9.). Very low levels of background 
hybridisation were observed in this experiment compared to the previous 
hybridisation with the Cyp probe 2 (Figure III.4., Chapter III.3.2.). The two cosmids 
identified with the Cyp probe 2 were not picked up with the specific 480 bp probe, 
suggesting earlier spurious hybridisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.9. Hybridisation of a nylon membrane spotted with 3072 S. sp. OH-4156 genomic 
cosmid library clones with a 480 bp 32P-labelled cypA probe. Fourteen putative cypA-
containing cosmids were identified from their double dot patterns. 
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III.5.2. Heterologous expression of the positive cosmids in S. 
venezuelae 
 
To determine which of the cosmids contained all of the genes required for 
cypemycin production, the vector backbones of nine of the hybridizing cosmids 
were PCR-targeted with a 5.2 kb SspI fragment from pIJ10702 containing oriT, 
enabling the cosmid to be conjugated into a Streptomyces host, and a φC31 
integrase gene and phage attachment site for integration of the cosmid into the 
genome of the heterologous host. Stable integration at the φC31 attB site obviates 
the need for antibiotic selection, greatly facilitating subsequent bioactivity assays. 
Streptomyces venezuelae was chosen as an initial heterologous host because of 
the relatively high level of nucleotide sequence identity between its genome and 
the Solexa data from S. sp. OH-4156. The nine exconjugants and a control strain 
with the integrated cosmid backbone were assessed for cypemycin production in a 
M. luteus bio-assay and by MALDI-ToF MS. Six of the nine strains produced 
cypemycin with MALDI-ToF peaks of: [M+H]+ = 2096 Da, [M+Na]+ = 2118 Da and 
[M+K]+ = 2134 Da, indicating that the integrated cosmids contained all of the genes 
required for cypemycin production (Figure III.10.).  
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Figure III.10. Heterologous expression of the cypemycin biosynthetic gene cluster in S. 
venezuelae. MALDI-ToF spectra for S. sp. OH-4156, S. venezuelae with the empty vector 
pIJ10702 (M1400), and S. venezuelae derivatives with cosmids containing all of the genes 
required for cypemycin production (M1401, M1402, M1403, M1404, M1405 and M1408) 
and those with a cosmid that does not (M1406, M1407 and M1409). 
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Levels of cypemycin production in the S. venezuelae exconjugants, judged by the 
sizes of inhibition zones (Figure III.11.), were much lower than those of the natural 
producer. Since it gave the largest zone of inhibition upon heterologous 
expression, pIJ12404 was chosen for sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.11. Heterologous expression of the cypemycin biosynthetic gene cluster in S. 
venezuelae. M. luteus bio-assay of the nine S. venezuelae derivatives with a cypA-
containing cosmid. S. sp. OH-4156 positive control, M1400 (EV, empty vector) negative 
control, and M1401-M1409 are the S. venezuelae clones containing hybridizing library 
cosmids. The halos observed for M1401, M1403, M1405 and M1408 are much smaller than 
that of the natural producer; while clones M1402 and M1404 failed to produce a halo, 
cypemycin production was confirmed by MALDI-ToF analysis. 
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III.6. The cypemycin biosynthetic cluster 
 
Analysis of open reading frames (ORFs) in the pIJ12404 nucleotide sequence 
identified a putative biosynthetic gene cluster of nine genes (Figure III.12.A.). 
Upstream of cypA and divergently transcribed from it is orf1, which encodes a 
putative transcriptional regulator. Seven genes with predicted biosynthetic and 
transport functions lie directly downstream of cypA, the first six of which are likely 
to be co-transcribed since their coding sequences overlap by several nucleotides 
(i.e. they appear to be translationally coupled). The first gene downstream of cypA 
is cypH, which encodes a product with no significant homology to functionally 
characterized proteins. CypH is likely a two-domain protein with partial homology to 
a conserved horizontally transferred transmembrane helix domain at its N-terminus 
(Schultz 2004) and a possible α/β hydrolase fold located towards its C-terminus. 
Following cypH is cypL, again with no functionally identified homologs. The next 
gene, cypD, encodes a decarboxylase of the HFCD family (Kupke et al. 2000), and 
could be responsible for the introduction of AviCys, analogous to LanD enzymes in 
lantibiotic biosynthesis. cypM is the fourth gene downstream of cypA and encodes 
an S-adenosyl methionine (SAM)-dependent methyltransferase presumably 
required for methylation of the N-terminal alanine of cypemycin. These biosynthetic 
genes are followed by an adenosine triphosphate (ATP)-binding subunit of an ATP-
binding cassette (ABC) transporter, designated cypT. The last gene in which the 
start codon overlaps with the upstream ORF is cypP, encoding a 516 amino acid 
protein with 12 predicted transmembrane helices and with no functionally 
annotated homologues in the public databases (Figure III.12.B.). Because of its 
location downstream of cypT, it was suggested that this protein forms a pore in the 
cytoplasmic membrane to allow cypemycin export from cell. No leader peptidase 
domains were found in CypT or CypP. cypI is the last gene that is transcribed in 
the same direction, but its start codon does not overlap with the coding sequence 
of cypP. CypI is a member of the large DUF255 family of conserved proteins with a 
thioredoxin domain. Analysis of the remaining ORFs in the pIJ12404 cosmid 
sequence did not identify any lantibiotic dehydratase homologues indicating, 
contrary to previous classification, that cypemycin is not a member of the lantibiotic 
family of modified peptides (Chatterjee et al. 2005). 
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A 
 
 
 
B 
 
Figure III.12. A) Schematic representation of the cypemycin biosynthetic gene cluster. 
Flanking genes not expected to be involved in cypemycin biosynthesis are in grey. Vertical 
arrows delineate the putative cyp gene cluster used to generate a minimal gene set. B) 
CypP is a putative pore protein. TMHMM analysis identified 12 putative transmembrane 
domains (red). Predicted cytoplasmic domains are indicated in blue and exterior domains in 
pink. 
regulation? modification       transport      modification
orf1 cypA cypH cypL cypH cypP cypI
cypD cypT
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III.7. Discussion 
 
Various attempts were made to identify the gene cluster responsible for the 
biosynthesis of the unusual post-translationally modified peptide antibiotic 
cypemycin. This section is devoted to a discussion of these approaches. Since the 
next chapter describes the genetic characterisation of the cypemycin gene cluster, 
the reader is referred to Chapter IV.6. for a detailed discussion of the functions of 
individual genes.  
 
Several experiments described in this chapter relied on the use of degenerate 
primers or probes to obtain sequence information for cypA. The main factors that 
likely contributed to the failure of these experiments were the short length and 
degree of degeneracy of the primers/probes, and the reduced sensitivity of DIG-
labelling compared to radioactive labelling. The predicted CypA propeptide 
sequence turned out to be correct apart from the occurrence of a Cys at position 
19 where Ser was expected (compare Figure III.3. and III.6.B.). Although this 
probably had only a minor effect on Southern hybridisations with Cyp probe 2, the 
PCR reaction using Cyp deg R would have been markedly compromised. 
 
Alternative approaches that could have been used to identify the cypemycin gene 
cluster could have included a genetic screen for likely biosynthetic enzymes and an 
activity based screen. However, when employed for cypemycin, both would have 
been problematic. Starting from the assumption that cypemycin was a lantibiotic, a 
genetic screen could have been directed at the identification of lantibiotic 
dehydratases, for example by using primers complementary to conserved regions 
found in the corresponding genes (Dodd et al. 2006). Since it later emerged that 
cypemycin belongs to a different peptide family, this would have been a futile 
exercise. An activity based screen could have been performed by introducing the 
S. sp. OH-4156 cosmid library in a heterologous host. Lantibiotic and other post-
translationally modified peptide gene clusters are relatively small and there is a 
reasonable chance that at least a couple cosmids from a genome library will 
contain all of the necessary genes. However, it is difficult to predict whether the 
cluster will be expressed, and if so, at what level. In the case of cypemycin, 
heterologous production was observed in S. venezuelae, S. lividans and S. 
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coelicolor, but production levels varied markedly between these strains and the 
expression levels were generally too low to allow for a screen with single colonies 
against M. luteus.  
 
In summary, with the benefit of hindsight, it can be concluded that the genome 
scanning approach was particularly useful for the identification of the cypemycin 
gene cluster. The unusual precursor peptide and the novelty of the biosynthetic 
enzymes would have made the cluster difficult to find using other means.  
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III.8. Bullet point summary 
 
• A genomic cosmid library was generated for the cypemycin producer S. sp. 
OH-4156. Approaches based on degenerate nucleotide sequences derived 
from mature cypemycin failed to identify cosmids harbouring the 
biosynthetic gene cluster. 
 
• A genome scanning approach yielded a contig containing cypA. The CypA 
propeptide contains a Cys at position 19, where a Ser would be expected 
based on previously documented peptides with the AviCys modification. 
 
• A specific probe for the structural gene region identified cosmids from the 
library that contained cypA. Subsequent heterologous expression identified 
cosmids that contain all of the genes required for cypemycin biosynthesis. 
 
• Bio-informatic analysis of the cypemycin gene cluster revealed novel 
enzymes and indicated that cypemycin is not a lantibiotic. 
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Chapter IV – Mutational analysis of cypemycin biosynthesis 
 
IV.1. Introduction  
 
The cypemycin biosynthetic gene cluster was identified in Chapter III and 
heterologous expression in S. venezuelae demonstrated. This chapter describes 
the genetic characterisation of the gene cluster. First, the generation of a minimal 
gene set will be described, identifying the genes required for cypemycin 
production. Next, the function of each individual gene from this minimal set will be 
analysed by constructing in-frame deletion mutants in the heterologously 
expressed cluster and marked mutants in the natural producer. A bioinformatic 
search for related gene clusters revealed a novel family of post-translationally 
modified peptides. Finally, an attempt to generate cypemycin variants will be 
mentioned. 
 
IV.2. Generation of a minimal gene set 
 
Bioinformatic analysis suggested that the cypemycin biosynthetic gene cluster 
extended from cypA (or possibly orf1) to cypI (Figure III.12.A.). The region to the 
left of and including orf1 is syntenous with SCO4966 to SCO4969 in S. coelicolor 
(the latter being the orf1 ortholog) (Bentley et al. 2002). Genes to the left of orf1 are 
predicted to be involved in mycothiol detoxification and no function in cypemycin 
biosynthesis is envisaged. Genes to the right of cypI encode rodlins and a chaplin 
(homologues of SCO2716 to SCO2719 (Bentley et al. 2002)) that have been 
implicated in morphological development in S. coelicolor (Claessen et al. 2004) 
and therefore are also unlikely to be involved in cypemycin biosynthesis.  
 
Because no convenient restriction sites were available to excise the putative 
minimal cypemycin biosynthetic gene cluster and subsequently confirm its identity, 
a PCR targeting strategy was devised to introduce unique restriction sites flanking 
the putative gene cluster (Figure IV.1.) Briefly, pIJ12404 was PCR-targeted to the 
left of orf1 to introduce a unique XbaI restriction site. The antibiotic resistance 
cassette was removed by FLP-mediated recombination and the resulting cosmid 
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targeted a second time downstream of cypI, introducing a unique SspI restriction 
site. The 12.2 kb fragment containing the putative minimal gene cluster was 
subsequently excised by digestion with XbaI and SspI and ligated into 
XbaI/EcoRV-digested pSET152 to give pIJ12421. S. venezuelae was abandoned 
as a heterologous host because of low levels of cypemycin production. Instead, S. 
coelicolor M1146, from which four antibiotic gene clusters had been deleted and 
which lacks antibiotic activity, was used. Upon conjugation, pIJ12421 integrated as 
a single copy into the φC31 phage attachment site of M1146, yielding a stable 
strain (M1412) that did not require antibiotic selection to maintain the construct. 
Cypemycin production was confirmed by both an inhibition assay against M. luteus 
and MALDI-ToF analysis. The halo produced in the bio-assay was comparable in 
size to that produced by M1411 (M1146 harboring pIJ12413), indicating that the 
putatively assigned minimal gene set was indeed sufficient for cypemycin 
production in a heterologous host (Figure IV.2.A.). 
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Figure IV.1. Strategy for the construction of a minimal cyp gene set. Starting with cosmid 
pIJ12404, PCR-targeting was used to introduce an apramycin resistance cassette and 
unique XbaI restriction site upstream of orf1. The resistance gene was removed by FLP 
recombination and the resulting construct subjected to a second targeting event 
downstream of cypI with a different apramycin resistance cassette, this time introducing a 
unique SspI site. The 12.2 kb gene cluster was then excised by digestion with XbaI and 
SspI, and cloned into pSET152 digested with XbaI and EcoRV. 
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Figure IV.2. M. luteus bio-assays for A) The minimal gene set construct. B) the different 
scar mutants in the heterologous host M1146. 
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IV.3. Mutational analysis of the cypemycin cluster 
 
To investigate the function of each individual gene within the minimal gene set, 
individual in-frame ‘scarred’ deletion mutants were generated by PCR-targeting of 
pIJ12404. The backbones of the mutagenized cosmids were subsequently targeted 
with the 5.2 kb SspI fragment from pIJ10702 to allow integration into the φC31 
attachment site of M1146. Data obtained from heterologous expression in M1146 
(Figure IV.2.B. & IV.3.) was corroborated by generating apramycin-marked 
deletions of all genes in the minimal gene set in S. sp. OH-4156 (Figure IV.4.). 
Unless otherwise stated, in the following discussion the mutant described is always 
the heterologously expressed in-frame deletion mutant. The ∆cypA strain did not 
produce cypemycin (confirmed by MALDI-ToF) and no halo was produced in the 
bio-assay with M. luteus (Figure IV.2.B.).  
 
Deletion of the putative regulatory gene orf1 had no effect on cypemycin 
biosynthesis (confirmed by bioassay and MALDI-ToF analysis) consistent with 
production of cypemycin by the ∆orf1 mutant of S. sp. OH-4156. Individual deletion 
of cypH and cypL abolished cypemycin production. The ∆cypD knock-out strain 
produced a compound with a mass corresponding to non-decarboxylated 
cypemycin ([M+H]+ = 2142 Da, [M+Na]+ = 2164 Da and [M+K]+ = 2180 Da) that did 
not inhibit growth of M. luteus. It was hypothesized that Cys19 in this compound 
would be modified to Dha and that Cys22 would still be intact because of the lack 
of decarboxylation. To confirm this, alkylation with iodoacetamide was carried out 
to identify the free thiol groups in the peptide. A mass increased of 57 Da indicated 
the presence of only one free thiol group (Figure IV.5.A.). To confirm that this thiol 
group was derived from the C-terminal Cys, the presence of the Dha residue at the 
position of the first Cys was verified by Q-ToF analysis (Figure IV.5.B.). 
 
M1146 (∆cypM) also produced a truncated version of cypemycin detectable by 
MALDI-ToF ([M+H]+ = 2068 Da, [M+Na]+ = 2090 Da and [M+K]+ = 2106 Da), but 
failed to produce a zone of inhibition against M. luteus. The mass corresponds to a 
non-methylated version of cypemycin, which was confirmed by Q-ToF analysis 
(Figure IV.5.C.). 
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Figure IV.3. MALDI-TOF spectra for scar mutants in M1146. Spectra for S. sp. OH-4156 
positive control, M1146 with the inserted empty vector pIJ10702 (M1410), full cosmid 
(M1411), minimal gene set (M1412) and individual mutants in orf1 to cypI (M1413-M1421). 
Cypemycin is detected as [M+H]+ = 2096 Da, [M+Na]+ = 2118 Da and [M+K]+ = 2134 Da. 
The non-decarboxylated version of cypemycin (in M1417) appears as [M+H]+ = 2142 Da, 
[M+Na]+ = 2164 Da and [M+K]+ = 2180 Da and the non-methylated intermediate (in M1418) 
as [M+H]+ = 2068 Da, [M+Na]+ = 2090 Da and [M+K]+ = 2106 Da. 
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Figure IV.4. MALDI-ToF spectra of the apramycin-marked mutants in S. sp. OH-4156. 
Spectra for M1427 (∆orf1) to M1435 (∆cypI) show the same phenotypes as the 
heterologously expressed mutants (See Fig. S5). No cypemycin intermediate was detected 
in the culture of M1431 (∆cypD), whereas its heterologous counterpart (M1417) produced 
non-decarboxylated cypemycin. A possible explanation for this is that the replacement of 
cypD in this mutant with the pIJ773-derived cassette is causing a polar effect on the 
downstream cypM gene, making M1431 a ∆cypDM double mutant. The product of this 
mutant (cypemycin lacking the AviCys and the Me2-Ala) is thought to be unstable, but has 
been isolated from a heterologously expressing ∆cypDM double mutant (results not 
shown). Differences in protease activity between M1146 and S. sp. OH-4156 could account 
for this observation.  
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Figure IV.5. Structural verification of the truncated cypemycin derivatives. A) After alkylation of 
the free thiol groups in the product of the ∆cypD mutant, a single mass shift of +57 Da was 
observed indicating the presence of only one free thiol group. Non-decarboxylated cypemycin 
appears as [M+H]+ = 2142 Da, [M+Na]+ = 2164 Da and [M+K]+ = 2180 Da. The alkylated version 
is observed as [M+H]+ = 2199 Da and [M+O]+ = 2215 Da. B) Q-ToF analysis of the compound 
produced by the ∆cypD mutant shows that Cys19 has been dehydrated to dehydroalanine. C) Q-
ToF analysis confirming that the mass difference of the compound produced by the ∆cypM 
mutant is localized to the first two amino acids and thus is very likely to reflect the lack of the two 
N-terminal methyl groups.  
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Deletion of cypT or cypP resulted in reduced halo sizes, but MALDI-ToF analysis 
revealed some level of cypemycin production. The S. sp. OH-4156 ∆cypT and 
∆cypP mutants displayed similar phenotypes when analysed by bio-assay and 
MALDI-ToF. It is possible that an alternative transporter could export cypemycin 
out of the cell or, given the hydrophobic nature of the peptide, that some level of 
diffusion through the membrane can occur.  
 
Deletion of cypI had no effect on the production or activity of cypemycin. By a 
process of elimination, CypI is a possible candidate for isomerization of the Ile side 
chains to form L-allo-Ile, a modification that cannot be studied by MALDI-ToF since 
no mass change accompanies the isomerization. Analysis of the S. sp. OH-4156 
∆cypI strain showed an identical phenotype. If cypI is required for introduction of 
the allo-Ile residues in cypemycin, they are not required for antibacterial activity.  
 
The five M1146 derivatives that contained a mutagenized cosmid with a 
biosynthetic phenotype (M1414 (∆cypA), M1415 (∆cypH), M1416 (∆cypL), M1417 
(∆cypD) and M1418 (∆cypM)) were complemented with wild-type copies of the 
respective genes to confirm that the mutant phenotypes were indeed due to the 
targeted mutations. The coding sequence of each gene was cloned downstream of 
the constitutive ermE* promoter and EF-Tu ribosome binding site of pIJ10257. 
Upon conjugation, this vector integrates into the φBT1 phage attachment site of the 
S. coelicolor M1146 genome; again, antibiotic selection is not required to maintain 
the construct. Complementation of the ∆cypA through ∆cypM mutants was verified 
by MALDI-ToF analysis. Interestingly, in the complemented cypL mutant, non-
decarboxylated cypemycin was also produced (Figure IV.6.). 
 
 
 
 
 
 
Figure IV.6. Analysis of the complementation of the ∆cypL mutant M1424 confirms 
production of both cypemycin and the non-decarboxylated form. 
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IV.4. Cypemycin is a member of a larger family of post-
translationally modified peptides, the linaridins 
 
A search of the NCBI sequence database identified ten cypL homologues. Their 
occurrence always coincided with the presence, in close proximity, of genes with 
homology to cypH (sometimes just to the 5’ half of cypH) (Figure IV.7.). 
Interestingly, in Streptomyces viridochromogenes, the cypL homologue is present 
in a cluster with two genes, one of which is homologous to the 5’ half of cypH while 
the other to the 3’ half. All of these clusters, with the exception of the one in 
Solibacter usitatus, contain a short ORF that could encode a prepropeptide (Table 
IV.1.). Both cypL and cypH were essential for cypemycin biosynthesis and were 
required for introduction of dehydrobutyrine (dehydrated threonine) residues into 
the mature peptide. Given the rarity of the cypH and cypL homologues, and their 
invariant co-occurrence, I propose that the gene clusters in Figure IV.7. represent a 
new family of post-translationally modified peptides. Given that these peptides are 
predicted to be linear (lin) and non-cyclised, and to contain dehydrated (arid) amino 
acids, I propose the name linaridins. Although most of the linaridin gene clusters 
identified thus far occur in Actinomycetes (Gram-positive bacteria known for their 
ability to produce a wide range of secondary metabolites), they also occur in other 
bacterial phyla and even in Archaea (Figure IV.7.).  
 
So far, the occurrence of a decarboxylase (the cypD homologue) is restricted to 
cypemycin and the orthologous cluster from S. griseus. SAM-dependent 
methyltransferases are more prevalent in linaridin gene clusters, indicating that a 
subset of compounds could be modified by methylation of their N-terminal amino 
acid. Examples of genes other than those in the cypemycin cluster that could play 
a potential role in post-translational modification are oxidoreductase-
dehydrogenases (SCAB84211 and SSQG_04385), a metallophosphoesterase 
(FrEUN1DRAFT_0187) and a multi-copper oxidase (Acid_3062). Interestingly, 
homologous genes encoding a protein of unknown function are present in or 
immediately adjacent to linaridin gene clusters in Mycobacterium vanbaalenii 
(Mvan_2779), Solibacter usitatus (Acid_3059) and Haloterrigena turkmenica (two 
copies: Htur_3023 and Htur_3024; black in Figure IV.7.). The presence of this 
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homologue only in the linaridin gene clusters suggests a role that is dedicated to 
the production of modified peptides. 
 
 
 
 
Figure IV.7. The biosynthetic gene clusters of the linaridin family of peptides. Genes are color 
coded according to the predicted function of their products: structural genes (purple), cypH 
homologues (orange for the N-terminus, red for the C-terminus), cypL homologues (brown), 
decarboxylases (dark green), SAM-dependent methyltransferases (light blue), transporters 
(dark blue), regulation (light green), catalytic (pink), unknown (grey), unknown but specific to 
the filaridin clusters (black). 
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IV.5. Generation of cypemycin variants 
 
In this section, the importance of particular modified residues for cypemycin activity 
was investigated. This analysis could also have indicated whether altered 
substrates were still recognised by the modification enzymes. I opted for cypA 
expression from a high copy number plasmid since only low levels of cypemycin 
production were obtained in strain M1422 (M1146 containing the integrated ∆cypA 
cypemycin cosmid complemented with cypA in trans) (Chapter IV.3.). pIJ86 (ApraR) 
can be used to express genes from the constitutive ermE* promoter, but it could be 
introduced into M1422 since no Apra selection would be possible due to the ApraR 
marker present within the integrated construct. Consequently, the neo gene from 
SuperCosI that confers kanamycin resistance was PCR-amplified with primers neo 
NheI F and R that contained an extended tail with a NheI restriction site. This PCR 
fragment was cloned in the NheI site of pIJ86, resulting in pIJ12477, an expression 
plasmid that can be used in a host that is already ApraR. 
 
Three altered cypA genes were generated for the production of cypemycin variants 
(Figure IV.8.). In the first, a synthetic cypA gene (Biomatik, Cambridge Ontario), all 
four Thr codons (Thr2, Thr5, Thr7 and Thr17) were replaced by Ser codons. The 
construct was cloned in pIJ12477 yielding pIJ12479 (cypA 4S). Successful 
production of this variant could indicate whether CypH/CypL can dehydrate Ser 
residues and what the effect of this would be on bio-activity. The other two 
constructs were generated by PCR from cypA WT template with a mismatch 
reverse primer. In the second pIJ12477-based construct, Ser16 codon was 
replaced by a Thr codon, yielding pIJ12480 (cypA S-T). This cypemycin variant 
could provide information on why Ser16 escapes dehydration. The third cypA 
variant gene contained a Thr codon in place of the Cys19 codon. The construct 
resulting from the cloning of this gene in pIJ12477 was called pIJ12481 (cypA C-T). 
Should the Thr19 in this variant be dehydrated, this could result in the formation of 
a C-terminal MeAviCys. 
 
The constructs described above, as well as the vector pIJ12477 and a construct 
containing the WT cypA (pIJ12478), were introduced into M1414 (M1146 
containing the integrated ∆cypA cypemycin cosmid) by conjugation. The resulting 
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strains M1459 (pIJ12477 (EV)), M1460 (pIJ12478 (cypA WT)), M1461 (pIJ12479 
(cypA 4S)), M1414 (pIJ12480 (cypA S-T)) and M1414 (pIJ12481 (cypA C-T)) were 
grown under cypemycin production conditions with Kan selection to maintain the 
plasmid. Production of cypemycin variants was analysed by MALDI-ToF MS after 
CHCl3 extraction of the supernatants. As expected, no cypemycin peaks were 
observed in the mass spectrum of the empty vector control strain (M1459) and 
cypemycin was detected for the positive control strain containing the introduced 
cypA WT gene (M1460). No mass peaks were observed in the spectra of M1461 
(cypA 4S) or M1463 (cypA C-T) that could be attributed to a cypemycin variant. 
This suggests that these variant CypA precursors may be degraded rapidly in vivo 
either because modification of important residues cannot occur (for example if they 
are no longer accepted as a substrate by the modification enzymes) or because an 
altered modified residue prevents the correct introduction of later modifications (for 
example in the formation of a MeAviCys).  
 
 
 
 
Figure IV.8. Schematic representation of the three cypemycin variants. 
IV – Mutational analysis of cypemycin biosynthesis 
 
 
118 
MALDI-ToF MS analysis of the M1462 (cypA S-T) strain identified a compound 
with [M+H]+ = 2110 Da, [M+Na]+ = 2132 Da and [M+K]+ = 2148 Da (Figure IV.9.A.). 
This corresponds to the calculated mass for the S-T cypemycin variant with one of 
the Thr residues left unmodified. Q-ToF analysis revealed that the Thr16 residue 
had escaped dehydration and that a Dhb was present at position 17 (Figure 
IV.9.B.). This indicates that the context of the amino acid residue at position 16 in 
cypemycin is important for dehydration, regardless of whether it is Ser or Thr. A 
similar observation has been made with some lantibiotics (Rink et al. 2005). 
Insufficient S-T cypemycin was produced to determine whether the amino acid 
change had an effect on bio-activity against M. luteus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.9. Mass spectrometric analysis of M1462 (cypA S-T). A) The MALDI-ToF 
spectrum shows that one Thr remained unmodified in the cypemycin variant. B) Q-ToF 
analysis shows that Thr16 escaped dehydration and that Thr17 is modified to Dhb. 
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IV.6. Discussion 
 
I have identified, by genome scanning, the gene cluster for cypemycin biosynthesis 
and showed, contrary to previous classification, that cypemycin is not a member of 
the lantibiotic family (Chatterjee et al. 2005), but instead represents the first 
characterized member of a novel family of post-translationally modified peptides. A 
putative minimal gene cluster was constructed and nine genes contained in a 8.3 
kb region were shown to be required for cypemycin production in a heterologous 
host. Individual in-frame deletions of these genes allowed identification of their 
functions in post-translational modification and transport.  
 
Cypemycin contains two modifications that are unique to ribosomally synthesized 
peptides, an N-terminal Me2-Ala and two L-allo-Iles (Minami et al. 1994). Recently, 
D-allo-Ile residues were also identified in the aerucyclamides, a family of cyclic 
cyanobacterial peptides (Portmann et al. 2008). The gene responsible for the 
isomerization of the side chains of Ile13 and Ile18 to form the L-allo-Ile residues 
present in cypemycin could not be unambiguously identified. CypI is a candidate 
isomerase and belongs to the DUF255 family of proteins that contain a thioredoxin 
domain and which show similarity to the N-acetyl-D-glucosamine epimerase 
superfamily. As yet, I have been unable to obtain enough pure peptide from the 
∆cypI mutants to verify whether the L-allo-Ile modifications are absent.  
 
N,N-dimethylation of the N-terminal Ala of cypemycin is unprecedented in  
ribosomally-produced peptides (McIntosh et al. 2009). I unambiguously identified 
CypM, a SAM-dependent methyltransferase, as the enzyme that introduces these 
two methyl groups. Non-methylated cypemycin was not active in a M. luteus bio-
assay.  
 
In addition to these two unique modifications, cypemycin contains structural motifs, 
Dhb and AviCys, found in many lantibiotics. However, much to our surprise, these 
are introduced through novel enzyme activities and/or via a pathway distinct from 
their lantibiotic counterparts. No conventional dehydratase was identified in the 
cluster, but both cypH and cypL were required for cypemycin biosynthesis. Our 
mutational analysis dictates, by a process of elimination, that CypH and/or CypL 
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must be responsible for dehydration of the Thr residues of cypemycin to Dhb. It is 
possible that this modification is an early step in biosynthesis and required for the 
subsequent modifications, hence the absence of other modified forms of the 
propeptide. Alternatively, the lack of the Dhb residues may lead to rapid protease-
mediated degradation. The mature cypemycin molecule contains an unmodified 
Ser; interestingly, lantibiotic Ser residues are also more likely to escape 
dehydration than Thr (Rink et al. 2005). 
 
The occurrence of Cys at position 19 in the propeptide, rather than the expected 
Ser (Blaesse et al. 2000; Chatterjee et al. 2005), initially led us to think that 
formation of AviCys in cypemycin occurred via a novel mechanism. Analysis of the 
∆cypD mutant revealed that CypD is solely involved in decarboxylation of the C-
terminal Cys22. Alkylation of the peptide produced by the cypD mutant with 
iodoacetamide and subsequent Q-ToF analysis confirmed that Cys19 had been 
converted to Dha. To our knowledge, such a dethiolation reaction is 
unprecedented. Since the chemistry behind this reaction is similar to the 
dehydration of Thr to Dhb, I propose that Cys dethiolation is also catalyzed by 
CypH and/or CypL (Figure IV.10.). 
 
 
 
 
Figure IV.10. CypH and/or CypL are involved in the dehydration of Thr residues to form 
Dhb and catalyse a similar dethiolation reaction that converts Cys to Dha. 
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I have shown that CypD decarboxylates the C-terminal Cys in a manner similar to 
the analogous reaction in lantibiotic biosynthesis, despite its relatively low identity 
to LanD enzymes. The product of the ∆cypD mutant is the first example of the 
isolation of a natural product lacking its (Me)AviCys residue. This might reflect a 
general role for AviCys in peptide stability, protecting the modified peptide from 
degradation by (carboxy)peptidases. AviCys, like the Me2-Ala residue, is essential 
for activity against M. luteus. A ∆cypDM double mutant produced a truncated 
peptide lacking both modifications. As expected, this compound did not display bio-
activity. 
 
The cypemycin leader sequence is removed by an as yet unidentified protease. No 
putative peptidase domains were identified in either CypT or CypP, and their 
respective mutants produced lower levels of cypemycin, indicating that they are not 
essential for modification or cleavage of the peptide, and presumably serve solely 
to export cypemycin.  
 
Deletion of orf1 had no effect on cypemycin production, which was perhaps not 
surprising since SCO4969, its orthologue in S. coelicolor, is syntenous with the 
other genes found upstream of the cypemycin cluster. Thus the cypemycin gene 
cluster (cypA – cypI) appears to be contained in a 8.3kb chromosomal fragment 
(Figure IV.7.). Interestingly, cypH, the first gene in the likely biosynthetic operon, 
contains a rare TTA codon suggesting that cypemycin production might be 
developmentally regulated and controlled by the tRNA-encoding bldA (Leskiw et al. 
1991). The cypemycin operon appears to be transcribed from a promoter upstream 
of cypA. A predicted transcriptional attenuator (a stem-loop structure with a 
calculated ∆G of -31.2 kCal) lies between cypA and the other biosynthetic genes, 
and may ensure appropriately different levels of production of the modification 
enzymes and their peptide substrate. 
 
Bioinformatic analysis identified ten additional gene clusters that contain a cypL 
homologue together with a gene with full or partial homology to cypH and, with one 
exception, a gene encoding a putative prepropeptide. These clusters are expected 
to be capable of producing linear (non-cyclised) dehydrated peptides I call 
linaridins. The gene clusters are phylogenetically widespread, occurring in different 
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phyla of bacteria and Archaea, suggesting that they play an important adaptive role 
in microbial physiology. While cypemycin has antibiotic activity against M. luteus, it 
is inactive against many other bacteria and fungi. This suggests that the primary 
role of cypemycin, and potentially the linaridin family of peptides, may be to 
function as extracellular signaling molecules. 
 
Interestingly, some of the putative linaridins from gene clusters with a full length 
cypH homologue contain Cys residues while peptides from clusters with genes 
homologous to just the 5’ end of cypH are devoid of Cys (Figure IV.7. & Table 
IV.1.). It is tempting to speculate that the C-terminal domain of CypH is involved in 
the dethiolation of Cys. The occurrence of other potential biosynthetic genes 
(depicted in pink in Figure IV.7.) suggests that other members of the linaridin family 
contain novel post-translational modifications. 
 
In vitro analysis of the cypemycin modification enzymes as well as the identification 
and characterization of other members of the linaridin family are ongoing. I 
anticipate that these peptides will reveal novel post-translational amino acid 
modifications that will add significantly to the four new biosynthetic enzymes 
described here, and that they will contribute to an expanding toolbox for post-
translational peptide tailoring. The phylogenetically widespread distribution of 
linaridins and the identification of ten gene clusters in ~2200 sequenced prokaryote 
genomes, suggests that many more remain to be discovered. 
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IV.7. Bullet Point Summary 
 
• A reduced gene cluster was constructed and nine genes contained in a 8.3 
kb region were shown to be capable of producing cypemycin in a 
heterologous host. 
 
• Individual in-frame deletions of the genes in the minimal gene set confirmed 
roles in post-translational modification and transport. 
 
• Mass spectrometric analysis of a non-decarboxylated cypemycin 
intermediate provided proof for a novel enzymatic conversion: dethiolation 
of Cys to Dha. 
 
• A bioinformatic search for related gene clusters revealed a novel family of 
post-translationally modified peptides, the linaridins. 
 
• A cypemycin variant in which the non-dehydrated Ser16 was replaced by a 
non-dehydrated Thr revealed the importance of sequence context for amino 
acid dehydration. 
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Chapter V – Biochemical analysis of cypemycin 
biosynthesis 
 
V.1. Introduction 
 
Investigation of the enzymatic mechanisms responsible for the post-translational 
modifications of peptides is a relatively young field of research. The first successful 
report dates back to 1994, describing the in vitro reconstitution of EpiD activity. 
EpiD is a flavin-dependent decarboxylase involved in the oxidative decarboxylation 
of the C-terminal cysteine in the lantibiotic epidermin, leading to the formation of 
the AviCys residue (Kupke et al. 1994). Interestingly, the biochemical 
characterisation of EpiD led to novel insights into the catalytic mechanism of PPC 
decarboxylases, related enzymes that are involved in coenzyme A biosynthesis 
(Kupke et al. 2000). 
 
The first report of the in vitro biosynthesis of a modified peptide followed in 1996 
with the bacterial DNA gyrase inhibitor microcin B17 (Li et al.). The microcin B17 
synthase was purified and consists of three different proteins. This complex 
introduces four oxazole and four thiazole rings into the microcin B17 prosequence, 
thereby generating the mature antibiotic.  
 
The in vitro biosynthesis of lantibiotics was delayed for a long time because the 
dehydratase activity could not be reconstituted in vitro (van der Donk 2006). 
Consequently, the in vitro formation of Lan and MeLan bridges could not be 
studied due to the lack of a substrate for the cyclase reaction. The turning point 
was the analysis of the bifunctional dehydratase/cyclase LctM (Xie et al. 2004). 
This breakthrough paved the path for the biochemical analysis of the LanC enzyme 
involved in nisin biosynthesis (Li et al. 2006).  
 
Lantibiotic biosynthesis has been well characterised and has led to the 
identification of compounds based on genome sequence information from the 
producing organisms. Examples include the identification of the two-component 
lantibiotic haloduracin (McClerren et al. 2006) and more recently venezuelin, an 
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unidentified Streptomyces lantipeptide that is generated by a novel type of 
bifunctional enzyme, LanL (Goto et al. 2010). This last example will be more 
thoroughly discussed in chapter VI of this thesis. Thanks to many efforts, mainly by 
the van der Donk group, the lantibiotic family is the most extensively biochemically 
studied family of post-translationally modified peptides.  
 
In this chapter, the in vitro analysis of the enzymes involved in cypemycin 
biosynthesis will be discussed. The generation of suitable substrates will be 
described, followed by the in vitro reconstitution of the CypD and CypM activities. 
The in vitro dehydration of the four Thr residues and the dethiolation of the internal 
Cys in pro-CypA was also attempted.  
 
V.2. Substrate peptides for the enzymatic reactions 
 
Two different peptide substrates were required to analyse the cypemycin 
biosynthetic enzymes in vitro. The first one, prepro-CypA, was needed because the 
leader sequence is predicted to be involved in recognition by CypH and/or CypL, 
the enzymes that introduce the Dhb residues. In lantibiotic biosynthesis, the leader 
peptide was shown to be important for recognition of the prepropeptide by the 
dehydration and cyclisation enzymes (Chen et al. 2001; Kluskens et al. 2005; 
Chatterjee et al. 2006; Li et al. 2006; Rink et al. 2007). The prepro-CypA substrate 
can also be used in a CypD assay to investigate the decarboxylation of the C-
terminal Cys. EpiD, a related LanD enzyme that was characterised in vitro, could 
use the prepro-sequence of EpiA as a substrate (Kupke et al. 1994), although it 
does not require the leader peptide for activity and oligopeptide substrates were 
also modified by EpiD (Kupke et al. 1995).  
 
A second substrate that lacks the leader sequence (pro-CypA), was required for 
the in vitro methyltransferase activity, since this modification is predicted to occur 
after leader cleavage in vivo. A TEV protease cleavage site cannot be located N-
terminal to the pro-CypA sequence in a fusion protein because a Gly or Ser 
residue would then be left in front of the first Ala upon cleavage. This would 
interfere with CypM activity, as a free N-terminal Ala is likely required for 
methylation. Instead, a factor Xa site could be introduced, since cleavage with this 
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enzyme results in a free N-terminus. Unfortunately, factor Xa is not an efficient 
protease. When a MBP-EpiD fusion protein was made with an internal factor Xa 
site, only 3 % of the fusion protein was cleaved after 20 hours of incubation (Kupke 
et al. 1992). 
 
Several methods have been employed to obtain the peptide substrates for the in 
vitro reconstitution of enzyme activities that introduce post-translational 
modifications (Kupke et al. 1993; Majer et al. 2002; Xie et al. 2002; Xie et al. 2004; 
McClerren et al. 2006; Li et al. 2009). For the production of substrates for the 
cypemycin modification enzymes, a Gateway-based vector system was used to 
yield proteins with different 6His-tagged fusion partners (Busso et al. 2005). This 
technology allows rapid screening of different conditions to obtain a product with 
good expression levels and solubility. This method was employed not only to 
generate substrates (pro-CypA and prepro-CypA) for the enzymatic conversions, 
but also to purify the biosynthetic enzymes themselves (CypH, CypL, CypD, CypM 
and CypI). All enzyme constructs were generated with a TEV protease site directly 
N-terminal of the desired enzyme, allowing it to be liberated by enzymatic cleavage 
after purification. Expression of 6His-MBP fusions resulted in soluble protein for all 
fusion constructs (Table II.1.). Purification of the fusion proteins was achieved by 
Ni2+-affinity chromatography (Chapter II.7.1.). SDS-PAGE analysis revealed few 
contaminating proteins after this one step purification and the yield was reasonable 
to very good for all expressed substrates and enzymes. The SDS-PAGE analysis 
for the purification of the 6His-MBP-proCypA fusion protein is shown in Figure V.1. 
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Figure V.1. SDS-PAGE analysis of the 6His-MBP-proCypA fusion protein purification. 
Purified fractions eluted from the column at imidazole concentrations between 20 – 35 %. 
Lysate Pellet
Soluble Purified fractions
kDa
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66.3
55.4
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V.3. Formation of the AviCys residue 
 
Genetic analysis of cypemycin biosynthesis unambiguously identified CypD as the 
decarboxylase involved in the oxidative decarboxylation of the C-terminal Cys 
(Chapter IV.3.). CypD belongs to the HFCD family of Cys decarboxylases that 
consists of PPC decarboxylases and LanD enzymes (Kupke et al. 2000). When 
CypD is used as a query in a BLAST search, surprisingly no LanD enzymes are 
identified. Instead, all hits are annotated as potential PPC decarboxylases, which is 
surprising, given that the substrate of CypD (a C-terminal Cys residue in a small 
peptide) resembles the substrates of the LanD enzymes more than that of the PPC 
decarboxylases ((R)-4’-phospho-N-pantothenoylcysteine). This could indicate that 
CypD has evolved from a common HFCD ancestor in a separate event from the 
LanD enzymes to perform a similar function.  
 
The structures of three HFCD members - two LanD enzymes (EpiD and MrsD) and 
one PPC decarboxylase (AtHAL3a) - have been determined (Blaesse et al. 2000; 
Blaesse et al. 2003; Steinbacher et al. 2003). These studies revealed the reaction 
mechanism of the oxidative decarboxylation and identified the residues that are 
important for catalysis and cofactor and substrate binding.  
 
Two striking differences become obvious from an amino acid sequence alignment 
of CypD (and the closely related GrmD from the grisemycin cluster of S. griseus, 
Chapter VI.2.1.) with all functional LanD enzymes (EpiD, GdmD, BsaD, MutD, 
MrsD and MicD) and the two biochemically characterised PPC decarboxylases 
(Dfp and AtHAL3a) (Figure V.2.). Firstly, the essential and strictly conserved active 
site His is not present in CypD and GrmD, but instead a Glu is found. Mutation of 
this His residue to Asn in EpiD completely inactivated the enzyme (Kupke et al. 
2000). A search of the NCBI database for other, functionally uncharacterised 
HFCD members did not identify any proteins with a different residue at the location 
of the conserved His. Since Glu has a comparable pKa (4.07 compared to 6.10 for 
His), the catalytic mechanism could still be similar to the other HFCD enzymes. A 
second sequence difference is the absence of the PXMNXXMW motif that has 
been shown to assist cofactor binding and fixes the backbone amide group of the 
substrate’s C-terminal Cys (Blaesse et al. 2000). 
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Figure V.2. Alignment of CypD with other HFCD-family decarboxylases. For the HFCD 
proteins, the catalytic His and conserved PASANT and PXMNXXMW motifs are boxed and 
depicted in red. Additional residues involved in cofactor binding are shown in yellow and 
pututative substrate binding clamps in blue. Sequences shown belong to the following 
organisms: EpiD from Staphylococcus epidermis (P30197.1), GdmD from Staphylococcus 
gallinarum (ABC94905.1), BsaD from Staphylococcus aureus subsp. aureus TCH70 
(ZP_04829285.1), MutD from Streptococcus mutans (AAG48568.1), MrsD from Bacillus sp. 
HIL-Y85/54728 (Q9RC23.1), CypD from S. sp. OH-4156 (this study), GrmD from S. griseus 
subsp. griseus NBRC 13350 (YP_001827875.1), MibD from Microbispora corallina NRRL 
30420 (ADK32557), DfP from E. coli str. K-12 substr. W3110 (AP_0014152.1) and 
AtHAL3a from Arabidopsis thaliana (NP_188430.1). 
EpiD            -----------MYG------KLLICATASINVININHYIVELKQH-FDEVNILFSPS--S 40 
GdmD            -----------MHG------KLLICATASINVVNINHYIVELKQY-FEEVNILFSPS--S 40 
BsaD            ------MEAYIMGE------NVLICLCGSVNSINISHYIIELKSK-FDEVNVIASTN--G 45 
MutD            ------MEEQNIEK------KILLCLTGSGPLLGIAEYITFLTVR-FKHVRVIISDN--A 45 
MrsD            -----MSISILKDK------KLLIGICGSISSVGISSYLLYFKSF-FKEIRVVMTKT--A 46 
CypD            -----VNVEKFEGA------ELHVHVTGSISAALVPWWIHWLREF-QPELVVNVSVTPAA 48 
GrmD            -----MNVEQFEGA------ELHLHVTGSISAALVPWWIHWLRQL-NPDVVVNVSVSRSA 48 
MibD            -----MTAHSDAGGDPRPPERLLLGVSGSVAALNLPAYIYAFRAAGVARLAVVLTPA--A 53 
Dfp             --------MSLAGK------KIVLGVSGGIAAYKTPELVRRLRDR-GADVRVAMTEA--A 43 
AtHAL3a         MENGKRDRQDMEVNTTPRKPRVLLAASGSVAAIKFGNLCHCFTEWAEVRAVVTKSSLHFL 60 
                                    .: :   ..            :         :  :      
 
EpiD            KNFINTDVLKLFCDNLYD-----EIKDPLLNHINIVEN--HEYILVLPASANTINKIANG 93 
GdmD            KKFINTDVLNLFCDNLYD-----ETQDPLLNHINIVEN--HEYILVLPASADTINKIASG 93 
BsaD            RKFINGEILKQFCDNYYD-----EFEDPFLNHVDIANK--HDKIIILPATSNTINKIANG 98 
MutD            AKMLPVAAITQLCEKVYTD--EVSFTDKQKSHIALTRW--ADITVVLPATANIIGKVANG 101 
MrsD            EDLIPAHTVSYFCDHVYS---EHGENGKRHSHVEIGRW--ADIYCIIPATANILGQTANG 101 
CypD            SRFLAVRALRHLANGKVWV--DSWDDPDVPPEVNSGKSGASECFLVFPATLDTVMRLAQG 106 
GrmD            TQFVTVKALRHLANGQVWT--DAWDDPSLPAEVNSGQSGAAECFIVFPATLDTLMRLAQG 106 
MibD            EGFLPAGALRPIVDAVHT------EHDQGKGHVALSRW--AQHLLVLPATANLLGCAASG 105 
Dfp             KAFITPLSLQAVSGYPVSDSLLDPAAEAAMGHIELGKW--ADLVILAPATADLIARVAAG 101 
AtHAL3a         DKLSLPQEVTLYTDEDEWS--SWNKIGDPVLHIELRRW--ADVLVIAPLSANTLGKIAGG 116 
                  :     :                      .:   .    :   : * : : :   * * 
 
EpiD            ICDNLLTTVCLTGY--QKLFIFPNMNIRMWGNPFLQKNIDLLKNNDVKVYSPDMN--KSF 149 
GdmD            ICDNLLTTVCLTGY--KSLYIFPNMNIKMWENPFLQKNIDLLKNNSVKVYPPDVN--KSF 149 
BsaD            ICDNLLLTICHTAF--EKLSIFPNMNLRMWENPVTQNNIRLLKDYGVSIYPANIS--ESY 154 
MutD            IADNFMTTTLLSSS--KPVLIYPCMNNIMWGNPVVQKNVEVLSGTQYKVIVGQES--ESF 157 
MrsD            VAMNLVATTVLAHP--HNTIFFPNMNDLMWNKTVVSRNIEQLRKDGHIVIEPVEI--MAF 157 
CypD            RADSPALMMLQLTD--APLVIADTFPG---SNEIVENNVQTLKLRPNVEFAPRVN--GVR 159 
GrmD            RADSPALLMLQVTD--RPIVIADTLPG---SNEIVESNLKTLRLRPNIAFAPRVT--GVR 159 
MibD            LAPNFLATVLLAAD--CPITFVPAMNPVMWRKPAVRRNVATLRADGHHVVDPLPG--AVY 161 
Dfp             MANDLVSTICLATP--APVAVLPAMNQQMYRAAATQHNLEVLASRGLLIWGPDSGSQACG 159 
AtHAL3a         LCDNLLTCIIRAWDYTKPLFVAPAMNTLMWNNPFTERHLLSLDELGITLIPPIKKRLACG 176 
                 . .                .   :            ::  *                   
 
EpiD            EISSGRYKNNITMPNI----------ENVLNFVLNNEKRPLD------------------ 181 
GdmD            EISSGLYKNSITMPNI----------ENVLSFILNSEKRPLD------------------ 181 
BsaD            ELASKTFKKNVVAPEP----------YKVLEFI--------------------------- 177 
MutD            ELASGKMKKNIAIPSL----------DELRRVVLENLQEER------------------- 188 
MrsD            EIATGTRKPNRGLITP----------DKALLAIEKGFKERTKHPSLT------------- 194 
CypD            ASNRQTAEVGFNLPGA----------LAAANRMRKEGRSGE------------------- 190 
GrmD            ASNRAAAEVGFNLPGA----------IAVANEMVKKGSVHE------------------- 190 
MibD            EAASRSIVEGLAMPRP----------EALVRLLGGGDDGSPAGPAGPVGRAEHVGAVEAV 211 
Dfp             DIGPGRMLDPLTIVDMAVAHFSPVNDLKHLNIMITAGPTREPLDPVRYISNHSSGKMGFA 219 
AtHAL3a         DYGNGAMAEPSLIYST-------------VRLFWESQAHQQTGGTS-------------- 209 
                                                .                            
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The PASANT motif characteristic of HFCD proteins, which supports the flavin 
cofactor, is conserved as well as other scattered residues that are involved in 
cofactor binding (indicated in yellow in Figure V.2.) (Blaesse et al. 2000). It could 
not be determined from the alignment whether CypD binds FMN (like EpiD) or FAD 
(like MrsD) as a cofactor since the affinity for either cofactor could not be attributed 
to a few distinct residues. Instead, a larger number of small contributions is thought 
to determine cofactor affinity (Blaesse et al. 2003). 
 
All characterised members of the HFCD family contain either FAD or FMN as a 
redox cofactor (Majer et al. 2002). Purified MBP-CypD has a bright yellow color 
(Figure V.3.A), indicating that the protein is likely to be folded with an associated 
flavin cofactor. The UV-Vis absorption spectrum of the purified MBP-CypD fusion 
protein was determined (Figure V.3.B) and the maxima at 377.97 nm and 455.70 
nm are characteristic of a flavin-containing enzyme, comparable to MBP-MrsD and 
MBP-EpiD (Majer et al. 2002). The cofactor is not covalently attached to CypD; it 
could be removed from the enzyme by boiling at 100 °C for 10 minutes and 
remained in solution after subsequent centrifugation. MALDI-ToF mass 
spectrometry was employed to identify the cofactor (Figure V.3.C.). The [M+H]+ of 
the cofactor was 786.171 Da, in good agreement with a calculated [M+H]+ of 
786.164 Da for FAD (the [M+H]+ of FMN would be 457.113 Da). This makes CypD 
the second HFCD enzyme with a FAD cofactor (together with MrsD). All other 
HFCD enzymes characterised to date contain an FMN cofactor (Majer et al. 2002).  
 
The activity of the LanD enzymes EpiD and MrsD and the PPC decarboxylases 
Dfp and AtHAL3a has been reconstituted in vitro (Kupke et al. 1994; Kupke et al. 
2000; Kupke et al. 2001; Majer et al. 2002). As is the case for the LanD enzymes, 
the natural substrate of CypD is a peptidyl-Cys. The substrate specificity of EpiD 
was investigated using oligopeptide libraries and mass spectrometric analysis 
(Kupke et al. 1995). Peptides as short as four amino acid residues were 
decarboxylated by EpiD and the enzyme exhibited broad substrate specificity. Most 
peptides with the C-terminal sequence [V/I/L/(M)/F/Y/W]-[A/S/V/T/C/(I/L)]-C could 
be used as a substrate. Note that the C-terminus of preproCypA (LVC) obeys this 
rule and would thus likely be modified by EpiD. Interestingly, a Val at the 
penultimate position (like in preproCypA) was found to give a catalytic reaction rate 
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that was close to the maximum observed with the natural substrate sequence 
(Kupke et al. 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V.3. Characterisation of the CypD cofactor. A) Purified 6His-MBP-CypD has a yellow 
colour. B) The UV-Vis absorption spectrum for 6His-MBP-CypD has maxima that are 
characteristic for a flavin-containing enzyme. C) MALDI-ToF spectrum identifies the purified 
cofactor as FAD. 
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PreproCypA was used as substrate for the CypD in vitro assay, and was obtained 
by purification of the fusion protein 6His-MBP-preproCypA (Table II.1.) and 
subsequent cleavage with TEV protease. A maximum efficiency of 60 % cleavage 
was obtained and the resulting mixture was used as a substrate in the CypD assay 
without further purification from the MBP and full length fusion protein (Figure V.4.).  
 
6His-MBP-CypD (~ 25 µM) was incubated with the preproCypA substrate (~ 120 
µM) at 30 °C in a 20 µl volume at pH 7.9 (50 mM Tris HCl) under reducing 
conditions (2 mM TCEP). After six hours of incubation, the reaction mixture was 
analysed by MALDI-ToF MS. The substrate peak with a mass of 6087 Da (as 
observed in the control reaction without the enzyme) was partially converted into a 
peak of 6041 Da (Figure V.5.). The 46 Da mass difference is in good agreement 
with the removal of two hydrogen atoms and one molecule of CO2. When the pH of 
the reaction was changed to 7.2, less substrate was decarboxylated (data not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V.4. Substrate preparation for the CypD decarboxylase assay. Cleavage of 6His-
MBP-preproCypA with TEV protease occurs at ~ 60 % efficiency. Liberated preproCypA 
migrates with the buffer front. 
CypA prepro-protein 
migrates in the buffer 
front
6His-MBP-preproCypA 
(estimated cleavage: 
60%)
Fusion protein CleavedkDa
200
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Figure V.5. CypD catalyses the in vitro decarboxylation of preproCypA. Upon incubation 
with the CypD enzyme, the mass peak corresponding to the 6087 Da substrate is partially 
converted to the 6041 Da decarboxylated product. 
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V.4. Methylation of the N-terminal alanine residue 
 
cypM was shown to be required for the N,N-dimethylation of the N-terminal Ala 
residue in cypemycin, leading to the formation of Me2-Ala (Chapter IV.3.). CypM is 
the first SAM-dependent methyltransferase that has been implicated in the post-
translational modification of a ribosomally synthesised peptide. Many examples of 
peptide bond amide N-methylation are known in NRPs and for some of these, the 
modification confers favourable pharmacokinetic properties on the resulting 
compounds (Lawen and Zocher 1990; Subtelny et al. 2008). A better biochemical 
understanding of the CypM methyltransferase could thus provide a valuable 
contribution to an enzyme toolbox for rational peptide design.  
 
CypM is predicted to catalyse the last modification reaction during cypemycin 
maturation. Removal of the leader peptide liberates the N-terminal Ala that can 
then be dimethylated on the free amine. Attempts to cleave the purified 6His-MBP-
proCypA fusion protein with factor Xa protease resulted in very low proCypA yields 
because of inefficient protease activity and a small peptide (2.7 kDa) to fusion 
protein (45.8 kDa) ratio. When proCypA was fused to a 6His-tag, no expression 
was obtained in E. coli. A fusion of proCypA to a smaller partner (thioredoxin, 14.6 
kDa) was made in E. coli, but nearly all of the fusion protein was found to be 
insoluble.  
 
The in vivo product of M1418 (∆cypM) was shown to share all post-translational 
modifications except for Me2-Ala (Chapter IV.3.). Since it is very likely the natural 
substrate of CypM, this non-methylated version of cypemycin was used as the 
substrate in the in vitro dimethylation assay. 
 
6His-MBP-CypM (~7.5 µM) was incubated with non-methylated cypemycin 
(unknown concentration) at 30 °C in a 20 µl volume at pH 7.2 (50 mM Tris HCl) 
under reducing conditions (1 mM TCEP) in the presence of added SAM (2.5 mM). 
After three hours of incubation, the reaction mixture was analysed by MALDI-ToF 
MS. The peaks corresponding to the non-methylated substrate ([M+H]+ = 2068 Da, 
[M+Na]+ = 2090 Da, [M+K]+ = 2106 Da) were mostly  converted into mature 
cypemycin ([M+Na]+ = 2118 Da, [M+K]+ = 2134 Da) by the addition of CypM 
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(Figure V.6.). A peak was also observed at 2110 Da, corresponding to the [M+H]+ 
of monomethylated cypemycin. A similar substrate conversion was observed when 
the reaction was incubated at pH 6.5 or 7.9. While some SAM-dependent 
methyltransferases require a divalent metal ion for activity (Kozbial and Mushegian 
2005), CypM does not, as shown by the reaction conditions above. The addition of 
1-10 mM MgCl2 or 1-10 mM ZnSO4 had no apparent effect on the in vitro reaction. 
 
 
 
Figure V.6. CypM catalyses the in vitro dimethylation of the N-terminal Ala in non-
methylated cypemycin. The non-methylated substrate ([M+H]+ = 2068 Da, [M+Na]+ = 2090 
Da and [M+K]+ = 2106 Da) was converted to mature cypemycin ([M+Na]+ = 2118 Da and 
[M+K]+ = 2134 Da) in the CypM methylation assay. Monomethylated cypemycin ([M+H]+ = 
2110 Da) was also formed. 
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V.5. Formation of the Dhb residues  
 
Genetic analysis of the cypemycin biosynthetic gene cluster did not identify a 
cypemycin intermediate that lacked either the Thr dehydration or the Cys 
dethiolation modifications (Chapter IV.3.). A possible explanation for this 
observation is that the intermediates lacking these modifications are unstable and 
rapidly degraded in vivo. Both the ∆cypH (M1415) and the ∆cypL (M1416) mutants 
resulted in loss of cypemycin production, making CypH and/or CypL candidates for 
the dehydratase/dethiolase activity. A BLAST search of the public databases with 
each as a query failed to identify homologues with an experimentally verified 
function (Chapter III.6.)  
 
The modification that most resembles the dehydration/dethiolation is the 
LanB/LanM dehydratase activity that results in the generation of Dha and Dhb 
residues from Ser and Thr. Unfortunately, the in vitro reaction conditions for  LanB 
dehydratases remain to be elucidated. In vitro dehydratase activity has been 
shown for two other types of lantipeptide modification enzyme families, namely 
LanM (Xie et al. 2004) and LanL (Goto et al. 2010). The domain that catalyses the 
dehydration is located in the N-terminal half of the protein in both types. These 
domains do not share homology with each other or with the LanB enzymes. 
 
The assay conditions used in an attempt to reconstitute CypH and CypL activity in 
vitro were based on methods that have been applied successfully for the LanM and 
LanL dehydratase activities (Xie et al. 2004; Chatterjee et al. 2005; Chatterjee et 
al. 2006; McClerren et al. 2006; Miller et al. 2006; Goto et al. 2010). PreproCypA 
was used as the substrate for the CypH and CypL reactions, since the leader 
peptide is predicted to be required for molecular recognition by these modification 
enzymes. The invariant co-occurrence of cypH and cypL homologs in all linaridin 
clusters suggests that both could be required together to introduce the 
modifications. Purified CypH and CypL were thus not only added individually, but 
also combined in the reaction mixes. Unfortunately, none of the conditions tested 
resulted in the reconstitution of the dehydration/dethiolation activity. 
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V.6. Discussion 
 
The in vitro characterisation of enzymes that introduce post-translational 
modifications into ribosomally synthesised peptides may well allow their 
subsequent use as tools in the design of novel compounds. Post-translational 
modifications contribute to the rigidity of the peptides and influence their activities 
(Rink et al. 2007; Walsh and Nolan 2008). They also have an effect on stability by 
increasing the peptide’s resistance to proteases. For example, dehydroamino acids 
have been shown to reduce proteolytic degradation and to enhance biological 
activity of linear peptides (Lombardi et al. 1998; Li et al. 2006). A recent study by 
Rink et al. (2010) showed that modification of the N- and C-terminus of 
pharmaceutical peptides protects them against amino- and carboxypeptidase 
action. Cypemycin is modified by an N-terminal Me2-Ala and a C-terminal AviCys 
(Minami et al. 1994). A better biochemical understanding of CypM and CypD, 
which are responsible for the introduction of these post-translational modifications, 
could lead to their use in protecting other peptides against peptidases. 
 
The cofactor of CypD was determined and the decarboxylase activity has been 
reconstituted in vitro. CypD is the fifth HFCD decarboxylase for which the in vitro 
activity has been demonstrated and the second one with an associated FAD (Majer 
et al. 2002; Blaesse et al. 2003). A BLAST search with CypD as a query only 
identified PPC decarboxylases (which decarboxylate (R)-4’-phospho-N-
pantothenoylcysteine) and no LanD enzymes. This suggests a separate 
evolutionary path for CypD from a common HFCD ancestor to perform a function 
similar to the LanDs, namely the decarboxylation of a peptidyl-Cys substrate. 
Unfortunately, the preproCypA substrate used the in vitro CypD decarboxylation 
assay is not easily quantifiable. In order to determine the kinetic parameters for the 
enzymatic reaction, it might be possible to use shorter peptides with the same 
amino acid sequence as the C-terminus of CypA as a substrate. For EpiD, 
peptides as short as four amino acids can be decarboxylated (Kupke et al. 1995). 
 
CypM is the first methyltransferase involved in the posttranslational modification of 
a ribosomally synthesised peptide for which the activity has been reconstituted in 
vitro. The non-methylated cypemycin substrate used in this reaction is not readily 
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quantifiable. It would be interesting to investigate the substrate specificity of CypM 
for short peptides that resemble the N-terminus of cypemycin and to determine the 
kinetic parameters for the dimethylation reaction. SAM-dependent methyl-
transferases are quite prevalent in the linaridin clusters (Chapter IV.4.), indicating 
that cypemycin might not be the only peptide that is N-methylated. If a structure 
could be obtained for CypM, this would shed light on the catalytic mechanism and 
the substrate binding pocket. Information on the substrate binding pocket would be 
useful for possible applications where CypM is used to methylate other peptide 
substrates.  
 
Biochemical reconstitution of the remaining two types of post-translational 
modification present in cypemycin remain to be established. Determining assay 
conditions for the dehydration/dethiolation of Thr and the internal Cys in cypemycin 
is hampered by the lack of CypH and CypL homology to characterised enzymes. 
Moreover, both enzymes might have to be added together in the reaction mix to 
obtain activity, which adds an extra level of complexity compared to a one enzyme 
reaction. Historically, the in vitro dehydration reaction in lantibiotic biosynthesis has 
proven to be notoriously difficult to reconstitute in vitro (van der Donk 2006). The 
dehydratase activity of LanM and LanL enzymes has been characterised (Xie et al. 
2004; Goto et al. 2010), but remains an enigma for the LanB enzymes. The 
problem in studying  the activity of the remaining modification is of a different 
nature. To study the likely CypI-mediated Ile isomerisation, a suitable assay for the 
detection of this modification will have to be first devised. This is difficult since no 
mass difference is associated with the Ile isomerisation. Once a suitable assay has 
been established, the in vivo product of the ∆cypI mutant (M1421) could be a 
candidate substrate for the in vitro reaction.  
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V.7. Bullet point summary 
 
• Peptides were produced to serve as substrates for in vitro modification 
reactions with cypemycin biosynthetic enzymes by producing both as fusion 
proteins in E. coli. 
 
• CypD was shown to decarboxylate preproCypA in an in vitro assay. 
 
• In vitro activity was shown for the dimethyltransferase CypM, using non-
methylated cypemycin as a substrate. 
 
• The Thr dehydratase/Cys dethiolase activity of CypH and/or CypL was not  
reconstituted in vitro. 
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Chapter VI – Characterisation of grisemycin, a linaridin 
produced by S. griseus 
 
VI.1. Introduction 
 
Characterisation of the cypemycin biosynthetic gene cluster led to the bio-
informatic identification of several related clusters, defining the linaridin family of 
linear post-translationally modified peptides (Chapter IV.4.). A linaridin gene cluster 
that closely resembles the cypemycin cluster was found in the genome sequence 
of S. griseus IFO 13350 (Ohnishi et al. 2008). This 6.4 kb cluster contains seven 
genes (SGR_6365.2 (not annotated) through SGR_6360) that are presumed 
orthologs (functionally equivalent homologue) of cypA through cypP. A cypI 
homologue (SGR_2558) was identified in S. griseus, but its genomic location is not 
adjacent to the cluster. The S. griseus cluster is predicted to produce a linaridin, 
named here as grisemycin. The grisemycin biosynthetic genes (SGR_6365.2 – 
SGR_6360) will hereafter be referred to as grmA through grmP, analogous to their 
counterparts in the cypemycin cluster (Figure VI.1.A.). An apparently orthologous 
cluster was later found in the draft genome sequence of S. sp. ACT-1. Its 
constituent ORFs share an average nucleotide sequence identity of 99 % with 
grmA through grmP.  
 
In this chapter, the identification and structural verification of grisemycin will be 
discussed. Genes required for grisemycin production were identified by 
heterologous expression of a minimal gene set in S. coelicolor M1146 and by the 
analysis of a ∆grmA mutant of S. griseus. 
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Figure VI.1. A) Comparison of the biosynthetic gene clusters for cypemycin and grisemycin 
production. The location of the NotI sites that flank the grisemycin gene cluster and that 
were used to construct pIJ12474 are indicated. Genes for which a partial ORF is present in 
the sub-cloned fragment are indicated with *. Only part of SGR_6359 is shown on the 
figure. B) Alignment of the precursor peptides GrmA and CypA. The leader peptidase 
cleavage site for both peptides is indicated by a red line. 
 
 
VI.2. Identification of grisemycin 
 
VI.2.1. Bio-informatic analysis of the grisemycin gene cluster  
 
The flanking regions on either side of the grisemycin biosynthetic cluster (grmA - 
grmP) are not syntenous with the regions adjacent to the cypemycin gene cluster 
(Ohnishi et al. 2008). The grisemycin cluster is flanked by a putative Type I PKS 
cluster upstream of grmA and a cluster of genes of unknown function downstream 
of grmP. Upstream of the cypemycin cluster, genes predicted to be involved in 
mycothiol detoxification are found and downstream, rodlins and a chaplin are 
present (Chapter IV.2.). Comparison of these two linaridin gene clusters and their 
flanking sequences aided in defining the likely boundaries for the cypemycin 
minimal gene set (Chapter IV.2.). 
 
orf1 cypA cypH cypL cypH cypP cypI
cypD cypT
6368* 6367      6366 grmA grmH grmL grmH grmP 6359*
grmD grmT
NotI NotI
1 kb
A
B
CypA   VRSEMTLTSTNS---AEALAAQDFANTVLSAAAPGFHADCETPAMATPATPTVAQFVIQGSTICLVC 64 
GrmA   MRLDSIATQETATALPESMATQDFANSVLAGAVPGFHSDAETPAMATPA---VAQFVIQGSTICLVC 64 
      :* :   *. .:   .*::*:*****:**:.*.****:*.*********   *************** 
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Directly upstream of grmA and divergently transcribed is a gene encoding a 
putative Streptomyces antibiotic regulatory protein (SARP) (Bibb 2005). This 
putative regulator does not show homology to the product of orf1 that lies adjacent 
to the cypemycin gene cluster. Deletion of orf1 showed that this putative regulator 
was not involved in the regulation of cypemycin biosynthesis (Chapter IV.3.). 
Extrapolation leads to the prediction that the putative SARP might not be required 
for grisemycin production but could instead be involved in regulating expression of 
the adjacent Type I PKS gene cluster. 
 
Amino acid sequence alignment of GrmA and CypA revealed that the propeptide 
sequence of GrmA is shorter by three amino acids, Thr-Pro-Thr, corresponding to 
positions 5-7 of cypemycin (Figure VI.1.B.). All other residues in both propeptides 
were identical. Comparison of the GrmA and CypA leader sequences also showed 
a high degree of conservation. Leader sequences of post-translationally modified 
peptides are proposed to act as a recognition signal for the biosynthetic enzymes 
(Oman and van der Donk 2010).  
 
Based on the modification enzymes that are encoded by the grisemycin gene 
cluster, GrmA is predicted to be modified in a similar way to CypA in cypemycin 
biosynthesis. The two Thr residues in the GrmA propeptide are predicted to be 
dehydrated to form Dhb, the N-terminal Ala would be di-methylated and an AviCys 
is predicted to be formed at the C-terminus after dethiolation of the internal Cys 
and decarboxylation of the C-terminal Cys. Since the S. griseus cypI orthologue is 
not present near the grisemycin cluster, it is not certain whether the Ile residues at 
position 10 and 15 of the GrmA propeptide are modified to form L-allo-Ile. 
 
VI.2.2. Grisemycin identification and structural verification 
 
S. griseus was grown under similar conditions to S. sp. OH-4156 for cypemycin 
production (a three day preculture in SOC medium followed by three days in MarM 
production medium). Culture supernatant was separated from the mycelium by 
centrifugation and extracted with CHCl3. The solvent was evaporated and the 
residual pellet dissolved in 5 % formic acid for MALDI-ToF analysis or MeOH for 
use in a M. luteus paper disc bio-assay. No activity against M. luteus was observed 
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for the S. griseus supernatant extracts (data not shown). However, MALDI-ToF 
analysis showed a set of three peaks with masses [M+H]+ = 1833 Da, [M+Na]+ = 
1855 Da and [M+K]+ = 1871 Da (Figure VI.2). If grisemycin is modified in a similar 
way to cypemycin, this would mean that the compound is shorter by the three N-
terminal residues Dhb-Pro-Dhb. The difference in mass between the two 
compounds would thus be 263 Da, which is in perfect agreement with the mass 
peaks observed for cypemycin ([M+H]+ = 2096 Da, [M+Na]+ = 2118 Da and [M+K]+ 
= 2134 Da, Chapter III.2.2.). 
 
The identification of grisemycin by MALDI-ToF in the same S. griseus culture 
supernatant that was used for the M. luteus bio-assay suggests that the compound  
does not possess potent antibacterial activity. Even when the residue from the 
CHCl3 extract was concentrated or dissolved in different solvents, it failed to 
produce a zone of inhibition in the M. luteus bio-assay. 
 
To verify that the compound observed in the MALDI-ToF spectrum was indeed 
grisemycin, the amino acid sequence of the mass peak [M+K]+ = 1871 Da was 
determined by Q-ToF mass spectrometry (Figure VI.3.). The analysis showed that 
both Thr residues had been dehydrated to Dhb. N-terminal di-methylation of 
grisemycin was inferred from the 183.12 Da b-ion, which corresponds to Me2-Ala-
Dhb (in good agreement with a calculated mass of 183.11 Da) and the 1688.85 Da 
y-ion (calculated mass 1688.86 Da). The presence of the C-terminal AviCys 
residue was inferred from the 395.16 Da y-ion (calculated mass 395.15 Da). No 
mass peak was observed corresponding to the calculated mass for a b-ion from 
the grisemycin fragment lacking its AviCys. This is probably due to a progressively 
decreasing signal intensity of the b-ion peaks at higher masses in the grisemycin 
Q-ToF spectrum. At present, it is uncertain whether grisemycin contains L-allo-Ile 
residues, since this modification can not be identified by mass-spectrometric 
analysis. 
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Figure VI.2. MALDI-ToF MS spectrum of grisemycin ([M+H]+ = 1833 Da, [M+Na]+ = 1855 
Da and [M+K]+ = 1871 Da) produced by S. griseus. 
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Figure VI.3. Q-ToF spectrum of grisemycin. Fragmentation of the modified linear peptide 
allows determination of the amino acid sequence, and the nature and locations of modified 
residues. The amino acid sequence between Pro3 and the AviCys residue (which does not 
fragment into easily interpretable masses) can be readily discerned and is shown above the 
spectrum. Note: It has not been determined whether grisemycin contains the L-allo-Ile 
residues at positions 10 and 15. 
VI – Characterisation of grisemycin 
 
 
146 
VI.3. Cloning and heterologous expression of the cluster and 
generation of a ∆grmA mutant 
 
VI.3.1. Cloning of the gene cluster and heterologous expression in 
M1146 
 
The likely boundaries of the minimal gene set for grisemycin biosynthesis were 
determined by comparison with the cypemycin gene cluster (Figure VI.1.A. and 
Chapter III.12.A.). The putative SARP-family regulator situated upstream of grmA 
was included in this construct to account for the possibility that it might be required 
for regulation of grisemycin biosynthesis. Sequence analysis identified a NotI 
restriction site on either side of the putative grisemycin gene cluster. Excision of 
the 10.6 kb NotI fragment would result in truncation of ORFs SGR_6359 and 
SGR_6368, leaving only one full length ORF encoding a putative oxidoreductase 
(SGR_6367) in the minimal gene set construct that was highly likely to be 
superfluous for  grisemycin production (Figure VI.1.A.). Since no S. griseus cosmid 
library was available, genomic DNA was isolated and digested with NotI. The DNA 
was separated on a 0.8 % agarose gel and fragments excised between 
approximately 10.1 kb and 11.2 kb. The fragments were purified, ligated with NotI-
digested pSET152 and introduced in E. coli DH5α by transformation. 56 DH5α 
transformants were analysed by colony PCR using primers grmA T1 and grmA T2, 
which amplify a 960 bp region containing the grmA structural gene. Two DH5α 
transformants were identified that appeared to contain the grisemycin minimal 
gene set cloned in pSET152 (hereafter referred to as pIJ12474). The constructs 
were isolated and verified by restriction digest analysis and by two different 
diagnostic PCRs. pIJ12474 was introduced into the S. coelicolor M1146 by 
conjugation, yielding strain M1457. Heterologous production of grisemycin was 
confirmed by MALDI-ToF analysis of CHCl3 extracted supernatant from a MarM 
production culture of M1457 (Figure VI.4.A.). This indicates that the minimal gene 
set construct pIJ12474 (Figure VI.1.A.) contains all of the genes required for 
grisemycin production. 
 
VI – Characterisation of grisemycin 
 
 
147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure VI.4. MALDI-ToF MS spectra for A) M1457, the heterologously expressed 
grisemycin minimal gene cluster in S. coelicolor M1146 and B) M1458, the S. 
griseus ∆grmA deletion strain. 
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VI.3.2. Generation of a grmA deletion mutant 
 
pIJ12474 could not be used to generate a ∆grmA deletion construct since its 
pSET152 backbone would cause it to integrate into the φC31 attachment site upon 
conjugation into S. coelicolor. pIJ12474 was digested with NotI to liberate the 10.6 
kb insert, which was subsequently cloned into NotI-digested SuperCosI, yielding 
pIJ12475. grmA was replaced in pIJ12475 with an Apra-resistance cassette by 
PCR targeting (Chapter II.6.). The resulting construct, pIJ12476, was introduced 
into S. griseus by conjugation. Double homologous recombinants were identified 
by their ApraR-KanS phenotype and verified by PCR analysis. The resulting ∆grmA 
strain (M1458) was grown in  grisemycin production medium and the culture 
supernatant extracted with CHCl3. MALDI-ToF analysis confirmed that the [M+H]+ 
= 1833 Da, [M+Na]+ = 1855 Da or [M+K]+ = 1871 Da mass peaks were not present 
in the spectrum, indicating that grisemycin was no longer produced (Figures VI.2 
and VI.4.B.). This experiment confirmed that grmA is the structural gene for 
grisemycin biosynthesis in S. griseus. 
 
VI.4. Discussion 
 
Several linaridin gene clusters were identified by bioinformatic analysis (Chapter 
IV.4.). The linaridin gene cluster most closely related to the cypemycin cluster was 
found in S. griseus. The pro-sequence of the structural peptide only differs from 
cypemycin by the absence of three amino acids, Thr-Pro-Thr, corresponding to 
positions 5 to 7 in cypemycin. The compound produced by the S. griseus cluster 
was identified by MALDI-ToF and Q-ToF analyses and was called grisemycin.  
 
It remains to be determined whether grisemycin contains L-allo-Ile residues. Apart 
from L-allo-Ile, all modifications present in cypemycin were also identified in 
grisemycin by mass spectrometric analysis. A reduced gene set construct was 
generated and used to produce grisemycin heterologously in S. coeilicolor M1146. 
To complement this data, a S. griseus ∆grmA mutant failed to produce grisemycin. 
Taken together, these data identify the gene cluster that is required for grisemycin 
biosynthesis in S. griseus. 
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No antibacterial activity could be shown for grisemycin in a bio-assay with M. 
luteus. Although there is no quantitative data on levels of production from the two 
gene clusters, this might indicate that the antibacterial activity of cypemycin against 
M. luteus is dependent on peptide length, since this is the most obvious structural 
difference between the two compounds. The mechanism of action of cypemycin is 
not known, but it could exert its activity by forming pores in the bacterial 
cytoplasmic membrane. A shorter peptide like grisemycin might not be long 
enough to cross the phospholipid bilayer. A study on the in vivo mode of action of 
pore-forming lantibiotics showed that the pore-forming ability of gallidermin 
depended on membrane thickness (Bonelli et al. 2006). It was speculated that the 
greater susceptibility to pore formation of micrococcal strains compared to 
lactobacilli could reflect in part their relatively thinner phospholipid bilayer. Bonelli 
et. al (2006) pointed out that the membranes of lactobacilli contain considerable 
amounts of phospholipids with an average chain length of 17 carbon atoms (In 't 
Veld et al. 1991), whereas in micrococcal membranes the most predominant 
phospholipid has a C15 acyl chain (Welby and Tocanne 1982).  
 
The lack of antimicrobial activity observed for grisemycin and the very narrow 
spectrum reported for cypemycin (Komiyama et al. 1993) suggests that these two 
compounds might serve a different role in the biology of their producing 
streptomycetes, for example as signalling molecules. 
 
The grisemycin cluster was shown to be highly activated by the bacterial γ-
butyrolactone hormone A-factor (Hara et al. 2009). This led us to investigate the 
DNA sequence upstream of grmA (and cypA) for AdpA binding sites. AdpA is a 
transcriptional regulator of the AraC/XylS family and adpA is the sole target of the 
A-factor receptor protein ArpA (Kato et al. 2004). AdpA thus acts as the master 
regulator downstream of A-factor signaling and transcriptionally activates many 
genes involved in secondary metabolism and morphological differentiation (Ohnishi 
et al. 2005).  
 
Putative AdpA binding sites were identified in the DNA sequence upstream of 
grmA (5’-TTGCGGGATT-3’) and cypA (5’-TGGCCGGATG-3’) that are in good 
agreement with the consensus sequence 5’-TGGCSNGWWY-3’ determined by 
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Yamazaki et al. (2004). It would be interesting to experimentally confirm the 
regulatory role of AdpA in grisemycin and cypemycin biosynthesis. 
 
Interestingly, the rare leucine codon UUA is found in the cypH transcript (no 
corresponding UUA codon is present in the mRNA of the S. griseus orthologue 
grmH, Figure VI.5.). This suggests that cypemycin biosynthesis could be under the 
regulatory control of bldA, which encodes the tRNA for the rare leucine codon UUA 
(Leskiw et al. 1991). Interestingly, in S. coelicolor, a species that does not produce 
A-factor, one of the bldA targets is its adpA orthologue (Takano et al. 2003). This 
suggests that if S. sp. OH-4156 does not have a γ-butyrolactone signaling system, 
cypemycin production could still be developmentally regulated not only through an 
effect from its bldA on its adpA orthologues, but also directly because of the UUA 
codon present in the cypH transcript.  
 
 
 
 
 
 
 
Figure VI.5. Alignment of the partial nucleotide sequences of cypH and grmH. cypH 
contains a rare UUA leucine codon (depicted in red), while the S. griseus orthologue grmH 
does not. The Leu residue is conserved in both proteins (bold in the partial acid sequences 
for CypH and GrmH above and below the alignment respectively). 
              Q   G   T   L   R   H   R   I   G   R   V   L   D   H 
cypH   181   CAA GGC ACA TTA CGA CAC CGG ATA GGC CGC GTA CTC GAC CAT   222
grmH   181   CCG GGA AGT CTG CGA CAC CGG CTC GGC CGC ACG CTC GAC CAT   222
             *   **  *    *  *** *** ***  *  *** ***     *** *** ***  
              P   G   S   L   R   H   R   L   G   R   T   L   D   H 
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VI.5. Bullet point summary 
 
• A second member of the linaridin family was identified in S. griseus and 
called grisemycin. 
 
• The propetide sequence of grisemycin closely resembles that of cypemycin, 
but is shorter by three amino acids. 
 
• Grisemycin was isolated from a S. griseus culture and its predicted 
structure verified by MALDI-ToF and Q-ToF mass spectrometry. 
 
• The functionality of the grisemycin biosynthetic gene cluster was shown by 
cloning and heterologous expression in S. coeilicolor M1146 and confirmed 
by generating a ∆grmA mutant in S. griseus. 
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Chapter VII - Cryptic lantipeptide gene clusters from 
streptomycetes 
 
VII.1. Introduction 
 
Among several different strains of S. venezuelae described in the literature, the two 
most well characterised ones are the original chloramphenicol producer 
ATCC10712 (or ISP5230) (Ehrlich et al. 1948) and strain ATCC15439, which is 
studied for its production of the macrolide antibiotics methymycin, neomethymycin, 
narbomycin and pikromycin (Xue et al. 1998). From here on, only the former strain 
will be discussed.  
 
S. venezuelae ATCC10712 was first isolated over 60 years ago from a soil sample 
taken near Caracas, Venezuela (Ehrlich et al. 1948). When grown on solid agar 
medium, S. venezuelae develops relatively quickly compared to other 
streptomycetes such as S. coelicolor. Its mycelium has fewer branches and is 
generally straight or slightly curved but no spiralling occurs (Ehrlich et al. 1948). 
Sporulating S. venezuelae colonies have a dark green colour and liquid grown 
cultures also form spores in some media, an ability that S. coelicolor lacks.  
 
The production of “chloromycetin”, the old name for chloramphenicol, has long 
been the main reason of interest in S. venezuelae. The antibiotic was introduced 
into clinical practice in 1948 and would later become the first antibiotic to be 
produced synthetically at large scale (McGhee and Anastas 1996). Its use as a 
broad spectrum antibiotic is currently in decline because of resistance problems, 
but it is still used as topical treatment for eye infections (Wareham and Wilson 
2002).  
 
The biosynthesis of chloramphenicol is linked to the shikimate pathway that 
assembles aromatic metabolites. It branches off this primary metabolic pathway at 
chorismic acid with the generation of p-aminophenylalanine (PAPA) (Teng et al. 
1985). The chloramphenicol biosynthetic gene cluster has been identified and 
cloned, and gene disruption studies have identified key enzymes (He et al. 2001). 
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S. venezuelae also produces a group of polyketide-derived antibiotics, the 
jadomycins (Doull et al. 1993; Doull et al. 1994). These angucyclines, of which 
jadomycin B is the main component, are generally produced only under certain 
environmental stress conditions, such as phage infection, and heat or ethanol 
shock (Doull et al. 1993; Doull et al. 1994). This observation fuelled an interest in 
the regulation of jadomycin biosynthesis. jadR2 was identified as a repressor gene 
that negatively influences jadomycin production. Disruption of jadR2 uncoupled 
jadomycin production from environmental stress (Yang et al. 1995). A more 
thorough analysis of the regulatory mechanism showed that jadR2 encodes a γ-
butyrolactone receptor homologue that has been hypothesized to perceive a signal 
produced by jadW1, an afsA homologue (Wang and Vining 2003). Inactivation of 
jadW1 not only affected the growth rate and ability to sporulate of S. venezuelae, its 
disruption also resulted in the loss of both jadomycin and chloramphenicol 
production (Wang and Vining 2003). In a recent study, S. venezuelae was 
engineered to produce jadomycin without the need for stress induction by replacing 
the pathway specific regulators and the promoter upstream of jadJ – the first gene 
in the biosynthetic operon of the jadomycin gene cluster – with the constitutive 
promoter ermE* (Zheng et al. 2007). This resulted in a two-fold increase in 
production compared to a stress-induced wild-type strain. 
 
The genome sequence of S. venezuelae ATCC10712 was determined by Diversa 
Corp. (now Verenium Corp.) as part of an effort to create a generic strain for 
industrial antibiotic production (Mervyn Bibb and Diversa Corp., unpublished data). 
The genome sequence contains several additional gene clusters that are predicted 
to be involved in the production of secondary metabolites, including lantipeptides 
and a thiopeptide. 
 
This chapter starts with a general bioinformatic analysis of all cryptic lantipeptide 
gene clusters that have been identified in sequenced streptomycetes. After this, 
attention will return to S. venezuelae. The expression of secondary metabolite 
gene clusters in S. venezuelae will be discussed in the context of bio-assays for 
putative lantipeptides made by the strain. Various approaches will be described 
that were taken with the aim of identifying the products of cryptic lantipeptide gene 
clusters in S. venezuelae. Finally, the in vitro approach of collaborators that led to 
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the identification of venezuelin, a cryptic S. venezuelae lantipeptide, will be 
discussed. 
 
VII.2. Bioinformatic analysis of cryptic lantipeptide gene 
clusters in sequenced streptomycetes 
 
At the time this PhD project started, the full genome sequence of four 
streptomycetes had been determined. The genome of the model strain S. 
coelicolor was sequenced in 2002 (Bentley et al.), followed shortly by the 
avermectin producer S. avermitilis (Ikeda et al. 2003). The genome of potato 
pathogen S. scabies was in a late stage of annotation and the S. venezuelae 
genome had been sequenced by a private company (Diversa Corp.). During the 
course of the PhD project, the genome sequence of S. griseus was completed 
(Ohnishi et al. 2008) and the Broad Institute (Cambridge, MA) provided sequence 
data from 17 additional Streptomyces species.  
 
Several cryptic lantipeptide gene clusters were identified in a bioinformatic analysis 
of the available Streptomyces genome sequences. The data from this analysis are 
summarised in Table VII.1. It is immediately apparent that lantipeptide gene 
clusters are widespread and abundant in streptomycetes. All biosynthetic enzymes 
were examined for the presence of essential catalytic residues and clusters that 
were likely to be inactive because of a defunct enzyme or the lack of LanA were 
omitted unless otherwise stated. The clusters from both S. roseosporus strains 
contained identical LanA peptides and were only  considered once. The same is 
true for the orthologous LanBC clusters SCO6930 from S. coelicolor and 
SSPG_07328 from S. lividans. Interestingly, no orthologous SCO0269 cluster 
could be found in S. lividans, possibly because of its location near the end of the 
chromosome. Clusters encoding predicted SapB-like morphogens that are involved 
in the erection of aerial hyphae during development (Kodani et al. 2004; Kodani et 
al. 2005) are present in all strains and will not be discussed further in this analysis. 
In five strains (S. avermitilis, S. sviceus, S. pristinaspiralis, S. sp. AA4 and S. sp. 
SPB78), no additional lantipeptide clusters were identified apart from the 
SapB/RamC orthologous cluster (Chapter I.4.3.c.) and these strains have been 
omitted from Table VII.1. 
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Table VII.1. Lantipeptide synthetases of the LanB, LanC, LanM and LanL types identified in 
streptomycete genomes. Enzymes that are predicted to be non-functional are indicated 
by *. Clusters for which no lanA could be identified are indicated by (-A). A gene cluster 
containing a functional lanC and partial lanM, but no lanA, is indicated by (MC). 
 
LanB LanC LanM LanL
SCO0269 SCO0270 
SCO6930 SCO6929
S. venezuelae ISP-5230 SMD01140* VenL
S. scabies  87.22 SCAB32031 SCAB32041
SGR_3847 SGR_3846 SGR_4809* SGR_152 (-A)
SGR_6574 (MC) SGR_6571 (MC)
S. albus  J1074 SSHG_00049
SSGG_02013* 
SSGG_04021
SSCG_01497 SSCG_01498 SSCG_02809
 SSCG_03317 SSCG_03318 
S. hygroscopicus  ATCC 
53653 SSOG_05509
S. sp.  C SSNG_01013*
SSQG_04548 SSQG_04549 SSQG_04194 
SSQG_04196
S. sp.  SPB74 SSBG_01042 SSBG_01043
SSAG_01528 SSAG_01529  
SSAG_03540 (-A) SSAG_03541 (-A)
SSAG_05771*  SSAG_07472* 
S. lividans  TK24 SSPG_07328 SSPG_07327
SSRG_00125 (-A)   SSRG_00124 (-A)  
SSRG_05139 (-A) SSRG_05140 (-A)
SSRG_06258 SSRG_06257
S. ghanaensis  ATCC 
14672 SSFG_06280*
S. sp. E14 SSTG_04682* SSTG_05266
S. viridochromogenes 
DSM 40736
S. sp. Mg1
S. griseoflavus  Tu4000
S. coelicolor  A3(2)
S. roseosporus  NRRL 
15998
S. griseus  IFO 13350
S. clavuligerus  ATCC 
27064
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Ten potentially functional LanBC clusters, four LanM clusters and three LanL 
clusters were identified in these streptomycete genomes. Four additional LanM 
enzymes were identified that do not contain the required catalytic and cofactor 
binding residues in their C-terminal cyclase domain, but they could be part of an 
active cluster as discussed below. Most genomes only seem to contain one or 
more clusters either of the LanBC or of the LanM type, whereas in S. griseus and 
S. viridochromogenes, both types are present. In S. griseus, a gene cluster was 
found with a potentially functional LanC cyclase (SGR_6574) and a gene with 
homology with the N-terminus of a LanM (SGR_6571). It was not possible to 
predict whether this truncated LanM would be capable of catalysing a dehydration 
reaction and no putative LanA could be identified near the cluster. Two potentially 
active orphan LanBs (SGR_5947 and SSFG_06284), two orphan LanCs 
(SCO4224/SSPG_03470 and SSMG_08135) and a LanL with no associated LanA 
(SGR_152) were also identified. Although not encoding a lantipeptide, a novel 
cryptic thiopeptide gene cluster was identified in S. venezuelae (SMD07779-
SMD07795) as well as a previously identified thiopeptide cluster in S. griseus 
(SGR_4410-SGR_4418, Wieland-Brown et al. 2009).  
 
For each enzyme type, all potentially active clusters could be subdivided into 
different subfamilies. This classification is based on their gene arrangement (Figure 
VII.1.) and the sequence of their predicted LanA (Figure VII.2.), with both criteria in 
good agreement. 
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Three distinct families of LanAs were identified for the LanBC gene clusters. 
Conserved positions for Ser/Thr and Cys were identified for each separate family, 
suggesting a common ring topology for compounds within each family. The LanA 
peptides in the first family all contain a C-terminal Cys but no LanD enzyme was 
found in their biosynthetic clusters. However, several lantibiotics possess a C-
terminal (Me)Lan, including salivaricin A, mutacin II and planosporicin (Ross et al. 
1993; Krull et al. 2000; Maffioli et al. 2009), and the same may be true for this 
family of compounds. These clusters are predicted to be the largest LanBC 
clusters and are the only family for which likely transport or immunity genes could 
be identified. This makes this family a good candidate for mining lantipeptides with 
antibiotic activity. The second and third LanBC families contain LanA peptides that 
are well conserved in both the leader and the propeptide sequence (in the third 
family, only SSCG_01496 does not align well with the other LanAs). The 
biosynthetic gene clusters from both of these families all contain genes with 
homology to L-isoaspartyl methyltransferases (light blue in Figure VII.1.). This 
enzyme family is involved in the repair of damaged L-isoaspartyl and D-aspartate 
groups in proteins (Ryttersgaard et al. 2002). No members of this family have been 
associated previously with the post-translational modification of peptide natural 
products. However, given their invariant co-occurrence with these two LanBC 
family clusters in which the LanAs contain conserved Asp residues, it is possible 
that these methyltransferases are involved in the introduction of a novel type of 
post-translational modification, i.e. methylation of Asp residues.  
 
The LanM gene clusters were divided into two families. The first family contains 
three similar gene cluster organisations, but the LanA sequences are quite 
dissimilar despite some conserved Ser/Thr and Cys positions in the propeptides. 
The leader sequences contain an area of greater homology, but no consensus 
sequence could be identified. This first LanM family appears to show the greatest 
variability in likely compound structures among all of the clusters analysed here. 
The second LanM family only contains one LanM with an active cyclase domain 
(SSHG_00049). The S. venezuelae LanM (SMD01140) has the conserved 
residues for the Zn-binding site, but lacks the catalytic His. All the other LanM 
enzymes in this family lack the entire Zn-binding motif. Thus, all but one of these 
clusters may be inactive. However, the amino acid sequences of the LanA peptides 
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are reasonably well conserved (Figure VII.2.), implying that they may still be 
functional. Moreover, apart from one C-terminal Cys in the S. venezuelae LanA 
(SMD01139), all of these LanAs are completely devoid of Cys residues, thus 
making an active cyclase domain redundant. If these gene clusters are capable of 
producing compounds, the resulting products are predicted to be linear dehydrated 
peptides. Before the cypemycin gene cluster was identified, analysis of the cryptic 
gene clusters of S. venezuelae was ongoing in parallel. At that time cypemycin was 
still believed to belong to the lantibiotic family of peptides, and to be the product of 
a cluster with a LanB or a LanM for the Ser/Thr dehydrations in combination with a 
LanD for the AviCys. We (wrongly) believed that SMD01139 from S. venezuelae 
represented a cypemycin-like modified peptide. The predicted product of this LanA 
is also a dehydrated peptide with a C-terminal Cys (no AviCys in this case because 
there is no LanD in the S. venezuelae cluster). With hindsight, this second LanM 
family could be involved in the production of compounds that are similar in 
structure to the newly identified linaridin family (Chapter IV.4.) regardless of the 
differences in the sequences of the respective biosynthetic genes. 
 
For the LanL type, only one family was identified with highly similar structural 
peptides which extended to the leader region. The predicted ring topology, as 
determined for venezuelin (Goto et al. 2010), is likely conserved, as indicated in 
Figure VII.2. 
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VII.3. Cryptic gene clusters in S. venezuelae 
 
In this section, the focus is on three cryptic lantipeptide gene clusters identified in 
S. venezuelae. One cluster (SMD01136 - SMD01140) is of the LanM-type and a 
second, very small cluster just consists of a gene encoding a RamC-type enzyme 
(Chapter I.4.3.c.) and an associated lanA (SMD01224 and SMD01224.2 
respectively). The third cryptic cluster (SMD01252 – SMD01254) contains a novel 
type of modification enzyme with an N-terminal phosphoSer/Thr lyase domain, a 
Ser/Thr kinase domain and a C-terminal LanC-like cyclase domain with catalytic 
His and Zn binding site residues. The predicted S. venezuelae RamC cluster 
(SMD09638 – SMD09642) was not analysed since its predicted structural peptide 
is very similar to the well characterised S. coelicolor SapB lantipeptide (Kodani et 
al. 2004). 
 
VII.3.1. Deletion of the modification gene for each cluster 
 
In a first attempt to identify the products of the cryptic gene clusters, ApraR  
replacement mutants were generated for the different modification genes as 
described in Chapter II.6. Deletion of a modification gene should result in the 
inactivation of the associated cluster, since the posttranslational modifications in 
the predicted lantipeptides are likely to be essential for biological activity. Provided 
that the gene cluster is expressed under the conditions used, this analysis would 
identify antibacterial peptides by lack of an inhibition zone in the mutant and 
morphogenetic peptides by an altered colony phenotype in the mutant. To 
maximise the chances of finding an interesting phenotype without interference from 
other secondary metabolites made by S. venezuelae, a screen was set up using 
several different agar media. 
 
Deletion of individual modification genes resulted in S. venezuelae mutants M1436 
(∆SMD01140::(oriT-aac(3)IV)), M1437 (∆SMD01224::(oriT-aac(3)IV)) and M1438 
(∆SMD01252::(oriT-aac(3)IV)). To rule out potential cross-talk between the 
SMD01140 and SMD01252 gene clusters, double mutants were generated as well 
by replacing the remaining lantipeptide synthetase in M1436 and M1438 with HygR. 
This second round of mutation yielded strains M1439 (∆SMD01140::(oriT-
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aac(3)IV); ∆SMD01252::(oriT-hyg)) and M1440 (∆SMD01252::(oriT-aac(3)IV); 
∆SMD01140::(oriT-hyg)). 
 
Two separate exconjugants for all of the above mentioned S. venezuelae mutants 
(M1436 – M1440) were grown on 14 different agar media (described in Chapter 
II.2.2.) and analysed for antibiotic activity against M. luteus after three and five 
days of growth. During incubation, mutant colony morphology was monitored in 
comparison to S. venezuelae WT on a daily basis. No morphological abnormality 
was observed for any of the deletion mutants and no differences in antibacterial 
activity against M. luteus were found when the mutants were compared to the WT 
strain on all 14 media. This screen did identify several conditions in which S. 
venezuelae WT as well as the mutants produced a zone of inhibition against M. 
luteus, indicative of the production of a biologically active secondary metabolite, 
possibly chloramphenicol or jadomycin. 
 
VII.3.2. Micro-array expression data for the different clusters 
 
It was deemed useful to identify the metabolite(s) causing the zones of inhibition in 
the aforementioned bio-assays, since the observed halos could be masking a  
smaller halo produced by the lantipeptide under study. The gene expression 
profiles of known and predicted secondary metabolic gene clusters from S. 
venezuelae were established by micro-array analysis (Maureen Bibb, unpublished 
data). It is important to note that the S. venezuelae RNA used for this experiment 
was extracted from liquid grown cultures, so the expression profiles may well be 
different from those existing in the agar-grown cultures used for the bio-assays. 
The data were therefore used only as a guide to identify possible candidate gene  
clusters responsible for the production of the inhibitory activity.  
 
The micro-array analysis indicated that several of the putative secondary 
metabolite gene clusters were transcriptionally active. Among these were two 
developmentally expressed putative siderophore gene clusters. Figure VII.3. shows 
the expression profiles for three clusters from which the predicted product could 
have antibacterial activity, namely chloramphenicol, jadomycin and a cryptic NRP 
cluster. The chloramphenicol cluster (SMD01679 – SMD01700) is transcribed 
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transiently at higher levels at 14 hours and returns to basal levels of expression 
shortly after. A similar spike is seen in the profile for the jadomycin cluster 
(SMD08944 – SMD08982) and the cryptic NRP cluster (SMD10419 – SMD10434) 
at ten hours. Expression levels become very low for these three clusters at later 
time points and the time frame is much shorter than that used for the agar-grown 
cultures (three and five days). However, stable metabolites could have been 
produced from one or more of these gene clusters that interfered later with the bio-
assay. 
 
The expression profiles of the cryptic lantipeptide gene clusters and their 
surrounding regions were also analysed. The LanM cluster (SMD01140) appeared 
to be expressed only at very low levels under the conditions tested (Figure VII.3.). 
The gene expressed strongly after 14 hours (SMD01145) is located upstream of 
the cluster and encodes a protein of unknown function. The small cluster with the 
RamC-like enzyme (SMD01224) was expressed at low levels (data not shown), but 
the lanA from the third cluster (SMD01252.2) was expressed at high levels, 
reaching its maximum at a late stage of growth (Figure VII.3.). The expression 
profiles of the other genes in this cluster are quite flat, suggesting they are 
expressed at low levels. A small increase in expression can be observed at 16 
hours for the two transport genes (SMD01253 and SMD01254), which coincides 
with the largest increase in lanA expression. These data suggest that the cluster 
might be producing a lantipeptide under the conditions tested. The expression 
profile for the RamC-orthologous cluster (SMD09638 – SMD09642) was included 
for comparison (Figure VII.3.). The two genes that are most active are first the 
ramS ortholog and then the ramR ortholog. ramC itself appears to be expressed at 
low levels. Note that is unknown whether active SapB is formed, since ramC was 
only expressed at very low levels and there would be no need for the surfactant 
activity during liquid growth.  
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To investigate whether the SMD01252 gene cluster produced an active compound 
in liquid culture, S. venezuelae WT and M1438 (∆SMD01252) were grown under 
conditions similar to those used for the micro-array experiment. When the culture 
supernatant was analysed in a paper disk assay against M. luteus, a zone of 
inhibition was formed for both the WT and mutant strains, again indicating 
interference by another secondary metabolite in the bio-assay. 
 
The chloramphenicol gene cluster was the most likely candidate for causing 
interference in the bio-assays and thus it was inactivated by generating the ApraR 
replacement mutant M1441 (∆cmlPH::(oriT-aac(3)IV)) as described in Chapter II.6. 
Gene disruption studies by He et al. (2001) have shown previously that the lack of 
either cmlP or cmlH results in total loss of chloramphenicol production without 
imbalancing the shikimate pathway.  
 
The antibiotic activity of M1441 (∆cmlPH) against M. luteus was assayed after 
growth on the same agar media that were used in the previous screens. Only one 
condition (MarM medium, three days of growth prior to overlay) was identified 
where the observed activity could be solely attributed to chloramphenicol 
production. On all of the other media, M1441 (∆cmlPH) behaved in an identical 
fashion to S. venezuelae WT. This indicates that all other zones of inhibition were 
caused by one or more secondary metabolite other than chloramphenicol. No 
attempts were made to inactivate additional gene clusters or to identify the 
antibiotic activity.  
 
VII.3.3. Heterologous expression of the clusters 
 
In an attempt to avoid the interference of other secondary metabolites produced by 
S. venezuelae in the bio-assays, the lantipeptide gene clusters were introduced 
into a heterologous host. S. lividans was chosen since it was known not to produce 
antibacterial activity under a variety of growth conditions. 
 
The predicted LanM cluster (SMD01140) lies close to the ends of two cosmid 
inserts in the S. venezuelae cosmid library (in cosmids 1-B5 and 4-G03). The 
region directly up- or down-stream of the predicted cluster is missing from one or 
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other cosmid. To account for the possible involvement of one or other of these 
flanking regions in lantipeptide synthesis, both cosmids were used for heterologous 
expression. Heterologous expression of the small RamC-like cluster (SMD01224) 
was not attempted. Cosmid 4H08 was used for heterologous expression of the 
SMD01252 cluster, which is located in the centre of the cosmid insert. The cosmid 
backbones were targeted with the integrative fragment of pIJ10702 (Chapter II.6.) 
and introduced into S. lividans by conjugation, resulting in strains M1447 (1-B5), 
M1448 (4-G03) and M1449 (4H08). A control strain (M1446) was generated by 
introducing just the vector pIJ10702. The strains were grown on the same media 
that had been used in the previously described screens. Morphology was 
monitored during growth and overlay assays were performed with M. luteus as an 
indicator after three and five days. No differences were observed between the 
strains with integrated cosmids and the WT and empty vector controls. 
 
VII.3.4. Chemical induction of antibiotic production   
 
Several studies have investigated the effect of growth media supplements on 
antibiotic production. N-acetylglucosamine (GlcNAc) has been identified by Rigali 
et al. (2008) as a starvation signal in S. coelicolor that elicits a response from the 
pathway-specific activators of antibiotic biosynthetic gene clusters. GlcNAc 
stimulated antimicrobial activity in several streptomycetes, suggesting that it may 
provide a valuable strategy for the activation of cryptic antibiotic gene clusters. A 
second small molecule that has been linked to increased antibiotic production is 
SAM. Overproduction of SAM synthetases in S. coelicolor, S. avermitilis and S. 
peucetius caused an increase in production of actinorhodin (Act), avermectin and 
doxorubicin, respectively (Okamoto et al. 2003; Yoon et al. 2006). Addition of 
exogenous SAM was also shown to enhance streptomycin production in S. griseus 
through increased adpA transcription (Shin et al. 2006). 
 
The effect of GlcNAc and SAM on the expression of the cryptic lantipeptide gene 
clusters of S. venezuelae was assessed. S. venezuelae WT and the lantipeptide 
synthetase deletion strains M1436 – M1440 could not be used in this assay, since 
they produce a zone of inhibition against M. luteus after growth on MM (1.5% 
LabM, 0.5 % mannitol). Instead, S. lividans strains M1447 – M1449 with the 
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introduced cosmids were analysed. The addition of 25 µM SAM to the medium did 
not influence production of antibacterial activity in a M. luteus bioassay (Fig. 
VII.4.A.). However, zones of inhibition were observed for the heterologous 
expression strains M1447 – M1449 and not the WT or empty vector (M1446) 
control strains when 1 % GlcNAc was added to the growth medium (Fig. VII.4.B.). 
Unfortunately, while this initial observation was repeated three times within one 
month, it could not be reproduced five months later, when additional S. lividans 
strains had been generated containing cosmids with an in-frame deleted lanA 
(M1450 – M1452) or modification gene (M1453 – M1455). The reason for this lack 
of reproducibility is not known, but it could reflect, for example, a change in a 
medium component. 
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Figure VII.4. Chemical induction of the heterologously expressed S. venezuelae 
lantipeptide clusters. S. lividans WT, and strains containing an empty vector control 
(M1446), the SMD01140 cluster (M1447 (1-B5) and M1448 (4-G03)) and the SMD01252 
cluster (M1449 (4H08)) were grown for three days at 30 °C on MM (1.5 % LabM, 0.5 % 
mannitol) containing A) 25 µM SAM, B) 1 % GlcNAc and C) no inducer. An overlay of M. 
luteus in SNA was applied and halos were scored after overnight incubation at 30 °C. The 
strains containing the S. venezuelae cosmids produced a zone of inhibition only on the 
medium with added GlcNAc. Unfortunately, the observation could not be repeated five 
months later (refer to text). 
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VII.3.5. Constitutive expression of the modification enzymes in each 
cluster 
 
An attempt was next made to constitutively express the genes encoding the 
modification enzymes from each cluster. A PCR targeting construct was generated 
that contained an ApraR marker, the strong constitutive promoter ermE*p and the 
EF-Tu RBS from pIJ10257 (based on the design by Sean O’Rourke). This cassette 
(pIJ10704) can be introduced directly upstream of the start codon of a target gene, 
resulting in its constitutive expression.  
 
The functionality of the ermE* construct was tested by introducing it in front of afsR 
in S. coelicolor, resulting in strain M1456 (ermE*-afsR). Previous work had shown 
that introduction of multiple copies of afsR had a stimulatory effect on the 
production of Act and undecylprodigiosin (Red), the two pigmented antibiotics 
produced by S. coelicolor (Floriano and Bibb 1996). M1456 (ermE*-afsR) 
exconjugants were easily identified by the copious blue droplets of Act on their 
surface when grown on SFM medium (Figure VII.5.; S. coelicolor does not produce 
significant amounts of Act on SFM). This experiment demonstrated that the 
expression construct was functional. 
 
The ermE* construct was introduced upstream of the three lantipeptide synthetase 
genes in S. venezuelae, resulting in strains M1442 (ermE*-SMD01140), M1443 
(ermE*-SMD01224) and M1444 (ermE*-SMD01252). When these strains were 
tested for antimicrobial activity against M. luteus, no difference was observed when 
compared to the WT strain. The supernatant of liquid grown cultures was analysed 
by MALDI-ToF, but no differences were observed for the spectra of the WT, the 
M1442 (ermE*-SMD01140) and M1443 (ermE*-SMD01224) expression strains. 
However, in the spectrum of the M1444 (ermE*-SMD01252) expression strain, a 
set of mass peaks was observed at much greater abundance than in the WT 
spectrum. All other peaks in both spectra were of comparable signal intensity. 
MALDI-ToF does not allow quantitative interpretation, but this observation led us to 
investigate the set of elevated peaks more thoroughly. A pattern of oxidations (+16 
Da mass increments), and sodium (+22 Da) and potassium (38 Da) adducts was 
observed for a compound with [M+H]+ = 2124.175 Da (Figure VII.6.A.). Similar 
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spectra have been observed for lantibiotics (Lucy Foulston and Robert Bell, 
personal communication) and are thought to be caused by oxidation of (Me)Lan 
prior to and during MALDI-ToF analysis. Up to four oxidations could be observed 
for the sodium adduct of the compound, indicating that if the compound with the 
[M+H]+ of 2124 Da is a lantipeptide, it could contain four (Me)Lan bridges.  
 
The calculated [M+H]+ of a SMD01252.2-derived lantipeptide with four bridges, 
cleaved from the leader peptide after Ala29 is 2125 Da. This is a difference of 1 Da 
compared to the observed compound. MALDI-ToF analysis of the supernatant of 
M1438 (∆SMD01252) revealed that all peaks apparently derived from the 
compound with [M+H]+ = 2124 Da were still present. To confirm that this compound 
was definitely not a product of the SMD01252 cluster, an ApraR replacement 
mutant was made for lanA as well: M1445 (∆SMD01252.2::(oriT-aac(3)IV)). None 
of the peaks disappeared in the mass spectrum of this mutant either.  
 
Q-ToF analysis of the unidentified compound required a much higher collision 
energy compared to the energy used for cypemycin fragmentation. The spectrum 
did not show fragment masses from which an unambiguous amino acid sequence 
could be derived. No further attempts were made to identify the structure of the 
[M+H]+ = 2124 Da compound. 
 
It is unlikely that the observed compound is the S. venezuelae SapB morphogen 
ortholog, which could possibly be produced in liquid media (Chapter VII.3.2.). The 
S. venezuelae SapB has not been characterised, but the structural peptide is 
nearly identical to S. coelicolor SapB (Kodani et al. 2004). Both are very likely to be 
processed in a similar fashion, yielding a compound with a predicted mass of 2013 
Da for S. venezuelae SapB (Figure VII.6.C.). Moreover, SapB only contains two 
Lan bridges, so this would not explain a pattern with four oxidations. 
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Figure VII.5. Act overproduction phenotype of S. coelicolor  M1456 (ermE*-afsR) on SFM. 
Blue droplets of Act were observed on top of the colonies, confirming the functionality of the 
ermE* construct. Plates had been incubated for five days at 30 °C when the pictures were 
taken. 
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Figure VII.6. Identification of a possible product from the cryptic SMD01252 gene cluster. A) 
MALDI-ToF spectrum for a compound with [M+H]+ = 2124 Da. Peaks representing oxidations, 
sodium or potassium adducts are annotated accordingly. B) Schematic representation of a 
possible product from the SMD01252 cluster. Ser/Thr residues in the prepropeptide 
sequence are depicted in red and Cys in blue. This colour coding is maintained in the model 
for the modified peptide which is based on a leader cleavage after Ala29 (indicated by a 
vertical red line) and the introduction of four dehydrations and subsequent cyclisations. The 
ring topology shown is completely speculative and not based on experimental data. C) 
Alignment of the SapB prepropeptide sequences from S. coelicolor (SCO6682) and S. 
venezuelae (SMD09641). The site of leader cleavage in S. coelicolor is indicated by a vertical 
red line. The only difference in the propeptide sequences is an Ile-Val substitution. 
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VII.4. Discussion 
 
A bioinformatic analysis of the 21 available streptomycete genomes (counting the 
two S. roseosporus strains only once) identified several cryptic lantipeptide gene 
clusters. Ten LanBC, four LanM and three LanL clusters contained a lanA and 
genes for apparently functional modification enzyme(s), as judged from amino acid 
sequence alignments and the presence of conserved residues. Four additional 
clusters were identified with a LanM enzyme that lacks the catalytic and Zn-binding 
residues in their cyclase domain. However, the LanA peptides that are associated 
with these enzymes are devoid of Cys residues (with the exception of a C-terminal 
Cys in SMD01139). Thus these clusters could still be active and might produce 
linear dehydrated peptides, bringing the total for potentially active LanM-like 
clusters to eight.  
 
A PCR approach with degenerate primers was previously used by Dodd et al. 
(2006) to screen about 100 actinomycete genomes for the presence of lanA and 
lanM genes. About 20 % of the strains tested proved positive, likely an 
underestimate given the restrictions imposed by the use of degenerate primers. A 
recent bioinformatic study by Begley et al. (2009) identified 89 LanM homologs in 
the publicly available bacterial genome sequences. The eight potentially active 
LanM clusters described in this chapter make up a significant proportion of this 
total, indicating that streptomycetes are good candidates for lantipeptide genome 
mining. The identification of bacteriocin gene clusters in newly sequenced 
genomes will be facilitated by the recently developed BAGEL2 software (de Jong 
et al. 2010). This program can be used for the annotation of lantipeptide clusters 
from the LanBC, LanM and even the recently characterised LanL types. All clusters 
could be classified into distinct families based on their gene organisations and their 
structural peptide sequences. This could mean that despite the relatively large 
number of clusters in Streptomyces genomes, the number of compound scaffolds 
with a specific (Me)Lan ring pattern could be limited. This apparent conservation 
may be indicative of a shared biological activity.  
 
There are several different strategies to obtain the product of a cryptic biosynthetic 
gene cluster, as reviewed by Zerikly and Challis (2009). Most of the genetic 
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approaches to identify products from the cryptic lantipeptide clusters of S. 
venezuelae were attempted, but none of them proved to be successful.  
 
A collaboration with the van der Donk group was initiated to employ the ‘in vitro 
reconstitution’ strategy on the SMD01252 gene cluster containing the novel 
lantipeptide synthetase. This involved the purification of the structural peptide and 
the modification enzyme to obtain a product from their combined incubation in an in 
vitro reaction. The in vitro reconstitution approach had already been successfully 
applied to identify haloduracin, the two-component lantibiotic product of a cryptic 
gene cluster found in Bacillus halodurans C-125 (McClerren et al. 2006). However, 
results have to be interpreted with caution, as additional mutagenesis studies 
required a revision of the haloduracin structure (Cooper et al. 2008). 
 
Upon incubation of the purified SMD01252.2 structural peptide with the purified 
modification enzyme SMD01252, a four-fold dehydrated and cyclised product was 
formed (Goto et al. 2010). This compound was named venezuelin and the genes in 
the cluster were reassigned with the standard lantibiotic nomenclature: venA for 
the structural gene and venTH for the two downstream transporter genes. The 
modification enzyme was called VenL, since its activity has now been shown and it 
belongs to a novel class of lanthionine synthetases designated LanL. The three 
distinct domains in VenL (a small N-terminal phosphoSer/Thr lyase domain, a 
central Ser/Thr kinase domain and a C-terminal LanC-like cyclase) were expressed 
individually and shown to be catalytically active, providing insight into the 
mechanism of LanL enzymes. The kinase domain initiates the modification of the 
propeptide by phosphorylating Ser and Thr residues. A subsequent elimination of 
the phosphate groups by the lyase domain results in the formation of Dha and Dhb 
residues. Finally, the cyclase domain catalyses the addition of Cys residues onto 
the dehydrated residues, forming (Me)Lan bridges. A series of VenA analogs was 
generated in which one Cys was replaced by Ala. Interpretation of the 
fragmentation patterns of tandem mass spectrometry analysis allowed 
determination of the venezuelin ring topology (Goto et al. 2010). Venezuelin had no 
antibacterial activity against three different indicator strains that are typically highly 
sensitive to various lantibiotics. 
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This could explain why venezuelin was not detected in the bio-assays described in 
this chapter. No antibiotic activity could not be demonstrated for the Sap 
lantipeptides, which are generated by related modification enzymes (Kodani et al. 
2004; Kodani et al. 2005). The biological function of venezuelin – and by extension, 
the products of many other cryptic lantipeptide clusters – may not be antibacterial. 
Apart from a possible morphological function, the compounds could, for example, 
serve as signalling molecules. Indeed, for some lantibiotics, a quorum sensing 
activity has been demonstrated involving the detection of the mature compound by 
a dedicated LanRK two-component system resulting in regulation of the 
biosynthetic and immunity genes (Kuipers et al. 1995; Stein et al. 2002; 
Kleerebezem et al. 2004).  
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VII.5. Bullet point summary 
 
• Bioinformatic analysis identified many cryptic lantipeptide gene clusters in 
sequenced streptomycete genomes. These clusters were classified into 
distinct families based on their gene organisation and their LanA 
sequences.  
 
• A novel type of lantipeptide modification enzyme containing an N-terminal 
phosphoSer/Thr lyase, a Ser/Thr kinase and a LanC-like cyclase domain 
was identified in one of the cryptic gene clusters from S. venezuelae. 
 
• Various in vivo approaches were unsuccessfully taken to obtain products 
from the three lantipeptide gene clusters in S. venezuelae. 
 
• An in vitro approach by collaborators identified the lantipeptide venezuelin 
as the product from the cryptic gene cluster with the unusual LanL enzyme. 
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Chapter VIII – General discussion 
 
Starting from its discovery in 1993 (Komiyama et al.), cypemycin has always been 
hard to classify on a structural basis. The occurrence of four Dhb residues and an 
AviCys in the mature peptide led to its understandable classification as a lantibiotic 
(Chatterjee et al. 2005). However, cypemycin does not contain the (Me)Lan 
residues that define the lantibiotic family. The genetic (and some preliminary 
biochemical) analysis performed in this thesis surprisingly revealed that cypemycin 
is not a lantibiotic, but the first representative of a novel class of post-translationally 
modified peptides we named ‘linaridins’.  
 
Genome scanning of S. sp. OH-4156 was of key importance for the identification of 
the cypemycin biosynthetic gene cluster, as discussed in Chapter III. A logical first 
step to take with this data at hand was a bioinformatic search for lantibiotic 
modification genes. At that time, CinM was the only characterised streptomycete 
lanthionine synthetase (Widdick et al. 2003), although several additional cryptic 
lanthionine synthetase-like genes had been identified in the sequenced genomes 
of S. coelicolor, S. avermitilis, S. scabies and S. venezuelae (Mervyn Bibb, 
unpublished data). Deletion and heterologous expression of the cryptic S. 
venezuelae lantipeptide clusters (Chapter VII) had just been completed and the 
genes encoding their respective lanthionine synthetases were used as the first 
BLAST queries to search the S. sp. OH-4156 genome scanning data. 
Encouragingly, several contigs were identified in this manner, but closer inspection 
of their nucleotide sequences revealed that they were about 95 % identical to the 
S. venezuelae sequences. This led initially to the incorrect conclusion that the 
genomic DNA submitted for sequencing was extracted from a culture that had 
been contaminated and usurped by S. venezuelae. Luckily, anxiety was soon 
replaced by renewed excitement when the cypA gene was identified in an 
additional tBLASTn search. The initial inspection of this ORF, which encodes a 
prepropeptide with two Cys precursors for the AviCys, taken together with the lack 
of apparent lanthionine synthetases in the S. sp OH-4156 sequence, hinted that 
cypemycin would indeed be a very special peptide. Full appreciation of this took 
shape after the biosynthetic gene cluster was sequenced and the function of the 
individual genes was confirmed by a deletion analysis (Chapter IV).  
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Comparative genomic studies of bacterial strains belonging to the same species 
have identified so-called species-specific ‘core genomes’ (Medini et al. 2008). 
These are arbitrary collectives containing the genes that are shared by every 
member of the species under analysis. Comparison of the preliminary S. sp. OH-
4156 genome scanning data with the full genome sequence of S. venezuelae 
revealed a remarkable degree of sequence homology (Figure III.7.A.). There 
appears to be a shared genomic ‘scaffold’ that differs only in the complement of 
secondary metabolite gene clusters. This might well be a common theme among 
different streptomycetes and could have implications for the use of genome 
sequencing for natural product discovery. When looking for the genes responsible 
for production of a known metabolite, genome scanning is probably the best 
starting point, as exemplified with cypemycin in this thesis and with the recent 
discovery of the ribosomal origin for thiopeptide antibiotics (Figure I.1.H.). A 
potentially useful lesson that can be learned from the core or ‘scaffold’ genes is 
that they could be used as guidelines for cloning predicted secondary metabolite 
gene clusters. In various cases it is probably safe to define a cluster’s boundaries 
based on where the core genome stops and additional genes begin, as exemplified 
by the chloramphenicol cluster (Figure III.7.B.).  
 
Bacterial genomes are full of small ORFs that are embedded in clusters containing 
putative biosynthetic genes. At the moment it is hard to estimate what proportion of 
these produce (post-translationally modified) peptides. There are potentially 
dozens of unusual peptide families or post-translational modifications that await 
identification with potentially novel biological functions. Most compounds are 
identified in activity-based screens, for example by looking for antibiotic activity. 
However, various types of modified peptides have been described that do not 
primarily have an antibiotic function. An example of this is the lasso peptides, 
which have an intriguing structure and underlying biosynthesis, but only two out of 
over ten structurally characterised compounds have significant antibacterial 
activity. Similarly, cypemycin, which was identified because of its cytocidal activity 
against mouse leukemia cells (Komiyama et al. 1993) would almost certainly have 
been discarded in an antibacterial screen. It would be interesting to investigate 
different bacteria (Figure IV.7.) for the production of linaridins as this could help in 
the identification of this family’s biological function, which might well be regulatory. 
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Indeed, Gram-positive bacteria are known to use diverse types of modified 
peptides specifically for quorum sensing. This does not exclude a supplementary 
function, since some lantibiotics have been shown to serve as auto-inducers for 
their own synthesis in addition to possessing antimicrobial activity. Another 
possibility is that the linaridins could serve a specific structural and/or 
developmental role like, for example, the Sap morphogens or the unmodified 
chaplins and rodlins in streptomycetes. No phenotypic differences could be 
observed upon deletion of cypA, so if cypemycin has a structural/developmental 
function, it is not involved in the processes required for growth under the laboratory 
conditions tested. Moreover, if the linaridins’ function was strictly developmental, 
their gene clusters would be expected to occur more commonly and be less wide-
spread among different bacterial lineages. Cypemycin’s hydrophobic nature and 
resulting affinity for the cytoplasmid membrane might provide a clue. Hydrophobic 
peptides have been identified that modulate the activity and/or stability of certain 
proteins inserted into the inner cell membrane of E. coli and Salmonella 
typhimurium (Alix and Blanc-Potard 2009).  
 
Recent advances in the understanding of post-translationally modified peptides 
cannot be attributed solely to genome scanning. Improvements in mass 
spectrometric techniques has also contributed greatly and not only to the 
identification of novel peptides and post-translational modifications, but also to the 
biochemical characterisation of their biosynthetic machinery. For this project, Q-
ToF MS has been extremely useful for the structural analysis of cypemycin and its 
variants, particularly the non-dehydrated version, which was shown to have its 
internal Cys dethiolated. The linear (non-cyclised) nature of cypemycin lends itself 
well to this type of analysis and the need for only small sample quantities makes it 
compatible with biochemical assays. It would be interesting to determine how the 
Thr dehydration and the Cys dethiolation reactions are catalysed. However, this 
could turn out to be quite challenging because the candidate enzymes lack 
homology to functionally characterised proteins and thus far the biochemical 
characterisation of LanB enzymes has proved particularly difficult. None-the-less, 
the N-methyltransferase CypM and the decarboxylase CypD are significant 
contributions to the ever-growing ‘enzyme toolbox’ that could be used for rational 
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peptide engineering. Modification of a peptide’s termini is expected to provide 
increased resistance against amino- and carboxypeptidases (Rink et al. 2010).  
 
In the future, it will become more straightforward to identify and characterise post-
translationally modified peptide natural products sourced from different organisms 
or ecological niches. Molecular genetic techniques will be developed to manipulate 
the producers and/or to design systems for heterologous production. Several 
genetic and biochemical strategies have already proven their merit in the activation 
of cryptic secondary metabolite gene clusters (Challis 2008). Two nice examples of 
peptides from Eukaryotes are the conopeptides and bombinins. Conopeptides are 
a diverse collection of post-translationally modified peptides that are produced by 
the conus snail as a venom to paralyse its prey (Lewis 2009). Bombinins are a 
family of hydrophobic peptides that contain D-allo-Ile and are secreted by frogs of 
the Bombina genus (Simmaco et al. 2009). The patellamides (Figure I.1.J. and 
I.1.K.) were originally identified in extracts from marine ascidians, but turned out to 
be produced by symbiotic cyanobacteria. Different niches that are currently being 
mined for natural products include marine organisms, ants that use bacteria to 
destroy pathogens in their cultivated fungus gardens, and human-associated 
microbiota. These efforts will of course identify compounds with all sorts of different 
chemical scaffolds and structures, but there will almost certainly be some 
(modified) peptides among those. To conclude, many more post-translational 
modifications and biochemical mechanisms remain to be discovered in the exciting 
and expanding peptide world. 
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